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The majority of vaccines consist of proteins derived from pathogens that, upon vac-
cination, provide humans with long-term immunity against infectious disease. Vac-
cine proteins are susceptible to environmental changes. Fluctuations in temperature
are the foremost cause of protein degradation and will result in vaccines being inef-
fective. In short, many vaccines lack thermal stability. Vaccine manufacturer’s there-
fore store and transport vaccines under continuous refrigeration (2 – 8 ◦C), known
as the “cold-chain”. This increases the longevity of vaccines but is also a very costly
procedure. Studies have shown several operational problems within cold-chain and
this is reflected in the high prevalence of vaccine-preventable diseases, especially
in developing countries.
This project investigated the application of a previously developed method, ensilic-
ation, to stabilise vaccine proteins with use of silica to prevent thermal denaturation.
This could provide an alternative to freeze-drying (lyophilisation) as some vaccines
use excipients to improve efficacy which makes them unsuitable for lyophilisation.
The ‘sol-gel’ method on which ensilication is based uses an inorganic compound,
tetra-ethyl ortho-silicate (TEOS), to produce a polymer particle which can link around
and interact with biomolecules present in buffered aqueous solution. This protects
against temporal fluctuations in dry powdered form. After storage, the ensilicated
protein can be released using a chemical method that removes the silica shell. Re-
combinant tetanus toxin c fragment (TTCF) was the model protein (antigen) utilised
here to establish the feasibility of vaccine ensilication.
Structural and physical analysis of ensilicated TTCF, pre- (native) and post-
ensilication (released), showed the retention of protein structure and functional prop-
erties. Additionally, in vivo animal experiments confirmed retention of released TTCF
immunogenicity in mice. This included ensilicated TTCF that was subjected to ex-
treme heat, displaying the thermal resilience of ensilicatedmaterial. Finally, synchro-
tron small angle x-ray scattering (SAXS) experiments elucidated the mechanism of
stabilisation. Overall, this study shows a promising application of ensilication for the
development of thermostable vaccines.
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One of humanity’s greatest achievements in reducing microbial infections was the
discovery of vaccines. Dr Edward Jenner (17 May 1749 – 26 January 1823) is the
inventor of the first vaccine1. The word vaccine is derived from the Latin word for
cow, ’vacca’ and was used as recognition of Dr Jenners exceptional work in improv-
ing global health. He studied the transmittance of Variolae Vaccinae, cowpox, from
horses to cows and subsequently to humans. Local farm staff were unknowingly
spreading the disease from horses which were being tended due to a heel infection
in which the virus was present. Without understanding of hygiene, the farm hands
and milk maidens transferred the cowpox virus via their hands to the nipples of cows.
Soon after, those who were infected started producing pustules at the site of infec-
tion. The disease would last for several days until it settled down. Unfortunately, it
was highly contagious and spread quickly to other animals and disrupted daily op-
eration.
The critical observation that Dr Jenner made was the inferred protection these
people gained against smallpox after exposure to cowpox. He studied twenty-three
cases with people of all genders and ages and inoculated them with eﬄuvia (liquid
from pustule) and subcutaneous injection of either cowpox and smallpox infectious
material. Those who previously had been exposed to cowpox and were inoculated
with smallpox displayed some clinical symptoms associated with smallpox but these
did not progress towards the normal severity of this disease. He also inoculated chil-
dren, who had not been exposed to cowpox, with exudate collected from a cowpox
pustule on the hand of farm workers and subsequently tested whether these chil-
dren were protected once exposed to smallpox. He found that all those who were
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exposed to cowpox, either recently or in their younger years were protected against
smallpox.
Thanks to his efforts and of those who improved the smallpox vaccine efficacy, this
disease has been completely eradicated2. However, it should be noted that small-
pox was a human specific pathogen with no additional reservoir species that could
transmit it through the population. It was also a highly stable virus that was not prone
to mutate. The key property of the vaccine was its stability at room temperature and
this was imperative to worldwide eradication.
1.1.1 Cold-Chain: Vaccine transportation
One of the crucial issues with vaccines is the instability they possess. They, as
many biological compounds, are not thermally stable (figure 1-1)3–8. Despite this,
with the success of smallpox vaccinations, the Expanded Programme on Immunisa-
tion (EPI) set out to vaccinate every child before the 1990s. Therefore, the World
Health Organisation (WHO) set out to introduce a straightforward way of increas-
ing vaccine shelf-life, the ’cold-chain’ (figure 1-2). This logistics network, built out of
refrigerated components, would ensure vaccine distribution at 2-8 ◦C from manufac-
turer to patient administration9. As with many large-scale projects, there were and
still are several challenges at hand which cause about 50% of vaccines transported
today being wasted11. In more detail, in 1977, researchers established an action
plan to fulfil the EPI strategy12. Monitoring of vaccine storage conditions was the
first challenge. Initially, refrigeration temperature was recorded by health workers
reading and documenting fridge temperatures. This was a highly unreliable method
and was difficult to maintain. This issue was resolved when cold-chain monitoring
(CCM) tools were developed. For example, blue wax absorption was able to indicate
whether a vaccine had been exposed to heat. Shortly after came an improved ver-
sion: A sticker, containing a polymer, that would change colour after heating and this
reaction could not be reversed. It was a major success that helped health workers
to identify redundant vials. The only obstacle left for CCM was identification of vials
that had been exposed to freezing.
Currently, the cold-chain utilises 30 day digital temperature recorders (30-DTRs)
which can be read at any time. This has drastically improved the vaccine vial monitor-
ing (VVM) system13,14. The following challenges were of infrastructural nature. Elec-
tricity, or the lack thereof, was a considerable problem in the early days. Absorption-
refrigerators used fuel to cool vaccines. Although used, they did not have the per-
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formance to meet the required cooling standard for vaccines. Additionally, due to
problems with the grid, electric-compression refrigerators could not be used as these
would not remain cool for more than several hours. Another challenge was the inter-
mediate forms of small-scale transport. Insulated boxes helped to cool vaccines but
would only last 48 hours. Therefore, engineers developed a way to improve cool-
ing. They lined both normal cooled-boxes and fridges with ice. These cooled-boxes
could now keep vaccines cool up to 5 days and ice-lined refrigerators (ILR) were
able to maintain cooling up to 8 hours without electricity thus making them the ideal
machine to utilise. With the addition of solar panels, the ILRs are now mainly used
in areas with poor infrastructure15.
The last problem with cold-chain is the operators or health workers. Inadequate
handling, documentation and under-staffing has led to significant losses of vac-
cines11. The WHO set up courses and training facilities in order to improve this
aspect of cold-chain. An important development was the shake-test. Vaccine vi-
als exposed to freezing conditions could form ice crystals after being shaken. This
method allowed elimination of those affected vials, instead of using these in immun-
isation programmes with no efficacy. As staffing is a difficult theme to tackle, elimin-Temperature sensitivity of vaccines 
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Figure 1-1: Thermal stability of EPI vaccines. Evident here is the segregation of liquid
and freeze-dried formulated vaccines. DTP and the pentavalent vaccine are both freeze and
heat sensitive. OPV: Oral polio vaccine; MMR: Measles, mumps and rubella; HiB: Haemo-
philus influenzae type b; BCG: Bacille Calmette-Guerin (against tuberculosis); T: Tetanus;
D: Diphteria; wP: whole Pertussis; HepB: Hepatitis B.10
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Figure 1-2: Cold-chain distribution. The logistics of vaccines requires strict conditions.
From factory to patient, temperature must be regulated and maintained between 2-8 ◦C.
The cold-chain is as strong as its weakest link which is situated at the end, the last leg of
vaccine journey. In many cases this is from either a warehouse or hospital to the patients
in difficult to reach areas and therefore require cooled-boxes for transportation which have
limited cooling capability.11.
ating the cold-chain over time with the development of more thermostable vaccines
is one of their main priorities. This will ease handling and prevent errors plaguing
the cold-chain infrastructure.
In 2011 the WHO set up the Global Vaccine Action Plan (GVAP) for 2011-2020. This
’Decade of Vaccines’ was aimed to provide vaccination for all those in need by 2020
and beyond. The WHO set up six guiding principles which would help developing
countries to take charge of their own vaccination programmes10.
A vaccine coverage survey from 2014 (table 1-3) showed high levels of vaccination
in developed regions. However, there are still a number of challenges in Asia and
Africa which have lower levels of vaccination16. Vaccination is most effective against
vaccine-preventable infectious diseases when a high percentage of the population
(80 - 95 %) is vaccinated, providing herd-immunity. This helps to prevent infectious
diseases from spreading within a population17,18. Therefore, attaining high vaccin-
ation levels in communities acts as the first line of defence against epidemics. To
achieve this, vaccines must be readily available, however in many occasions the
distribution of vaccines to and within countries with poor infrastructure is comprom-
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Vaccination coverage
WHO region HepB BD HepB3 DTP3 Hib3 Rota last PCV3 Rubella MCV1 MCV2
Total (worldwide) 38 82 86 56 19 31 46 85 56
African 10 77 77 77 30 50 10 73 11
Americas 69 88 90 90 71 83 92 92 51
Eastern Mediterranean 24 83 82 72 22 45 42 77 66
European 39 82 95 85 7 44 94 94 84
South-East Asia 29 75 84 30 0 0 12 84 59
Western Pacific 80 92 96 21 1 2 91 97 93
Figure 1-3: Vaccination coverage by vaccine and WHO region — worldwide, 2014*.
HepB BD = hepatitis B vaccine birth dose; HepB3 = 3 doses of hepatitis B vaccine; DTP3 =
3 doses of diphtheria-tetanus-pertussis vaccine; Hib3 = 3 doses of Haemophilus influenzae
type b vaccine; Rota last = last dose of rotavirus series; PCV3 = 3 doses of pneumococcal
conjugate vaccine; MCV1 = 1st dose of measles containing vaccine; MCV2 = second dose
of measles-containing vaccine. Numbers represent % vaccine coverage.*Weighted regional
average.16
ised19–21. At present, the incidence of mortality due to vaccine preventable disease,
mainly caused by ineffective vaccine transport, is approximately equal to the number
of lives, 2.5 million, saved by vaccination yearly. Half of the deaths (approximately
1.5 million) are of children aged under 5 years22. This all relates to the share of vac-
cines that loses efficacy during the last stage of cold-chain and accounts for about 45
% of all vaccines transported23. The most recent report on the Decade of Vaccines,
written by a group of experts at request of the WHO, concluded that the aims will
not be met by 202024. This conclusion came from observations that overshadowed
successes gained. Especially, the outbreaks of measles and diphtheria in areas
which held elimination status were major setbacks and displayed a novel difficult
problem24.
Vaccine complacency and hesitancy have been a growing issue over the past few
years25–28. This resulted in pockets of low vaccination coverage in developed coun-
tries and were followed by these outbreaks. Not only these problems influence vac-
cination coverage. The volatile and uncertain political environment in many coun-
tries today affects budget spending on national immunisation programs24. All these
factors combined results into a fragile system of protection. The experts advised




Several published case studies elucidated the weak links, illustrating the problems
within cold-chain. Early investigations into the cold-chain performance in South
Africa showed that vaccines were kept at optimal conditions within a hospital. How-
ever, vaccines were exposed to heat for a longer duration than allowed once they
needed to be sent out to remote locations. It was found that 18% and 90% of the
stored and transported vaccines, respectively, were exposed to heat that could det-
rimentally affect their potency29.
Surveys undertaken to investigate the cold-chain integrity during transportation of
vaccines between Sydney and Hunter, Australia, showed an average temperature to
be above 10◦C. This inadequacy was also found within the storage conditions. Only
25% of the used refrigerators were described to be effective. These reports raised
serious concerns regarding the efficacy of these distributed vaccines30. These con-
ditions were also reflected in rural Tanzania31.
Another investigation focused on trained cold-chain personnel in Madrid and showed
their unawareness of the freezing effect on vaccines32. This was an understandable
outcome for the researchers as much effort had been put towards the prevention
of vaccine exposure to elevated temperatures. They found approximately 50% of
staff to be unaware of the freezing effect on DTP vaccine and only 32% knew how to
perform the vial shake test. The study concluded that more effort should have been
put towards identifying frozen vials.
Freezing was also found to be a serious problem to Hepatitis B vaccine transporta-
tion in Indonesia with 75% of shipments recording temperatures below 0◦C33. The
cold-chain in Bolivia was monitored in an extensive investigation for the DTP-HB-
HiB vaccine21. Shipments to numerous communities from three central stores were
monitored. All recorded shipments displayed freezing temperatures up to 50% of
the shipment duration. In Thailand there was a similar problem at hand. Vaccines
were exposed to freezing conditions, however only mildly. The temperature recor-
ded on average was -0.5 ◦C for Hepatitis B vaccines. The vial shake test confirmed
no damage had been inflicted19. Several other studies showed good vaccine stor-
age conditions, however had infrastructure that needed to be improved or required
additional staff training34,35. Overall, there is a trend in vaccine exposure to heating
in warmer climates. This is then combated with extra refrigeration that over-performs
and inflicts freezing. The solution required is the development of thermostable vac-
cines as this would solve all of the above.
23
1.1.2 Immunology of vaccination
The field of immunology established itself from the efforts undertaken by scientists
working on vaccines36–39. Researchers discovered a vast and complex system of
cells present in human blood which would serve as guardians of the human body.
This was the immune system and it was established that it possessed two main di-
visions: the innate and adaptive immune system40. The former consists of natural
borders such as mucus membranes, stomach acid, skin, ubiquitous proteins and a
number of other factors. The latter was described following the observation that im-
munity was developed after vaccination. Therefore, something must have adapted
or changed within the human body. White blood cells (leukocytes) were discovered
during infection and elucidated to be the active part of the adaptive immune system.
White blood cells recognise pathogens they have encountered before and elimin-
ate such threats. The most important of these is the memory B-cell, a subset of
leukocytes that is responsible for providing latent protection.
During an infection, a pathogen enters the human body and is identified by the ad-
aptive immune system (figure 1-4). Crucial to this process is antigen recognition.


























Lymph node   Spleen        Lung
Tonsils Bone Marrow
Figure 1-4: Vaccine antigen recognition. After vaccination, two major pathways are in-
volved with antigen processing. MHC type 2 and B-cell activation allow for class switching
of B-cells into memory B-cells. These subsequently migrate to the lymphatic system and
remain there to provide latent protection.
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classified as continuous; recognition of a exposed linear sequence in the peptide
chain, or discontinuous; recognition of exposed amino acids formed by native fold-
ing of the antigen41. The latter is found in the majority of antigenic proteins. The
recognition elicits an immune response which is mediated by antibodies42 present
on the surfaces of B-cells43. These cells were named after the Bursa of Fabricius
where they were originally discovered44. Activated B-cells switch to produce a single
kind of antibody45, unique against a specific antigen. Other activated B-cells will pro-
ceed towards a lymph node and linger there. These will keep producing the soluble
specific antibody which will provide latent protection and become memory-B-cells.
B-cell activation can also be achieved when cells utilise the Major Histocompatib-
ility Complex (MHC) as another way for antigen recognition46. The MHC allows
for uptake and processing of foreign proteins which are then presented on cell sur-
faces. These proteolytically cleaved epitopes span around 8 - 11 amino acids and
are recognised by another subset of immune cells, T-cells, matured in the thymus47
(hence T) which mediate the cellular immune response. Specifically, CD4+ T-cells
(T-helper cells) recognise the foreign peptide processed by an antigen presenting
cell (APC) , part of the innate immune system, and recruit more cells to induce an
immunological response. Both pathways are necessary for generating a sufficient
immune response to provide long term immunity.
Vaccination utilises this process by mimicking a natural infection using the immuno-
genic part of the pathogen, thereby inducing both T- and B-cell responses. It results
in the formation of memory-B-cells without clinical disease occurring. The majority
of vaccines consisting of antigens require adjuvants to induce latent protection.
1.1.2.1 Adjuvants
Vaccine adjuvants aid or enhance the development of protective immunity after vac-
cination48. These compounds are necessary for many vaccines that only consist of
antigens compared to those with attenuated (weakened) pathogens. Although anti-
gens themselves may elicit an immune-response this often lacks sufficient immun-
ogenicity, therefore the necessity for adjuvants. Mineral salts, Freund’s adjuvant, oil
in water/water-in-oil emulsions, saponins, particles etc. are examples of adjuvants
used today in various types of vaccines49–51.
In particular, alum (AlOH3) has been used for decades52. The mechanism of action
for this compound is still relatively unknown. It was suggested that the aluminate
gel used in vaccine formulations provided a sustained load of antigen release at
site of injection (also referred as "the depot effect")52. This resulted in improved
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uptake of the antigen by APCs and increased immunological activity around the site
of injection. This initial understanding was amended after several studies found the
depot effect not to be the key event for providing the immune response49,50.
Another type of adjuvant is Freunds’ adjuvant53. This is a crude cocktail of bacterial
fragments created during the purification process previously used in the vaccination
against bacterial toxins. It provides an excellent immunological stimuli but has had
several concerns regarding safety and side-effects.
Oil-in-water/water-in-oil emulsions have exclusively been used as adjuvants in veter-
inary vaccines49,51. Dependent on the formulation somemight cause local reactions
on site of injection, this and other concerns are the reasoning behind the exclusivity.
Adjuvants not only improve immune-response they also reduce the amount of anti-
gen needed, therefore lowering the cost of vaccine manufacturing.
In contrast, there are concerns regarding vaccine stability, specifically alum ad-
juvanted vaccines. This is highlighted in section 1.3.2.
1.1.3 Protein structure
Vaccines come in many flavours as they may consist of proteins, sugars, genomic
structures, viral particles or whole organisms54. Here, focus will be given towards
protein-based vaccines.
Proteins are technically polypeptides, polymers of linked amino acids in a sequence.
Their structure and function is based on the specific arrangement of nucleotides
within genomic DNA that encodes for the amino acids55. DNA, read by specific
enzymes, is transcribed and subsequently translated into a protein using the pro-
and eukaryotic machinery present for this purpose56.
Proteins have four levels of structure57. The linear amino acid polypeptide is the
primary structure. There are 20 different amino acids commonly found in proteins
(figure 1-5). These are subdivided in four groups: non-polar (hydrophobic), polar
(uncharged), acidic and basic. They all possess the fundamental structure of an
amino acid with their specific group, R, attached. This is made of an (alpha)α-carbon
bound with an amino, H3N+ and carboxyl group, COO– with the side-chain R for
defining the amino acid in a tetrahedral conformation. This gives most amino acids
chirality and is due to the asymmetry inherent. Polypeptides are formed by reacting
the carboxyl group of an amino acid with the amino group of another (amide)57. This
forms a (poly)peptide bond with the direction from N- to C-terminus, also known as











































































































































Figure 1-5: Commonly found amino acids in proteins. The conserved model shows the
amino and carboxyl group with specific R-group attached. These can be subdivided based
on their R group as non-polar hydrophobic (orange), polar (green), acidic (red) and basic
(blue).
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(a) peptide bond formation
(b) alpha-helix (c) beta-sheet
Figure 1-6: Polypeptide bond formation and super secondary structures. (a) peptide
bond (amide) formation via the hydrolysis of a carboxyl group with an amino. (b & c) intra-
chain hydrogen bonding (yellow dotted) between oxygen (red sphere) and hydrogen (white
sphere) forms two major secondary structures: α-helix and β-sheet.
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The secondary structure is a convolution of α-helices, (beta) β-sheets and random
coils57. The first two have a major role in protein structure. They are formed by the
intra-chain hydrogen bonding between amino acids. An α-helix is formed of one
polypeptide whereas the β-sheet can consist of two or more (intra- and inter-chain).
Both of these structures are periodic and possess a repetition interval. For alpha-
helices, there is a turn every 3.6 Å. Here, the hydrogen bonding is parallel to the
helix axis and provides the rigidity of this structure.
Within the β-sheet, the peptide backbone is nearly linear. This allows for parallel
or anti-parallel hydrogen bonding, perpendicular to the peptide backbone and forms
a pleated sheet. There are additional regions of combined α-helices and β-sheets
forming super-secondary structures labelled motifs. β- meanders and β-barrels are
two notable ones. Secondary structures influence the tertiary level. Proteins mainly
consisting of either α-helices or β-sheets will form fibrous proteins. Others with good
proportion of both secondary components will form globular structures which tend to
be soluble in aqueous solutions. In comparison, fibrous proteins are insoluble. This
clear distinction evidently shows the influence of peptide backbone arrangement.
Tertiary structure is the conformationally active form of a protein in which it carries out
its function57. Proteins maintain their folding via several factors (figure 1-7). Hydro-
Figure 1-7: Tertiary protein structure factors.(1) Covalent bonding, disulphide bridge
(2) Electrostatic interaction (3) Metal ion coordination (4) Hydrophobic interactions (5) Side
chain hydrogen bonding.
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gen bonding has been related to secondary structures, however within the tertiary
level it plays an important role with the hydrogen bonding of amino acid side chains.
This also involves salt-bridges between amino acid residues and solvent interac-
tions. Charged groups use electrostatic attractions to stabilise the overall protein
structure. This can be between amino acids and ionic ligands present. Hydrophobic
interactions of non-polar side chains on the peptide backbone will obscure them
from the aqueous environment58. This will expose the hydrophilic polar regions to
the solution. Van der Waals (or covalent) bonding, disulphide bridges, will reinforce
the protein structure via conformational restriction. In all, the native state of a protein
is present when the combined energy of all atoms at its lowest. Notably, hydrophobic
interactions are a major factor of protein folding and occur spontaneously, governed
by entropy: ∆Suniverse > 0.
Quaternary structure, the fourth level, is applicable when multiple proteins combine
into one larger structure. This can be applicable for enzymes. The same forces at
tertiary level maintain this structure.
Heating and freezing of proteins leads to protein unfolding (denaturation) by dis-
ruption of hydrogen bonds and weakening of hydrophobic interactions55,59. In both
cases, there is a change of energy that affects the native state of the protein.
1.1.3.1 Thermodynamics of protein folding
The change from polypeptide towards a folded state is associated with the change
in (Gibbs) free energy60 (∆G) which cannot be calculated. However, the change is
measurable using the formula for calculation of ∆G (kJ/mol). This is a combination
of the first two laws of thermodynamics:
∆G  ∆H − T∆S (1.1)
Here, the change in enthalpy ∆H (kJ/mol) is described as the heat of a reaction
at constant pressure. T is temperature, in Kelvin (K), and ∆S (J·mol−1·K−1) is the
entropy of a system. Entropy (S), disorder, can be explained as, for example, the
mobility of a molecule. The more dispersed in space, the higher a molecule’s en-
tropy. The levels of protein structure have various values, with polypeptide having
the highest amount of entropy, decreasing with each increasing level. When ∆G is
negative, a reaction occurs spontaneously and is responsible for the hydrophobic
effect61. This can be achieved when ∆H > 0 & ∆S > 0 or ∆H < 0 & ∆S > 0.
Proteins exist in the folded (F) and unfolded (U) state in solution60. Whether the
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system favours folded or unfolded state, the chemical equilibrium ratio constant K
can be identified by establishing the relationship between Keq and the free energy




relates to ∆G o  −RT ln(Keq) (1.2)
Where R is the gas constant, 8.314 J·mol−1·K−1, T is temperature, in Kelvin (K).
When Keq > 1 the folded state is preferred and when Keq < 1 the unfolded state is
preferred . When Keq = 1, there is an equilibrium between both states and this results
in ∆G o = 0 as there is no change occurring.
Protein unfolding is frequently observed as a two-state transition60,62. This can
be measured using fluorescence, UV absorbance, circular dichroism (CD), nuclear
magnetic resonance (NMR) etc. The output of measurement, F (y), can be plot-
ted against temperature, T (x). The data would allow for calculation of the apparent
equilibrium constant (Kapp) via non-linear least squares fitting of appropriate models.
These could define the heat capacity, ∆Cp, and van ’t Hoff enthalpy change, ∆HVH,
which would provide the heat constant required for the reaction and cooperative units
per mole for unfolding.
Fitting would also accurately define the mid-point of transition temperature, Tm,
which is influenced by buffer composition, changes in folding and other chemical
contributors, and is a key parameter of protein stability.
1.1.4 Vaccine formulation and stability
Vaccines come in two formulations: liquid and dried. Liquid formulations have sev-
eral key parameters which influence protein stability: pH, ionic strength, osmolarity
and excipients57.
pH is simply defined as the 10-base logarithm of [H+] ions in an aqueous solution.
This is applicable to strong acids and bases. pH of a solution defines the acidity or
alkalinity and affects protein folding. Usage of the Henderson-Hasselbach equation
allows for calculating the pH of, for example, a buffer with consideration of weak
bases and acids. It is written as followed:









The [HA] and [A-] are in molar concentration. pKa is defined as the dissociation con-
stant, similar to pH value, at which the acid and basic forms of a particular compound
are equally dissociated in solution. pH influences the protonation and de-protonation
of exposed amino acids invariably affecting hydrogen bonding and salt bridges. Re-
searchers found that pH close to the isoelectric point, the pH at which the protein
has zero charge, maintains native structure. Changes in pH can also have a det-
rimental effect on proteins. The hydrolysis of peptide bonds occurs at low pH and
deamidation at high pH result in chemical degradation which is irreversible.
Ionic strength is defined as the capability of ions in solution to provide a shielding







where the sum of all ions with concentration mi in molar and valency -z2i squared
provides the ionic strength I. The higher this value, the greater the capacity of ions
to mask charges present on proteins that could cause the protein to fold in an altern-
ative conformation.
Osmolarity is related to ionic strength. It is defined as the individual compounds of
a solute when dissolved in an aqueous solution. For example, 1 molar of NaCl is 1
mole of each ion in 1 litre, which is molarity. However, the osmolarity of NaCl gives
each ionic component 1 osmole in 1 litre which gives rise to two osmole in 1 litre
total as Na+ and Cl– are recognised as individual contributors to the solution. This
difference between these two properties accounts for additional aspects of soluble
compounds.
As noted previously, efforts towards stabilising vaccines are mainly aimed at solution
stability. However, vaccines are also prepared in dried powdered form. There are
several methods that are utilised: freeze-drying (lyophilisation), Xerovac™, spray
drying or spray freeze-drying.
Lyophilisation or freeze-drying is the foremost used method in dried preparation of
proteins63–65. Using the triple point of water (0.01 ◦C), a solution is rapidly frozen
to form ice crystals, of which size is dependent on the cooling rate66–68. Under va-
cuum, the frozen water molecules move from solid to gaseous phase, sublimation
takes place (primary drying)69,70. Hereafter, the mixture is further dried to remove
non-frozen bound water attached to the protein (secondary drying)71. The resultant
material has "a cake" like appearance. This procedure can be harsh on many pro-
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teins. Several factors that support native structure are affected by the removal of
water. Concentration, viscosity, ice crystal formation, pH and ionic strength are con-
siderably altered during lyophilisation65,69,71. Therefore, most formulations require
cryo-protectants and other chemical modulators to ensure retention of protein after
reconstitution65.
Xerovac™is a similar technique compared to freeze-drying which utilises a two
staged drying process, without sublimation72. The powder is formed purely using
dehydration with fluctuations of product temperature. It forms a foamy glass-like
matrix. This method was utilised to develop a rinderpest vaccine72–74.
Spray drying is performed as its name75. The mixture of interest is fed into an at-
omiser that sprays small droplets into a drying chamber filled with inert gas. The
dried particles are collected into a glass vial. Spray freeze-drying is identical to
this method with the major difference that particles are formed at subzero temperat-
ures75. Both methods were evaluated for use in developing influenza vaccines that
could be delivered nasally via inhalation76–78.
1.1.5 Stabilising excipients in vaccines
Excipients are added to vaccines for the purpose of increasing protein stability, sol-
ubility, pH control, preventing aggregation and limiting degradation79. There are nu-
merous excipients currently employed for various types of vaccines, both liquid and
dried. Commonly used excipients are: glycine, thimerosal, gelatin, formaldehyde,
Tween-80, sucrose, human/bovine albumin, phenol, glycerol, Triton X-100, formalin
and sorbitol.
Glycine (C2H5NO2, 75.067 g/mol) is an amino acid (figure 1-8) that functions as














Figure 1-8: Structure of glycine and sucrose. (left) A non-essential amino acid. It is the
simplest of amino acids. Regulates osmotic pressure by influencing hydration of proteins.
(right) Sucrose, a form of sugar, lowers the surface tension of water and affects protein in
the same way glycine operates.
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tion80–84 of a protein in solution occurs with the addition of glycine. This favours a
protein to retain its native conformation and is due to the change in free energy of
the solution. Another compound which employs a similar mode of action is sucrose.
Thimerosal (C9H9HgNaO2S, 404.811 g/mol), UIPAC: sodium (2-carboxylatophenyl)
sulfanyl-ethylmercury, is a controversial excipient used in vaccines (figure 1-9).
This compound was developed in the 1930s and brought on the market as Mer-





Figure 1-9: Structure of thimerosal (left) and phenol (right). Preservatives used in vac-
cines. The anti-fungal and antibacterial function of these compounds enhances the lifespan
of vaccines.
bacterial properties that enhances vaccine lifespan. Notably, the incidence of aut-
ism was correlated with the use of thimerosal in vaccines. This publicly accep-
ted conclusion at the time is still debated with many studies showing no evidence
that thimerosal, at its low-dose present in vaccines, is the causative agent92–94. At
higher concentrations, thimerosal has shown to impair neurological development in
vivo95–97. This caused vaccinemanufacturers to reconsider their formulations, either
switching to phenol (C6H5OH, 94.113 g/mol), 2-phenoxyethanol98 or benzethonium
chloride as preservatives. The National Health Service (NHS) in the UK does not
use thimerosal in any of their vaccines during immunisation programmes.
Figure 1-10: Structure of gelatin. Gelatin has protein stabilising capacity which have not
been elucidated.
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Gelatin is another generally regarded as safe (GRAS) stabiliser frequently used in
vaccines99 (figure 1-10). Obtained from the degradation of porcine skin, its mac-
romolecular structure finds its basis from collagen. The mechanism of stabilisation
for (vaccine) proteins has not been elucidated thus far. The use of gelatin has had
some controversy as several individuals have allergic responses towards it. Other
considerations are those of religious reasons.
Sorbitol and glycerol are noted stabilisers used in vaccine formulations100 (figure
1-11). As co-solvents, they increase the aqueous phase viscosity and strengthen
repelling forces between protein particles via electrostatics. This aids to prevent











Figure 1-11: Structure of sorbitol (left) and glycerol (right). Both co-solvents exercise
their function through hydrogen bonding, electrostatics and solute viscosity.
Human or bovine serum albumin (HSA/BSA) is a ubiquitous protein found in blood.
Its function is the trafficking of several ionic ligands around the human body for the
purpose of increasing protein solubility101–103. It also possesses chaperone-like
functionality, preventing aggregation in solution when the environment is exposed
to heat or other physical types of stress. However, there are consequences of us-
ing blood products in vaccines. There is an increased, theoretical, risk of microbial
infection and the European Medicines Agency is pursuing blood product free vac-
cines92,104.
Regardless of these measures influencing vaccine stability, those which come liquid
formulated will have limited shelf life once exposed to temperatures outside storage
conditions.
1.1.6 Efforts in thermostabilisation of vaccines
Stabilisation of vaccines, specifically providing increased thermal resilience, has
been a key topic in vaccine development. One of the earliest reported studies
showed deuterated (heavy) water, D2O, improve the thermal stability of live virus
vaccines105. The authors contributed this to the increased strength between pro-
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tein side chains and deuterium compared to hydrogen bonding. With the addition of
magnesium chloride (MgCl2) they observed an even greater stability and retention
of infectivity106,107. This study was conducted on the three strains of poliovirus used
in the vaccine and was supported by another study which investigated yellow fever
virus108,109.
Magnesium displayed its stabilising capacity in another study which investigated the
thermal stability of lethal anthrax toxin. Here, researchers studied the effect of addit-
ives to improve antigen uptake. They foundmagnesium sulphate (MgSO4) to provide
82.7% recovery of functionality. Other additives showed reasonable values of reten-
tion. The mode of action was contributed to the increase in surface tension and
increased energy for solvent cavity formation. This in effect prevented the expos-
ure of hydrophobic regions present in the anthrax toxin proteins, therefore improved
thermal stability when exposed to elevated temperatures110.
The mechanism of D2O-MgCl2 was elucidated in a subsequent study. It was found
via utilisation of tryptophan fluorescence spectroscopy (295 nm) and circular dichro-
ism of secondary structures. The results showed decreased interaction of the viral
capsid of poliovirus with the aqueous solvent, therefore maintaining native capsid
state. This would prevent deformation when the solvent environment was heated,
thus presenting the thermostabilising effect of this conjugate system111.
All of these findings led to a study that investigated the thermostabilisation of egg
grown influenza virus strains A and B with the utilisation of D2O112. The study found
optimal retention of viral infectivity with use of 90% deuterium oxide. A striking result
was the thermal inactivation of influenza virus with a 2-log reduction of D2O stabil-
ised compared to 7-log decrease in minimal essential medium at 56 ◦C for up to 30
minutes. Researchers proposed three hypotheses for the increase in stabilisation.
The first two have been described earlier which stated the increased strength of hy-
drogen bonding. Secondly, the decreased exposure to the aqueous environment
and thirdly, the suggested effect of D2O on proteolytic enzymes present in allantoic
eggs. This reduced their enzymatic activity due to the presence of D2O could relate
to the survival of a higher percentage of viral particles.
Another study into the stabilisation of protective antigen (PA) of anthrax improved
the formulation design to utilise glycerol and other polyols to prevent aggregation113.
This was found to be the causative event detrimental to the protein when monitored
at 20 ◦C. The half-life of PA increased 6-fold when heated at 40 ◦C in the presence
of glycerol and NaCl compared to no additives. This dramatic increase in thermal
stability was very promising in stabilising the recombinant vaccine against anthrax.
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Researchers developed a novel approach to thermostabilisation of vaccines with
the employment of carbohydrate glass114. This study used sugars such as sucrose
and trehalose, known to aid protein stabilisation, mixed with viral particles in solu-
tion. During drying of this mixture, it underwent vitrification. This formed a sugar-
glass matrix (powder) in which virus was embedded. The study displayed reten-
tion of infectivity up to 6 months stored at 45 ◦C for an adenovector type virus. As
many vaccine manufacturers use adenovirus as a vector based system to produce
pathogen-derived proteins, it suggested a major impact on vaccine production. The
investigators suggest this platform to be suitable for developing countries with poor
infrastructure.
The usage of sugar-glass was extended to the preparation of a porcine reproductive
and respiratory syndrome (PRRS) vaccine115. The researchers employed several
excipients mixed with the live attenuated virus and performed vacuum foam drying
(VFD). With significant increase in thermal stability, the researchers found similar
titres comparable to the commercial lyophilised vaccine.
Another interesting study utilised poly(lactic-co-glycolic acid, PLGA) to form micro-
particles with vaccine proteins embedded116–119. This was aimed to improve drug
delivery while providing enhanced thermal stability. Researchers made micro-
particles that would encapsulate inactivated polio virus (IPV) with required excipi-
ents120. PLGA is made up of glycolic and lactic acid monomers giving it an overall
negative charge. It has been approved by the Federal Drug Administration (FDA,
USA) for usage of vaccine delivery. The micro-particles are made by addition of
protein in aqueous buffer to an organic solvent containing the PLGA polymer. This
mixture is added to a final aqueous buffer containing a stabilising agent which upon
evaporation activates the precipitation of PLGA subsequently forming solid micro-
particles121. Lyophilisation of the formed solution produces the final material. By
varying formulation composition, the researchers achieved a good release profile
with protective levels of immunological markers. These were the first studies where
a polymer was introduced with the intention of vaccine thermostabilisation116,121.
A more recent study into the preparation of buffalopox vaccine investigated the op-
timal formulation for freeze-drying and reconstitution122. Researchers found that the
live attenuated virus in combination with lactalbumin hydralysate and sucrose was
the optimum formulation to be freeze-dried. Reconstitution with identical formulation
showed retention of efficacy after extended storage.
Overall, the development of thermostabilisation strategies for vaccines have become
widespread. From simple molecular osmolytes, polyols and ionic effectors towards
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polymer matrices and micro-capsules it is apparent that researchers are employing
interesting approaches towards tailor made solutions. Unfortunately, these methods
have their own limitations concerning heating or freezing during vaccine transporta-
tion. Especially the strategies for solution stability will have no avail against handling
errors and thermal fluctuations. PLGA and sugar-glass methodologies have shown
to be very promising for future use. However, the production of PLGA using organic
solvents and lyophilisation at the end does raise concerns regarding the retention of
antigen conformation not to mention the energy cost required. Sugar-glass matrices
also present some difficulties. Reconstitution of this material produced some large
fragments which do not dissolve. The researchers aim to use a filter syringe for
injection. Importantly, carbohydrate-glass could be a nutrient source if there is a
microbial contaminant present which would require strict verification of produced
material.
1.2 Silica, an inorganic matrix
Silica, silicon dioxide, SiO2 (60.083 g/mole), has many uses in modern society.
Ceramics, glasses and a range of other compounds are made out of silica. It is the
most abundant form of silicon (Si) found in the earth’s crust which is a semi-metal
on the periodic table. Its electronic configuration is [Ne]3s23p2 with a molecular
weight of 28.086 g/mole. Pure silica is found in nature in the form of quartz, which
grows naturally with a highly crystalline structure. It contains a SiO2 chain giving
rise to the classical helical arrangement of tetrahedral along the channels in one
crystallographic direction. Each turn has three silicon and oxygen atoms with six of
them forming the characteristic hexagonal shape. The exact repetition of this struc-
ture throughout the material defines quartz as crystalline. Glass, used for windows,
contains silica molecules randomly linked with others in a non-uniform pattern that
defines it as an amorphous material. These differences in molecular arrangement
help to classify materials (figure 1-12).
Structurally, silica has a tetrahedral configuration with each tetrahedron consisting of
a silicon atom and four oxygen ions or atoms123. These tetrahedra are considered
almost rigid and have bond angles of 109.5° and Si-O bond distances of 1.61 Å.
Other kind of familiar silicate glasses are borosilicate (Pyrex™) or lead crystal used
for producing wine glasses.
There are also many living organisms who employ silica for survival, defence or
longevity approaches. A few notable ones are; nettles have silicate needles for pro-
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CRYSTALLINE AMORPHOUS
Figure 1-12: Molecular arrangement of silica. (left) Quartz (β-quartz here), the crys-
talline and most common form of silica. (right) Amorphous, random, arrangement of silica
molecules. This material forms common glass used in windows.
tection;124 diatoms make their shells from silica125–127 and tardigrades coat them-
selves in glass to prevent death128.
The use of silica in biological applications showed that silica, utilised via the sol-
gel process, enhances protein stability. There has been extensive research on this
topic with a particular focus on enzymes. The use of silica substrates to drastically
increase the catalytic properties of enzymes has been a key interest of the pharma-
ceutical industry129.
Silica-based materials have gained more popularity in biomedical applications due
to their biocompatibility130. 3D scaffolds for soft and hard tissue regeneration, bio-
molecule entrapment matrices and mesoporous silica nanoparticles are a few ex-
amples131–134.
1.2.1 Sol-gel processing of silica precursors
The start of sol-gel science, around 150 years ago, can be credited to several re-
searchers. The work of Graham (1864) on silica sols135, Ebelmen (1846) on the
production of transparent glass using SiCl4 and EtOH136, Patrick (1912) on the de-
velopment of a rapid sol-gel method to up scale silica gel production137 and Kistler
(1931) who synthesised the first "aerogel"138, a highly porous network of silica. Gra-
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ham was also the first to coin the term "sol-gel".
Sol-gel, short for solution-gelation, is a processing technique that utilises a metal
alkoxide (MOCHx) to form a gelated (gelled, gel) solution139. The sol consists of col-
loidal ( 1-1000 nm) particles in solution. These are formed by reacting metal alkoxide
with water. The subsequently hydrolysed molecules interact with each other forming
larger structures with water and alcohol released as by-products of condensation.
Depending on the precursor molecule, the number of bonds it can form defines
the connected structure. Precursors that have 2 bonds available are bi-functional
and create a linear polymer. This is defined as the macromolecular structure of
monomers attached to one another. Hydrolysed metal alkoxides having more than
2 bonds, poly-functional, can create complex branched 3D structures. This forma-
tion is defined at random and excludes crystalline materials. The gel is formed once
a continuous skeleton of polymer extends throughout the solution and allows for a
semi-solid state. The basis of this is the static aggregate formed by polymer interac-
tions. This display of percolation sets the fundamental theory behind this transition.
Once the gel has formed, shrinkage via evaporation, heating or sublimation creates
different types of materials. Aero-gels, xerogels and several types of ceramics can
be made with this method. Most ceramics formed will be of amorphous nature after
drying.
1.2.2 Ensilication for thermostabilisation
Ensilication, encapsulation in silica, is based upon the acid-catalysed hydrolysis of
tetra-ethyl orthosilicate (TEOS)139. This compound has a central Si atom bound
with oxygen’s linking to a total of four ethyl groups. TEOS is made by dis-
solving SiO2 in HCl which forms silica-tetrachloride SiCl4. By reacting SiCl4
with ethanol CH3CH2OH it undergoes alcholysis and forms TEOS Si(OCH2CH3)4.
Hydrolysis of this compound results in the formation of silicic acid species
Si(OH)4 –n123,139–141(figure 1-13). This soluble form of silica is able to condens-
ate and polymerise with itself under the right conditions. This chemical reaction is
derived from sol-gel technology and has been widely used in many industrial ap-
plications such as the production of silica spheres for use in column packing. In
general, sol-gel is the condensation and polymerisation of a monomeric species to
form particles which link with each other to form a gel. Mixing water and TEOS in a
1:1 ratio and adding HCl as a catalyst results in the hydrolysis of ethyl groups. This
biphasic system will proceed to react until the miscible solutions turn homogeneous.
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• 1. Hydrolysis:
Si(OR)4 + H2O −−→H+ Si(OR)4 –n(OH)n + n(RO)
• 2. Condensation:
2Si(OR)4 –n(OH)n −−→ Si(OR)4 –n –O– (RO)4 –nSi + H2O
Si(OR)4 –n(OH)n + Si(OR)4 –n −−→ Si(OR)4 –n –O– (RO)4 –nSi + n(ROH)
Figure 1-13: Sol-gel chemical reactions. Initial hydrolysis of TEOS mixed with water in an
acidified environment. The subsequent reactions creates particles with water and ethanol
as by-products. R = CH2CH3.
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Our application intends to form nano-particles of protein and silica which stabilise
before the solution gels. This technique physically immobilises the protein inside
silica, rendering it unable to unfold when exposed to heating and freezing. The
silica shell can be later removed using a buffer to dissolve the silica and release
the protein into solution. Added benefit is the ability of performing this technique
at ambient temperatures or lower which favours protein native state. Ensilication is
further described in Chapter 3.
1.3 Tetanus as a model for thermostabilisation
Tetanus is the clinical name of the disease acquired by an infection caused by the
bacterium Clostridium Tetani142–144. This bacterial pathogen is a ubiquitous Gram+
bacillus normally found in soil and the stool of domesticated animals. It has not been
identified within humans. It grows under anaerobic conditions in necrotic or infected
tissues. C.tetani has abilities such as sporulation and motility using flagella. It has
a distinct tennis racket like appearance when it contains a spore (figure 1-14). Its
virulence comes from the exotoxins it produces145. DNA for these are encoded on
Figure 1-14: Clostridium Tetani. A Gram+ bacteria found in soil and animal stool. Infection
with this organism causes tetanus. Source: Centre for Disease Control (CDC).
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a plasmid that is circulated between various strains. The two toxins produced are
tetanospasmin and tetanolysin146–148. The latter destroys healthy tissue, releasing
nutrients which allows the infection to spread. The former causes clinical disease.
Tetanospasmin binds to neurological receptors present on nerve cells149,150. Once
bound, the toxin is internalised by endocytosis and transported to motor neuron cells
in the spinal cord151. Here, it blocks neurotransmitters from being released and this
causes clinical symptoms such as lockjaw152,153. The mode of action is similar to
that of botulism toxin where the toxoid, inactivated toxin: Botox, is used in plastic
surgery154,155. The mode of action of the toxin results in acute spasm. This leads
to death in infected individuals. Treatment of tetanus is not possible, prevention is.
1.3.1 Tetanospasmin, tetanus toxin C fragment
Tetanospasmin has a molecular size of 150 kDa and can be separated into two
fragments156. This two-chain polypeptide has a 50 kDa light chain (L, fragment A)
responsibly for blocking neurotransmitter release at the site of infection and a 100
kDa heavy chain (H) which binds to nerve cells and allows for cell uptake. If the toxin
load is high, tetanospasmin might enter the bloodstream causing body wide symp-
toms. Furthermore, the heavy chain (H) can fragmented in to three segments (figure
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Figure 1-15: Protein segments of tetanus neurotoxin. TTCF is composed of two HC
fragments of 25 kDa. These help binding to ganglioside receptors and mediate cell toxin
uptake.
1-15). These make up a 50- and two 25 kDa fragments. The first fragment at the
N-terminus is labelled HN (fragment B). The second and third are HC-N and HC-C.
These latter two fragments together are named the tetanus toxin C fragment (TTCF)
displayed in figure 1-16. The function of HC-C has been elucidated where HC-N
has yet to be resolved. HC-C is responsible for ganglioside binding and allows the
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Figure 1-16: TTCF 3D structure from the Protein Database Bank (PDB):1A8D.164 Re-
solved structure of TTCF showing the two linked HC-N and HC-C fragments.
toxin to bind with the membrane of peripheral motor axons157–161. As well as stud-
ies into the toxicity and tetanospasmin mode of action, TTCF has triggered interest
from researchers looking at central nervous system diseases such as amyotrophic
lateral sclerosis (ALS, also named motor neuron disease)162,163. In this setting, it is
used as a non-toxic carrier or reporter protein to understand processes occurring in
various stages of this disease.
1.3.2 Vaccination against tetanus
The first vaccine against tetanus was available in 1923 with routine vaccination start-
ing, in the UK, in 1961. At 2 months of age, vaccination is initiated after which a
secondary (booster) shot is given one month after. This second immunisation in-
duces latent immunity. A final booster shot at 5 years of age extends the duration of
immunisation over a longer period. During pregnancy and early neonatal stage, the
infant is protected by maternal antibodies which are passed on from the mother. The
vaccine is routinely administered to children and comes in the form of a diphtheria,
tetanus and pertussis vaccine (DTP)16. However, for people that are bitten by wildlife
there is a tetanus only vaccine available.
The current vaccine for tetanus (DTP, or TT) contains tetanus toxoid. This inactive
form, of the full length neurotoxin containing the TTCF fragment, is created by form-
aldehyde treatment of the protein. It induces multiple inter-chain crosslinkages and
renders tetanospasmin inactive but remains highly immunogenic165. Both TT vac-
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cines contain an alum salt, AlOH3, adjuvant166,167. The purpose of this is to boost
the immune response. However, the adjuvant has a detrimental effect on its thermal
stability during storage and transportation.
Freezing has a particular effect on the aluminium adjuvant which is used in the DTP
vaccine formulation. It causes a morphological change which results in the forma-
tion of conglomerates of adsorbed aluminium168–171. These crystalline flocculates
sediment due to the increase in size each time a freeze-thaw cycle occurs. The
vial "shake test" is the only method to quickly asses vaccine vial freezing. The WHO
studied the freezing times at various temperatures. Researchers found that 110-130
minutes are required at -10 ◦C, 25 to 45 minutes at -20 ◦C, and 9 to 11 minutes at -70
◦C169. Additionally, due to the stationary nature of the vial throughout transportation,
supercooling occurs. Handling of these vials results in increased crystallisation due
to the agitation that is then induced. These effects lower the potency of the DTP
vaccine. It was found that the tetanus toxoid component of the DTP vaccine lost
60% of its potency after three freeze-thaw cycles169,171.
45
1.4 Aims and Objectives
The challenges with cold-chain vaccine distribution have created difficulties in
maintaining storage and transportation conditions. This exposed vaccines to cir-
cumstances beyond the capabilities of added preservatives within the formulation.
Ultimately, it affected and still affects millions of people that receive no protection
from ineffective vaccines. The routinely used DTP vaccine is sensitive to heating
and freezing, therefore a good candidate for thermostabilisation.
This study aims to apply a previously developed methodology, ensilication, to ther-
mostabilise vaccine proteins. Utilising the electrostatic attractions between a pos-
itively charged protein and the negative silicic acid, the goal is to coat the protein
with a protective layer of silica. The research aims to stabilise TTCF, part of the DTP
vaccine, in order to set the precedent for thermostable vaccines via ensilication. The
project is focused on understanding protein stability, mechanism of stabilisation and
the physiochemical analysis of the material obtained. Future outcomes could re-
move the need for vaccine continuous refrigeration. This will be achieved by the
following objectives:
• Understand and assess the native state of TTCF and its biochemical parameters
• Successfully ensilicate TTCF and analyse the material obtained
• Verify the retention of TTCF protein structure before and after ensilication
• Elucidate the stabilisation mechanism via small-angle x-ray scattering
• Measure the influence of silica on the native and released state using calorimetry
• Confirm the retention of immunogenicity in vivo
• Determine the thermal stability of ensilicated TTCF after heating





Described in this chapter is the expression, purification and protein characterisation
of recombinant TTCF. These procedures are well-established and shall be utilised
to prepare TTCF for ensilication.
TTCF is derived from tetanus neurotoxin, a potent lethal protein that disrupts neur-
onal signalling149,150. This pathogenic effect leads to mortality in humans infected
with C. tetani. However, the neurotoxin (tetanospasmin, 150 kDa) can be separated
into two segments. The light (50 kDa) and heavy chain (100 kDa) individually do not
possess the toxic effect155,156. This benefited studies investigating the fragments
to elucidate each respected function154,172. The proportion of heavy chain com-
posed of HC-N and HC-C contains neuron receptor binding regions157–160,173,174
and these segments combined are labelled the tetanus toxin C fragment. It com-
prises immunological targets for the immune system to act against.175 The TTCF
protein contains 452 amino acids with a molecular weight of 52 kDa and has a the-
oretical isoelectric point of 6.83176 (see Appendix A.1 for more information). The
recombinant version has an addition of 10 histidine amino acids for purification177
on a nickel (Ni2+) column, described in detail later. Structurally, TTCF consists of
two large sections, a 25 kDa segment containing 16 β-sheets and 4 α-helices in
a jelly roll motif and another 25 kDa segment containing 10 meandering β-sheets
in a barrel formation157–160,173,174. This information will aid in characterisation us-
ing SDS-PAGE178,179, circular dichroism119,179,180 and ELISA119,161 at all structural
protein levels. Sizing and electrophoretic mobility in solution will be assessed using
dynamic light scattering (DLS). The results gathered from protein characterisation
provide a reference control to compare against after ensilication.
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2.2 Preparation of recombinant TTCF
To prepare a pure monodisperse solution of TTCF, a number of steps were taken.
The preparation comprised of transformation, expression and purification of TTCF.
Each step was analysed using biochemical methods to verify the outcome.
The expression of recombinant TTCF is based on the exploitation of internal bac-
terial machinery (figure 2-1). Usage of the Lac operon and multiple cloning site
(MCS) allowed researchers to incorporate the DNA sequence for TTCF into a bac-
terial vector (plasmid) using restriction enzymes180,181 (figure 2-2). The copied DNA
(cDNA) sequence was optimised previously from native C. tetani to be expressed
in E. coli182. The modified vector, a double stranded DNA ring, can be then taken
up into a susceptible bacterial host. Isopropyl β-D-1-thiogalactopyranoside (IPTG),
a lactose analogue, binds to the lac promoter region which induces an enzyme,
RNA polymerase, to start expressing TTCF protein internally. Additionally, the TTCF
sequence was extended by 10 amino acids situated at the N-termini for purifica-
tion purposes183. The immobilised metal-ion chromatography (IMAC) technology


















Figure 2-1: Schematic of TTCF production. A plasmid containing TTCF is incorporated
in a susceptible E. coli host. Antibiotic screening and subsequent growth in large volumes
is followed by purification using a his-tag binding nickel column.
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2.2.1 Transformation of BL21(DE3) E.coli
The plasmid (kindly provided by Dr. K. Marchbank) was transformed into susceptible
bacteria via the heat-shock approach. This method temporarily makes the bacterial
membrane permeable to favour uptake of the plasmid. Following heat-shock, the
bacterial solution was spotted and distributed on a Luria Broth (LB) agar plate con-
taining ampicillin. This is purely intended for screening as the plasmid contains an
additional gene that enables ampicillin resistance. After overnight growth at 37 ◦C,
the observed colonies that grew had incorporated the plasmid successfully. From
this, a colony was grown in liquid media to make starter stocks for large media preps
for expression.















Figure 2-2: TTCF pET-16b-HisTag vector. The commercial pET-16b-HisTag vector was
cleaved using BamHI restriction enzyme whereafter the 1446 aa sequence of TTCF was
inserted. The plasmid was closed using DNA ligase. Transfection of susceptible E.coli
was screened for antibiotic resistance to confirm the successful transfection after overnight
incubation.
In more detail, the pET-16b TTCF HisTag plasmid was reconstituted from a filter
paper by carefully cutting out the spotted section. This was then incubated with
nuclease-free water in an eppendorf for 10 minutes (min) at room temperature (RT)
to liberate the plasmid. After centrifugation at 13,000 revolutions per minute (rpm) for
1 min, 5 µl was taken and added to a vial of thawed BL21(DE3, Novagen UK) E.coli.
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The heat-shock method involved a 45 second (sec) incubation at 42 ◦C whereafter
the vial was placed on ice. Bacterial medium (LB, 10 g/L Tryptone, 5 g/L Yeast
Extract, 5 g/L Sodium Chloride, Sigma, in ddH2O) was added to the vial and this
was placed into a 37 ◦C incubator with shaking at 200 rpm. Agar plates (LB, 10 g/L
Tryptone, 5 g/L Yeast Extract, 10 g/L Sodium Chloride, 15 g/L agarose, Sigma, in
ddH2O) containing 10 µl/ml of ampicillin were used to plate out the bacterial solu-
tion after a short incubation to solidify the agar . The plates were incubated at 37
◦C overnight and screened for bacterial colonies the following day, which indicated
successful transformation. One of these colonies was then cultured in 15 ml of LB
with ampicillin overnight at 37 ◦C. Stocks were made by addition of 30 % glycerol
and stored at -80 ◦C until further use.
2.2.2 Expression of TTCF
The production of TTCF in E.coli was initiated with an overnight starter culture of
transfectedE.coli in LBmedium (+ampicillin) grown at 37 ◦Cwith 200 rpm shaking for
aeration. The culture was expanded 100-fold in fresh LBmedia containing ampicillin.
This was incubated until optical density (OD) at 600 nm was between 0.4 - 0.6.
At this point, isopropyl β-D-1-thiogalactopyranoside (IPTG) was added to start the
expression of TTCF. The media was then incubated until the OD reached 2 - 2.5.
Thereafter, the dense turbid solution of E.coli was centrifuged at 5000 x g to collect
the bacterial pellets for storage at −80 ◦C or immediately purified.
2.2.3 Purification of TTCF
Following expression of TTCF, the collected pellets were re-suspended in binding
buffer (IMAC25, 0.5 M NaCl : 0.1 M Tris : 25 mM Imidazole, pH 8.0) for immob-
ilised metal-ion affinity chromatography (IMAC). Protease inhibitors (Protease In-
hibitors Cocktail Set VII, cat:539139, CalBiochem UK) were added, 10x diluted, to
prevent protein degradation via enzymatic cleavage. Once homogeneous after re-
suspending, the solution was sonicated (Soniprep™ 150) at amplitude of 10 for
15 seconds with 45 seconds rest, repeated 10 times. This disrupts the bacterial
cell membranes to release the expressed TTCF into the solution. Centrifugation at
20,000 x g separated the cell membranes from the proteins in the solution. The
clear supernatant was collected and filtered through a 0.22µm filter before running
IMAC. This method included use of an Akta™ fast protein liquid chromatography











Figure 2-3: Schematic representation of histidine and imidazole. The imidazole ring
present in histidine allows for protein separation using his-tags as these bind to a nickel
loaded column.
individual pumps trough the system. The sample was connected via a SuperLoop™
injection column with a maximum sample volume of 50 ml. The purification column
used was either a FastFlow™ (cat:17531901, GE, Life Sciences, UK) or High Per-
formance™ (cat:17524701 GE, Life Sciences, UK) nickel sepharose column with a
column volume (cv) of 1 ml. The principle behind IMAC purification is the use of
histidine and imidazole. Histidine contains an imidazole ring (figure 2-3). They both
bind the nickel column. The protocol ran at a flow rate of 1 ml/min. First, the column
was equilibrated with 10 x cv of IMAC25 whereafter the sample was loaded until the
loading column was emptied. Before elution, the column was washed with 15 x cv
of IMAC25. Finally, the elution buffer (IMAC500, 0.5 M NaCl : 0.1 M Tris : 500 mM
Imidazole, pH 8.0) was added at a gradient of 0 - 100 % over 20 cv’s. Fractionation
started at sample injection with a fractionation volume of 3.5 ml which changed for
elution to 2.5 ml. After elution, the column was washed with binding buffer, ultra-
pure water and 20% ethanol for storage. The purification was monitored via the
attached UV absorbance unit which was situated after the column. It measured ab-
sorbance of the solution at 280 nm and confirmed when protein came off the column
before the elution buffer reached 100%. Following peak fraction collection of purified
TTCF, the solution was buffer-exchanged (dialysed) into tris buffer at neutral pH. The
Slide-a-Lyzer™ (cat:87731, G2 Dialysis Cassettes, 10K MWCO, ThermoFisher, UK)
cassettes were used to dialyse a maximum of 15 ml purified TTCF per cassette.
2.3 Analysis of TTCF purification
In order to assess and verify the outcome of each step during the preparation of
TTCF, the following methods were employed for analysis.
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2.3.1 Optical density monitoring of E.coli growth
OD 600 nm measurement is a standard approach to estimate at which stage of
growth the bacterial population is.184 Note that a wavelength of 600 nm is in the vis-
ible spectrum of electromagnetic radiation, e.g. visible light. This allows measuring
turbidity of the bacterial solution. In short, bacterial growth consists of four stages,
the lag, log, stationary phase and eventually death. The OD measurement allows
monitoring of bacterial growth to identify the right phase for induction of expression
and collection of bacterial pellet for further processing.
The spectrophotometer (Biophotometer, Eppendorf) was set tomeasure absorbance
at 600 nm. Blank calibration was done using growth media by adding 0.2 ml in a
transparent cuvette (UVette, Epppendorf) with blurry sides. After blanking, 0.25ml of
bacterial solution was added to the rinsed cuvette and measured. Data was output in
arbitrary units of absorbance (AU). Absorbance is described in more detail in section
2.3.4.
2.3.2 Bicinchoninic acid assay: protein concentration
Bicinchoninic acid, 2-(4-carboxyquinolin-2-yl) quinoline-4-carboxylic acid, assay
(BCA assay) is a colorimetric method to determine protein concentration using UV-
vis absorbance of a formed complex185. This method utilises the biuret reaction
where Cu2+ is converted to Cu1+ via interaction with peptide bonds in an alkaline
environment. The Cu1+ ion then forms a stable conjugate complex with BCA. The
intensity of this formed complex increases proportionally to a determined range of
protein concentration (figure 2-4). Incubation at 37◦C increases the sensitivity of the
method. Copper-sulphate solution is mixed with BCA reagent and added to standard
and sample protein solutions. The absorbance of standardised bovine serum albu-
min (BSA) at 562 nm can be used to calculate the unknown protein concentration
via linear regression and interpolation within the standard.
2.3.2.1 BSA protein standard and sample preparation
To prepare a protein standard for use in the BCA assay, first, 100 µL stock of 2 mg/ml
BSA was diluted with 100 µL 0.2 M NaOH. Four separate other solutions were made
by taking 40, 30, 20 and 10 µL and topping them up to 50 µL with 0.2 M NaOH. This
resulted in a protein standard concentration range of: 1, 0.8 , 0.6 , 0.4 and 0.2 mg/ml
of BSA. In duplicate, 10 µL was added to wells for each concentration respectively.
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Figure 2-4: BCA reaction scheme. Schematic of reactions involved during the BCA assay.
Peptide bonds present in proteins reduce Cu2+ to Cu1+ (left) which forms a stable complex
with two BCA molecules (right). This forms a purple complex which can be read using
absorption spectroscopy.
Samples were diluted 2x, 1:1 with 0.2 M NaOH, 10 µL was added in duplicate.
2.3.2.2 Substrate and data acquisition
Pierce BCAReagent A (8%Na2CO3 ·H2O, 1.6%NaOH, 1.6%Na2 tartrate, NaHCO3
to pH: 11.25) and reagent B (4% CuSO4 · 5H2O) were mixed at a 50:1 ratio. The
resultant green coloured solution is the combination of Cu2+ ions and BCA. 200 µL
was added to each well.
Absorbances were read at 565 nm using a microplate reader (Pherastar FS, BMG
Labtech, UK). The protein standard absorbances were corrected with blank absorb-
ances and fitted with a linear regression y  ax+ b. Samples were interpolated and
adjusted for dilution factors. Results were output in mg/ml.
2.3.3 SDS-PAGE analysis of TTCF molecular weight
Sodium-Dodecyl-Sulphate Poly Acrylamide Gel-Electrophoresis (SDS-PAGE) is a
biochemical method that allows for proteinmolecular weight screening186. It is based
upon the negative charge SDS provides when mixed with proteins.
SDS is a detergent that unfolds proteins, however disulphide (-S-S-) bonds are not
affected by this. Therefore, dithiothreitol (DTT) was used as a reducing agent to
completely denature (linearise) the protein. The gel is made out of polymerised






























































Figure 2-5: SDS-PAGE gel formation schematic. Acrylamide monomers are polymerised
using TEMED as initiator with APS providing free radicals for polymerisation. Crosslinking
of bisacrylamide molecules creates a porous gel type material. Linearised proteins coated
in SDS can move through the gel based on electrophoretic mobility.
conductivity. There are two parts to the gel, a stacking section and a resolving
section. The stacking gel allows smaller molecular weight protein to move faster
downwards into the resolving gel where, as the name states, molecular weights
can be resolved based on electrophoretic mobility. This method allows screening of
various protein sizes dependent on the percentage of acrylamide gel. For TTCF, 10
% is used in all screenings. Samples were denatured at 95 ◦C for a minimum of 5
minutes.
2.3.3.1 Gel preparation
The SDS-PAGE gel was made using a BioRad Mini Protean 3™ cassette assembly
unit. One glass plate with notches on either side was assembled with a flush glass












Figure 2-6: Schematic of SDS and DTT chemical structures. SDS (top) and DTT (bot-
tom) used in sample preparation for SDS-PAGE analysis.
prepared using 5 ml of 30% (w/v) acrylamide, 5 ml resolving gel stock (1.5 M Tris-
HCl, 0.4% (w/v) SDS, pH 8.8), 5 ml double-distilled (dd)H2O, 100 µL ammoniump-
ersulphate (APS) at 100 mg/mL and 8 µL Temed (Sigma, UK).
Iso-propanol was added on top to prevent the gel from drying out during polymerisa-
tion. The stacking gel was prepared using 3.4 ml acrylamide, 5 ml stacking gel stock
(0.5 M Tris-HCl, 0.4% (w/v) SDS, pH 6.8), 7.5 ml ddH2O, 100 µL APS at 100 mg/mL
and 20 µL Temed and was cast after discarding the iso-propanol and washing with
deionised water (figure 2-5).
2.3.3.2 Sample preparation, electrophoresis and staining
A 10-well comb was used to create slots in the gel. These hold up to 30 µL of
sample volume. To normalise samples on the gel, 1 - 5 µg (w/v) was added to lanes
for molecular weight screening. Each sample consisted of sample, sample buffer
(Leamli buffer) and 0.1 M DTT (10% volume). After incubating at 95 ◦C for 5 - 10
minutes, samples were inserted into sample wells (figure 2-6).
Once the sample and gel were prepared, the assembly was put into a container
and filled with running buffer (0.025 M Tris-HCl, 0.1% (w/v) SDS, 0.2 M glycine,
pH 8.3). When all samples were loaded, a protein standard containing reference
molecular weight proteins was pipetted into a sample well. This is used to identify
molecular weights. The gel was run at 200 V for 35-45 min, which was indicated
by the sample tracking dye reaching the bottom of the gel. The gel was removed
from the cassette and placed into a plastic container before washing several times
to remove buffer traces. Thereafter, PageBlue™ a staining solution, was added to
the gel and incubated for either 1 hour or overnight at room temperature.
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2.3.4 UV-visible spectrum analysis of TTCF
Ultra violet (180-400 nm) - visible spectrum (400-700 nm) spectroscopy is a method
based on absorbance (or transmission) of a conjugated compound188. This can be
in gaseous, liquid, aqueous or solid phase. Light, electromagnetic radiation, has an
energy Eh·f where h is Planck’s constant, f the frequency of light. f can be found
in the relation cf ·λ (c: speed of light, λ: wavelength in nanometre). Combining
these formulas gives rise to:
E  h × c
λ
(2.1)
Here, there is a clear correlation between the energy and associated wavelength.
Lowering the wavelength results in a higher energetic transition occurring. Aromatic
amino acid residues present in proteins such as tryptophan, tyrosine and phenylalan-
ine are conjugate systems with molecular orbitals. The principle behind UV-vis is
the molecular electronic shift from highest occupied molecular orbital (HOMO) to
the lowest unoccupied molecular orbital (LUMO). These can be indicated as aro-
matic pi− > pi* transitions. Only transitions between similar types of bonds can
take place. The spectrophotometer is able to identify compounds based on their
maximum absorption at specific wavelengths. Using the Beer-Lambert law:
A  ε × c × l (2.2)
where A: absorbance (arbitrary), ε: molar absorption coefficient, c: concentration
g/L (or mg/ml), l: path length (in M or cm), accurate measurements can be made
depending on purity of the samples. Protein absorbance is normally measured at
280nm.189
Sample volume of approx 2-3 ml was pipetted into a UV-vis polystyrene cuvette.
Spectrum analysis depended on the type of sample which was either liquid or
powder. The spectrophotometer (Lambda 650S, PerkinElmer, USA) was setup to
record the spectrum. Data were output in arbitrary units of absorbance.
2.3.5 Circular Dichroism of TTCF secondary structure
CD is a method based on far-UV (180-260nm) or near-UV (260-320 nm) absorp-
tion of optically active chiral molecules, such as proteins190–192. Chirality is defined
by asymmetry of the absorbed polarised rotational light, left and right-handed.
The absorbance (Beer-Lambert) from each rotational direction, at a set range of
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wavelength, is subtracted CD = Ar − Al and in combination with the Beer-Lambert
law gives rise to ∆A  ∆ε · c · l. Another form of output is ellipticity which relates to
absorbance by a factor of 32.98, θ  32.98 · ∆ Abs. This is commonly associated
with reporting CD data. Molar ellipticity [θ] takes protein concentration, path length,
and molecular weight into account and allows normalisation.
2.3.5.1 Sample preparation
TTCF was dialysed into 10 mM sodium-phosphate buffer at pH 7.0. The stock solu-
tions: 0.2 M NaH2PO4, MW:119.98 g/mol and 0.2 M Na2HPO4, MW:141.96 g/L in
100 ml ultra-pure H2O were combined by adding 57.7 and 42.3 ml of each volume
respectively in a bottle and filling up to 1L with ultra-pure water. Protein concentra-
tion was adjusted to above and near 0.2 mg/ml. pH adjustments were avoided as
chlorine ion interferes at low wavelength.
2.3.5.2 CD measurement and processing
The (Jasco) Chirascan was used to record the far-UV CD spectra for TTCF. The
machine was equilibrated for 30 min with nitrogen gas pumping through the system.
Following this was initiation of the water bath, temperature controller and switching
on the system. Finally, the lamp was ignited and let to warm for 15 min. Using a
quartz cuvette (1 mm, Starna Scientific, USA), with a path length of 0.1 cm, 400 µL
of sample was inserted into the sample space of the cuvette. This was then placed
into the sample holder and a spacer was inserted to hold the cuvette in place. The
program output was set to millidegrees with a selected wavelength from 260-185nm.
As this method is non-destructive to protein samples, multiple scans were recorded
and averaged to increase quality. Bandwidth was set at 2 nm, step at 1 nm with
active background subtraction (buffer only). Output files were converted to workable
format. CD data in millidegrees were converted to delta epsilon (∆ε) values via:
∆ε  θ × (0.1 ×MRW)(p × c) × 3298 (2.3)
where θ: measured data in millidegrees, p: path length in cm, c: concentration
in mg/ml and MRW : mean residual weight = protein mean weight in atomic mass
unit (daltons) divided by the number of residues. This allowed for normalisation and
comparison of samples.
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Figure 2-7: Schematic of ELISA for detection of TTCF tertiary structure. Bound TTCF
was detected using a specific antibody. Binding of this antibody is measurable by using a
secondary antibody conjugated with a reporter enzyme. The substrate conversion is meas-
ured using UV-vis absorbance.
2.3.6 ELISA of TTCF immunologic properties
Enzyme Linked ImmunoSorbent Assay (ELISA) is based on the antibody recogni-
tion of complementary amino acid sequences (or epitopes) present on the target
protein161,193,194. In many cases, this can be only detected when the tertiary struc-
ture of the protein is in native conformation or near native state. As a result, the
ELISAmethodology is sensitive to changes in tertiary structure and is an appropriate
technique to analyse released protein structure. 96-well high biding microtitre plates
(Greiner, USA) were coated with native TTCF, released TTCF, released heated TTCF
and denatured TTCF at 1 mg/ml, 100 µl / well and incubated at 4 ◦C overnight. The
following day, the plate is incubated with, in chronological order, blocking agent, spe-
cific detecting antibody, secondary antibody conjugated with reporter enzyme and
substrate. Substrate conversion is timed and stopped with acid (figure 2-7). This
signal can be read using absorbance and plotted versus concentration or dilution.
2.3.6.1 Analysis of TTCF
TTCF at 1 mg/ml was diluted to 10 µg/ml in 50 mM bicarbonate buffer (NaHCO3,
Na2CO3) at pH 9.6. This solution was added to a high binding 96-wells microtitre
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plate, 100 µl/well and incubated overnight at 4 ◦C. This results in 1 µg of TTCF to
be bound to bottom of the well. Following day, the plate was washed 3 times with 1x
phosphate buffered saline (PBS) and incubated with 1% casein in PBS + Tween20
(0.05%) for 1 hour at room temperature. Washes were repeated and a monoclonal
antibody against TTCF binding sites (10G5161) was serially diluted two-fold. Starting
at 1 µg/ml, 100 µl was added to each well vertically and incubated for 1 hour at
RT. Washes were repeated followed by the addition of a goat-anti-mouse IgG
horseradish peroxidase (HRP) enzyme conjugated antibody in 1:10,000 x dilution
(PBS + 0.05 % Tween20) for another hour. Substrate solution was prepared during
this incubation. 5’-5’ tetra-methyl-benzidine (TMB, Sigma, UK) was dissolved in 1
ml of dimethylsulfoxide (DMSO, Sigma, UK) at 10 µg / ml and 100 µl was added
to 10 ml of 0.1M sodium acetate pH 6.0 with addition of 1.5 µl of 30% (v/v) H2O2.
The plate was washed 4 times after 1 hour incubation and tapped dry. Substrate
solution was added to each well, 100 µl/well, and left to develop for approx. 10
minutes while the enzyme converted substrate into a blue colour. 2 M sulphuric
acid H2SO4 stopped the development. The microtitre plate was read using a plate
reader at 450 nm with samples accordingly blanked after measurement.
2.3.7 Dynamic Light Scattering (DLS) of purified TTCF
DLS, also known as Photon Correlation Spectroscopy, was utilised to measure the
protein dimension in solution. This is based on the refraction of laser illuminated
particles, at particle angle θ, in solution that move according to Brownian motion.195
It is able to measure as little as 0.1 nm particles. This methodology combines the
measured scattering intensity with the electric field equation and allows the Stokes-
Einstein equation to be used. The scattering intensity correlation function g2 meas-
ures the intensity, I, of a particle at a time, t, over a period τ. The signal changes in





This, in an ideal situation, can be a single decay relating to a monodisperse solution
containing 1 type of uniform particle. The equation can be correlated to create the
Siegert relationship combining the second order function with a first order autocor-
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relation function g1.
g2(q; τ)  1 + β[g1(q; τ)]2 (2.5)
The measured g1 function can be fitted with an exponential decay. Here, Γ relates to
the diffusion coefficient Dt based on the scattering wave vector q. In this equation,
λ is the laser (HeNe) wavelength at 632.8 nm, n0 is the sample refractive index, θ
is the angle of detector location oriented from the sample.










Once the diffusion coefficient is calculated, this can be inserted into the Stokes-
Einstein equation. Where η: viscosity in cP, κB: Boltzmann’s constant, T: temper-




It is a very effective method to look at protein size in solution and is sensitive enough
to detect buffer effects or protein unfolding. This method was applied to verify a
monodisperse solution of column-purified TTCF.
Zeta potential is obtained frommeasuring the electrophoretic mobility (µe) in solution





whereV = particle velocity (µm/s), E = electric field (Volt/cm). This can be processed




where εr = relative permittivity/dielectric constant, ε0 = permittivity of vacuum, ζ =
zeta-potential, f (Ka) = Henry’s function and η = viscosity at experimental temper-
ature.
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2.3.7.1 Sample preparation and measurment
TTCF was analysed for size and zeta potential. Both measurements required spe-
cific sample cells. Polystyrene cuvettes (ZEN0040, Malvern Instruments, UK) were
used to measure native solution. Zeta potential measurements were carried out
in folded capillary cells (DTS1060, Malvern Instruments, UK) with gold-plated elec-
trodes on each side of the channel196. These conduct a small charge through the
solution and cause particles to move in the direction of neutral charge. This motion
was recorded and correlated with a zeta value. The consensus indicates a stable
particle to have a zeta potential >+40 mV or <-40 mV. Particles that fall between
this range are susceptible to aggregate with the most unstable particle charge to
be around 0 mV. TTCF in buffer at 1 mg / ml was centrifuged at 16,000 x g for 20
minutes to remove any particles that could interfere with the measurement, such as
dust.
The NanoSizer S (Malvern Instruments, UK) was used for measurements. The ac-
quisition protocol is set to measure 10 seconds of counts for 3 repeats. Outputs in
size by volume and size by intensity.
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2.4 Results & Discussion
2.4.1 OD 600 nm E.coli monitoring
A colony of transformed E. coli was taken from an ampicillin containing agar plate
and incubated overnight in 20 ml of LB media at 37 ◦C. The next step involved
incubating a larger volume of media, 500 ml per flask (total of 3) with the transformed
E.coli and monitoring the bacterial growth using OD 600 nm measurements. The









OD [600nm] BL21(DE3) E.coli
Figure 2-8: OD 600nm measurement growth of BL21(DE3) E. coli. Growth curve shows
optimal induction stage between 2-3 hours.
optical density monitoring of the initial run (figure 2-8) displayed the time window of
induction to be between 2-3 hours. This time was taken from the moment E.coli was
added to the growth media. Small sample volumes (0.5 ml) were taken at induction
and then at hourly intervals following until pelleting and storage. The samples were
prepared for molecular screening as described earlier (section 2.3.3.2) and run on
an SDS-PAGE gel.
2.4.2 TTCF expression verification
The expression of TTCF was confirmed via SDS-PAGE analysis (figure 2-9). The
visible increase in intensity of a protein band at approximately 50 kDa represents the
expression of TTCF over time. Each lane corresponds with a time point in hours. All
samples were normalised and 10 µg was used for each sample. The concentration
was determined using the BCA assay.
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Figure 2-9: SDS-PAGE analysis of TTCF expression. Samples taken during the OD 600
nmmonitoring of E. coli growth and induction were analysed using SDS-PAGE. At T=0, IPTG
was added to induce TTCF expression.
2.4.3 TTCF purification analysis
Subsequently, the collected bacterial pellets were processed to release the TTCF
and the supernatant was run over a his-tag binding nickel column. The chromato-
graph (figure 2-10) displays the several stages of the automated purification protocol.
Important features are:
• Increase in absorbance (mAU at 280 nm) during sample injection (in IMAC25).
• Returning to baseline (UV 280 signal) after sample injection, ending the
column binding phase.
• Single peak elution appearing after the concentration of reservoir B (IMAC500)
reaches the critical level to out-compete histidine binding.
• Baseline return after full elution and re-equilibration.
• Peak fractions were collected and pooled for dialysis in 50 mM Tris at pH 7.
Samples were collected during each of the purification steps. The protein concentra-
tion of these was determined using a BCA assay, interpolating the unknowns using
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Figure 2-10: AKTA chromatogram of TTCF purification. Signals represent (blue) UV
absorbance at 280 nm, (green) % elution buffer, (red) fractions taken. The peak elution
seen after the wash contains TTCF protein.
a BSA standard fitted with a linear regression (figure 2-11). Samples were analysed
on a SDS-PAGE gel to determine whether optimisation was needed.








Figure 2-11: BSA standard used in BCA. Bovine serum albumin (BSA) standard with fitted
linear regression. This was used for interpolating unknown samples in the BCA assay.
The BCA analysis showed an overall reduction in protein concentration (table 2-1)
with detectable levels of purified TTCF protein. There are clear distinctions between
different stages visualised in the SDS (figure 2-12). The reduction of bands through-
out the purification process indicated the successful removal of unwanted proteins.
The purified TTCF showed a thick band at 50 kDa in the peak fraction sample. It
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# sample description dilution mg/ml final conc. (mg/ml)
1 T=0 (hr) IPTG added - - -
2 T=5 (hr) IPTG 4.6 based on OD -
3 Resuspended sonicated pellets 100 0.29 29.25
4 Supernatant (after sonication) 10 1 10.03
5 TTCF peak fractions A10-14 (Akta) 2 0.43 0.85
6 Flow through (Akta, unbound) 10 0.43 4.29
7 TTCF dialysis / 50 mM Tris pH=7 2 0.48 0.95
Table 2-1: Protein concentration of intermediate purification steps. BCA analysis of
samples from protein expression to purified TTCF solution.
Figure 2-12: SDS-PAGE of TTCF expression and purification. Horizontal numbers rep-
resent samples from table 2-1. Vertical numbers represent molecular weights designated
by the ladder.
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presented some extra faint bands. However, with the small amount of protein loaded
on to the gel there was no cause to add another purification step. The results con-
firmed that the process successfully purified TTCF and removed the majority of non-
his tag proteins from the supernatant.
2.4.4 Circular Dichroism of native TTCF
After purification and dialysis, 1 ml of native TTCF was buffer-exchanged into so-
dium phosphate (10 mM Na2HPO4, NaH2PO4, pH 7) for CD measurement. Buffer-
exchange was achieved using a desalting column (PD-10, ThermoFisher UK). Tris
buffer and chlorine ions present interference in CD and were therefore not used as
solvent or for adjusting pH. Triplicate CD scans of native TTCF (0.2 mg/ml) from 260-
180 nm displayed consistent results (figure 2-13). The averaged TTCF CD pattern








Figure 2-13: Circular Dichroism of native TTCF. Delta epsilon calculated from conversion
of measured ellipticity in millidegrees. Conversion variables were the Mean Residual Weight
(53545 da / 467 aa), path length of 0.1 cm and concentration of 0.286mg/ml. Triplicate scans
were conducted before conversion.
obtained is a combination of various secondary structural levels. This absorption of
polarised rotational light at far UV wavelength was used as a signature reference for
native TTCF. The signal is composed of alpha helices, beta sheets and random coil
absorbance. More on the deconvolution of TTCF CD patterns described in Chapter
6.
2.4.5 DLS & Zeta of native TTCF
DLS of native TTCF in Tris buffer proved to be challenging. Many adjustments were
attempted until a sample was obtained of high purity and dust free. Centrifugation
66
and filtration were used to obtain an appropriately clean sample. Themeasured scat-
tering of TTCF in solution (figure 2-14) was a single exponential decay that reached
baseline after a short amount of time.The diffusion coefficient was calculated using









































Figure 2-14: Dynamic light scattering of native TTCF. (top) Dynamic light scattering cor-
relogram, (bottom) size by intensity and volume plots. Measured correlation coefficient and
processed output for native TTCF. Sizes displayed are 8.235 d.nm (± 2.424 SD) and 6.454
d.nm (± 1.832 SD).
the apex of decay and put through the internal SOP for calculating size by intensity
and size by volume. Values obtained indicated the average hydrodynamic diameter
(d.nm) for TTCF to be 7.345 ± 2 (d.nm). The hydrodynamic size accounts for the
protein and solvent layer present in solution. The difficulty of obtaining a clear clean
sample for sizing was explained by the zeta-potential measurement of TTCF. Result-
ing value for the electro-kinetic mobility of TTCF was 3.54 mV. This indicates TTCF
at neutral pH in Tris buffer will flocculate or aggregate over time.
2.4.6 ELISA analysis
Up to this point, native TTCF was analysed based on its molecular weight (primary
structure) and chirality (secondary structure). This method allows analysis of con-
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formational structure, tertiary level. Here, TTCF was coated on a microtitre plate.
Then a detection antibody, 10G5, was used. If the right complementary exposed
amino acid residues were present in native conformation, this protein would bind
TTCF. Following this, the reporter antibody allowed for substrate conversion. This
would relate to the concentration of bound antibody. The graph depicts a dose re-


















Figure 2-15: ELISA of TTCF. Converted substrate absorbance at 450 nm based on the
antibody binding capacity of native TTCF.
of antigenic epitopes necessary for antibody binding. As TTCF is an antigen, this
correlates directly to its function. Therefore, it was assumed that TTCF was ex-
pressed and purified in native state. Blank wells were used as control. These wells
contained TTCF but no primary antibody was added during the analysis. This would
help elucidate if any of the secondary antibody would bind. No detectable signal
was obtained from these samples. With this evidence it was safe to interpret that
the signal displayed was that of specific TTCF binding. Additionally, the 10G5 an-
tibody did not work when the protein was analysed using Western Blot (described
in 5.2.2) which requires denatured protein for analysis. It can therefore be inferred




TTCF is the heavy chain, 52 kDa, sub-fragment of the full tetanus neurotoxin pro-
duced by the bacterium Clostridium Tetani. The immunologic epitopes that will in-
teract with the human immune system are found in each of the fragments of TeNT.
Fragment A, the light chain, contain epitopes, P12 (amino acids 233–248) and P13
(amino acids 225–243), found in its zinc (Zn) binding domain197. These are recog-
nised by T-cells after processing using the MHC type I and II pathways198. B-cell
recognition was found for epitope P13198. Fragment B, the heavy chain (N-terminus
region), has seven T-cell epitopes199–201. Fragment C, TTCF (HC-N and HC-C), has
3 epitopes which monoclonal antibodies bind, B-cell specific202. It was found that
antibodies binding fragment A and C were potent neutralizing antibodies compared
to fragment specific antibodies as fragment C is responsible for receptor binding
and translocation of the light chain202. Split into fragments, they do not possess the
synaptic properties that make the whole tetanus toxin lethal180. Therefore, TTCF is
an ideal protein to be studied. Additionally, TeNT is a secreted protein which makes
it relatively more stable in solution. Researchers were able to incorporate the gene
into a bacterial plasmid. This enabled high yield expression of the protein for struc-
tural analysis181. The first part of the study was to investigate the structural and
functional properties of TTCF in buffered solution before progressing towards stabil-
isation in silica, ensilication.
Firstly, reporter genes were utilised to verify the transformation of susceptible E.coli.
Then the expression was verified using SDS-PAGE molecular weight screening and
this agreed with published results178. This indicated the increasing amount of a pro-
tein band at the expected molecular weight. Passing this sample through various
purifications steps led to a purified TTCF sample. Usage of column chromatography,
BCA assay and SDS-PAGE allowed visualisation of the purification process. After
this stage was completed, TTCF was dialysed into tris buffer which is a widely used
standard biological buffer. At neutral pH is where most proteins display their mode
of action.
Subsequently, progress was made towards analysis of secondary and tertiary pro-
tein structure. CDmeasurement displayed the native conformation of TTCF in agree-
ment with literature180. The pattern measured is a convolution of several secondary
structures. For the tertiary structure, ELISA analysis was conducted. It revealed
good binding of a specific antibody against TTCF and was similar to other studies161.
Binding of antibodies to an immunogenic protein directly correlates with its structural
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integrity and function. Therefore, it was safe to say the immunogenic properties were
present. Finally, scattering and absorbance analysis of the purified protein revealed
monodispersity and presence of aromatic amino acids. In summary, TTCF was pro-






Ensilication is a methodology that utilises silica to stabilise proteins203. It is based
on solution-gelation139 (sol-gel) where condensation and polymerisation of a mono-
meric species form particles. These then link and form a gel. Ensilication is per-
formed by adding soluble silica, hydrolysed TEOS to a buffered solution contain-
ing protein of interest. Stabilisation is achieved by polymerising silica that attaches
electro-statically around these proteins, forming nano-particles. After a specific dur-
ation of time, the solution is vacuum filtered and dried at room temperature. The
dried nano-particles in powdered form contain the protein. This ensilicated material
can then be stored at room temperature and subjected to various thermal fluctu-
ations, established previously203.
Previous work on ensilication included studies using lysozyme, haemoglobin and
insulin203. The result of these investigations determined this methodology to be ap-
plicable for a range of different proteins. The current "gold standard" in industry
of protein preservation is freeze-drying (lyophilisation)63–65. This method freezes
the sample in solution, then uses vacuum pressure to sublimate water molecules.
Material that is lyophilised changes into a powder that can be stored at room temper-
ature69–71. However, there are a number of protein based compounds that cannot
be lyophilised. Many biopharmaceuticals, such as vaccines containing adjuvants,
cannot be freeze-dried as this renders them unusable. Therefore, ensilication is an
interesting alternative to employ.
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3.2 Ensilication of TTCF
Once a pure mono-disperse solution of TTCF was produced and characterised, the
next step was to apply ensilication to this protein. The isoelectric point (pI or IEP) is
a key protein parameter in ensilication. TTCF has a theoretical IEP of 6.83 (pH)176.
TTCF in tris buffer was identified to have a zeta potential (zp) of 3.54 mV196. If the
zeta potential comes close to zero in difference with the IEP it will cause floccula-
tion or aggregation of particles in solution. The ideal situation is to have the IEP
and zeta potential as far apart possible. This is because zeta potential is an im-
portant parameter of dispersion stability196, IEP is the surface charge of a particle
at neutral pH176. Zeta potential can be influenced by buffer composition. Ensilica-
tion requires tris buffer at pH 7.0 with no sodium present (figure 3-1). Sodium ions
interfere with ensilication as it is a positive ion139. The aim of ensilication is to dir-
ect negatively charged silicic acid towards positive residues on the proteins205,206,
Figure 3-1: Sol gel time and stability. Gel time is relevant to ensilication. At pH 7 there is
a boundary between rapid aggregation and particle growth. The particles formed are stable
at this pH which also favours native protein state.204
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these are lysine, arginine and histidine57. Analysis of TTCF using bioinformatics
indicated the presence of these residues on TTCF176. By taking the PDB model,
1A8D164, of TTCF, calculations207 were able, using the adaptive Poisson-Boltzmann
solver208,209 (APBS) software, to create and overlay an electrostatic map (figure 3-
2) of the protein. Regions positively charged are indicated in blue and negative in
red. This visualised whether there were clustered positive or negative charged re-
gions. The simulated model indicated multiple positive regions which aligned to the
presence of said amino acid residues. Therefore, it was decided that TTCF is a vi-
able candidate for ensilication. This protein is also a realistic model to use as it can
determine whether vaccine proteins could be compatible with this method. It could
then be a stepping stone for future projects to build upon.
(a) (b)
(c) (d)
Figure 3-2: APBS simulated electrostatic model of TTCF with amino acid comparison.
(a & c) Front and back view of the simulated electrostatic map of TTCF. Blue and red indicate
postive or negative charged regions, respectively. (b & d) Blue and light-blue regions indicate
the presence of lysine and arginine respectively.
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3.2.1 Buffer preparation
The established protocol for ensilication requires 50 mM of Tris buffer at pH 7.0
with no sodium present. Therefore, 3.03 g of Trizma-Base (MW: 121.14 g/mol, cat:
T666-1kg, Sigma UK) was weighed out to make 500 ml buffer. In a beaker, 400 ml
of ultrapure (MilliQ, MilliPore UK) water was added to the weighed Trizma and using
a magnetic stirrer this was dissolved. The pH was set using 32% (v/v) hydrochloric
acid. Finally, the solution was filled up to 500 ml final volume with ultrapure water.
3.2.2 Hydrolysation of TEOS
In a glass beaker, 20 ml of TEOS (cat:86578-1L, Sigma UK) was added to 20 ml of
ultrapure (MilliQ) water with stirring at 350 rpm at room temperature. Hydrochloric
acid 32% (v/v) was added to this solution in a 1:500 ratio to initiate the acid catalysis
of TEOS into Si(OH)–4 . Once both components formed a clear homogeneous solu-
tion, ethanol was evaporated with slow stirring (60 rpm) for 20 minutes. The solution
was then ready to be used within a window of 20 minutes.
3.2.3 TTCF ensilication
Several batches of ensilicated TTCF were made (figure 3-3). On average, a volume
of 15 ml TTCF at 1 mg / ml was used. The volume of pre-hydrolysed TEOS added
to the protein solution was determined by the volume provided from TTCF expres-
sion and purification. Total time of reaction was optimised and set to 15 minutes.
Figure 3-3: Schematic of ensilication. Hydrolysed TEOS is added to a buffered protein
solution. Condensation and polymerisation of silica species around the protein grow over
time and particles developed. The solution that becomes turbid over time is vacuum filtered
and collected. After ambient storage, the samples are released for protein stability testing.
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Figure 3-4: Stages of ensilication. Protein solution (translucent) becomes turbid after
ensilication.
The sample was collected using a Buchner funnel containing a glass wool fibre pad
filter with a size cut-off of 0.03 µm. After drying for 48 hours at room temperature,
the material was scraped and collected into an eppendorf tube (figure 3-4). Small
sample weights, 1 - 5 mg, were used for further analysis.
3.3 Release of ensilicated TTCF using NaF
Removal of silica from ensilicated TTCF, release, was performed using a previously
developed method203. Sodium fluoride (NaF) in water acidified with HCl to pH 3.0
forms hydrofluoric acid, HF– 210. This compound is highly reactive to oxygen species
due to its electron-negativity. In water, it forms an azeotrope with a boiling point of
120 ◦C. The following scheme displays the dissolution of silica using this method210.
1. Release buffer: NaF + HCl
ultrapure H2O−−−−−−−−−→ Na+ + Cl– + HF– (aq, pH 3.0)
2. Added to ensilicated material: 4 HF– + SiO2 −−→ SiF4 + 2H2O (aq)
3. Intermediate I: SiF4 + 3H2O −−→ H2SiO3 + 4HF– (aq)
4. Intermediate II: 2 SiF4 + 4HF– −−→ 2H2SiF6 – (aq)
5. Total = 3 SiF4 + 3H2O −−→ H2SiO3 – + 2H2SiF6 – (aq)
The final products are ortho-silicic acid and hexafluorosilic acid. HF- will be com-
pletely converted during this process. The final complexes are stable and there-
fore allow safe handling of the released sample. Previous investigations using NMR
spectroscopy have confirmed no silica to be left after subsequent dialysis of released
protein203.
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3.4 Visualization of ensilicated TTCF
Ensilicated TTCF was collected by scraping the filter paper on which it was filtered.
Due to the small volume of ensilication, much care was taken to obtain the ensilicated
material.
3.4.1 Field Emission - Scanning Electron Microscopy
FE-SEM211 was used to image the dried final material after vacuum filtration. This
technique is based on electron microscopy (EM). Here, a conductive filament (e.g.
Tungsten) is put under high current until it emits electrons. These are passed through
magnetic coils that redirect it onto the sample. Electrons have elastic and inelastic
interactions with the sample. The first describes backscattering electrons at an angle
greater than 90° which are deflected by the material off the incident beam211. The
latter describes excitation of the sample that results in secondary electrons with a
lower voltage. These two types of interactions allow FE-SEM to topologically map
the sample. In SEM the sample is scanned and the scattered electrons are detected
and displayed onto cathode ray tubes. From here, parameters to increase resolution
can be adjusted and subsequently an image is captured. FE-SEM is an appropriate
method to image the morphology and size distribution of solid silica protein nano-
particles.
Ensilicated material was crushed into a fine powder and distributed across a square
of carbon sticky tape. This was fixed onto a metal stub that would fit into the FE-
SEM sample holder. The sample required dessication overnight before imaging.
The JEOL FESEM6301F was used to take images up to 50,000x magnification.
3.4.2 UV-vis spectroscopy
UV-vis, described 2.3.4 was used to analyse the ensilicated material for presence
of protein to examine whether TTCF was incorporated within the material. Native
protein and powdered silica were provided as references to compare against.
The spectrum of 3 ml thawed TTCF, 1 mg/ml, from -20◦C stock was analysed from
320-240 nm with 50 mM Tris pH 7.0 as buffer background. Silica and ensilicated
material were analysed using a powder sample holder with air as background.
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3.4.3 FT-IR spectroscopy
Fourier-transform infrared spectroscopy (FT-IR) is a method used to analyse com-
pounds that absorb electromagnetic radiation in the infrared region212–215. The ab-
sorbance is based on the dipole movement of a diatomic molecule. There are two
main events in molecules that indicate infrared absorbance, vibrations and rotations.
These movements describe the various quantum states molecules will have when
absorbing infrared radiation. The energy difference of these can be measured and
plotted either based on absorbance or transmittance. The principle of FT-IR is based
on interferometry (figure 3-5). Analysis using FT-IR produces an interferogramwhich
is a complex convolution of signals. Within the IR spectrometer a radiation source
emits infrared light which passes a beam splitter, at 45° angle, creating deflected
and unaffected beams of infrared light. The beams are directed towards a station-




















Figure 3-5: Schematic of FT-IR. The FT-IR spectrometer uses a radiation source that
passes an angled beam splitter. Two beams of stationary and variable phase interact with
a diatomic molecule present in the sample. The interferogram obtained is processed using
the Fourier-Transform and produces the FT-IR spectrogram.
77
The movable mirror allows for constructive or destructive interference by changing
the difference in phase between the two beams. The detector passes information
via a computer that applies the Fourier Transformation (equation 3.1), producing an






The Fourier Transformation allows conversion of time or space, function f (t), into
frequency or spatial frequency, F(v), respectively. As infrared is part of the radiation
spectrum with notated wavelength as unit, which is a unit of space, the output is
spatial frequency or wave number.
Samples were analysed using a PerkinElmer Spectrum™100, FT-IR attenuated total
reflectance (ATR) spectrometer. The background used for powdered samples was
air, ultrapure water for liquids. Backgrounds were read before scanning of the
sample. The samples were tightly clamped before scanning. Scans were carried
out between wave number 4000 and 500. Each measurement was scanned for a
minimum of 8 scans. This was to improve the signal-to-noise ratio (SNR). Data were
outputted in % transmission versus wave number. Peak analysis was done using a
custom MatLab™script. Peak values were identified using literature databases.
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3.5 Results & Discussion
3.5.1 Overview of TTCF ensilication attempts
TTCF was ensilicated on several occasions at 1:50 ratio of ensilication based on the
previous success with lysozyme203. All parameters for ensilication were reported
in table 3-1. The important parameter here is the ensilication efficiency, based on
release concentration. Ensilication and material efficiency % are calculated using
the following equations:
ensilication % =
release concentration × release volume
powder weight used for release
(3.2)
material % =
supernatant concentration × supernatant volume
protein concentration used for ensilication
(3.3)
Volume TEOS Conc. Time Powder Flow Ensilication Material
(ml) (ml) (mg/ml) (min) (mg) (mg/ml) (%) (%)
25 0.5 1 20 27.2 0.172 66% 83%
25 0.5 1 20 19.4 0.078 12% 92%
24 0.5 1 20 17.2 0.106 1% 89%
20 0.4 1 10 14.7 0.026 44% 97%
25 0.5 1 10 16.1 0.183 39% 82%
15 0.3 1 15 21.0 0.037 71% 94%
15 0.3 1 15 16.1 0.291 64% 62%
15 0.3 1 15 15.4 0.191 54% 62%
15 0.3 1 15 21.5 0.151 73% 85%
15 0.3 1 15 22.6 - 52% N.D
15 0.3 1 15 16.5 0.060 40% 94%
Table 3-1: Ensilication of several batches. Key parameters are displayed. Volume = the
amount of TTCF solution being ensilicated; TEOS = the volume of pre-hydrolysed TEOS
used during the ensilication; concentration = concentration of TTCF protein in buffer meas-
ured using BCA assay; time = the ensilication time; powder = the yield after subtraction of
the weighed filter containing the ensilicated material with the empty start weight of the filter;
flow = the supernatant concentration measured using BCA after ensilication; ensilication =
released concentration multiplied with the release volume divided with the powder weight
used for release; material: supernatant concentration times the supernatant volume divided
by the protein concentration used for ensilication.
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Ensilication efficiency describes the usable amount of ensilicated material while the
material efficiency describes the total amount of ensilicated material produced. The
difference between ensilication and material efficiency is due to some of the filtrate
being embedded within the filter which cannot be collected. Therefore, using the
supernatant protein concentration it is possible to estimate the total incorporation
of TTCF within the silica. With an average 64% ensilication efficiency, it appears a
reasonable amount of protein is being stabilised within silica.
3.5.2 UV-vis
Protein incorporation was determined using UV-vis spectroscopy. This is verified
by measurement of aromatic amino acid residue absorbance such as, tryptophan,
tyrosine, phenylalanine and histidine57. Analysis of the UV-vis spectra 320-240 nm
of native TTCF (in tris buffer), silica (dry powder) and ensilicated material spectra
showed the ensilicated TTCF absorbance to be a convolution of both signals (figure
3-6). The broad band of absorption unique to proteins is apparent in native and en-
silicated material. Moreover, a powder usually presents sharp absorption peaks, the
absence suggests presence of trapped water within the material189. This could be
due to drying step which is limiting the evaporation of water within cavities present in
the material. Another explanation is that the hydration layer around the protein is pre-
served after ensilication. The increase of absorbance below 240 nm can be directed
at the amide absorption relating to the secondary and tertiary protein structures.

















Figure 3-6: UV-vis absorbance spectra of native TTCF, silica and ensilicated TTCF
between 320 - 240 nm. Native TTCF in buffer corrected using buffer blank. Silica and
ensilicated materials analysed as powder with air as background.
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3.5.3 FT-IR of ensilicated TTCF
Ensilicated TTCF was analysed using FTIR and compared to native TTCF (in buffer)
and silica (powder) spectra (figure 3-7). The FTIR spectra for ensilicated TTCF
displayed several strong peaks in the fingerprint region (1500 and above) and weak
signals below that range. From observation of the various spectra, it is evident that
the ensilicated material FTIR is a convolution of organic contributions217 and silica
bond absorption216 (table 3-2). The spectra clearly divide the amide bonds versus
the Si-O-Si (1079/1039) and Si-OH (952) signals represented for TTCF protein and
silica respectively. Water, used as background for TTCF, removes the strong O-H
(3320/3274) signal. Moreover, tris itself has organic bonds contributing to the TTCF
spectra. These contributions are represented by amide I C––O, amide II C–N, N–H
and C–H bonds. This result indicated the combination of protein and silica bonds
within the ensilicatedmaterial. Therefore, thismethod also confirmed the ensilication






























Figure 3-7: FTIR of silica (powder), TTCF (in buffer), ensilicated TTCF andwater (back-
ground). Percentage transmittance between wavenumber 4000 - 500 cm-1 for each sample
scaled on y-axis. Labels correspond to index values for specific diatomic molecules listed in
table 3-2.
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Wavenumber (cm-1) Strength Bond Type Mode
3274 weak O–H stretching
2165 weak C–––C (triple bond) stretching
2029 weak C–H bending
1979 weak C–H bending
1639 strong C––O Amide I - stretching
1515 strong C–N,N–H Amide II - CN stretching, NH bending
1391 medium O–H bending (carboxylic acid)
1039 strong Si –O–Si stretching
952 strong Si –OH stretching
Table 3-2: FT-IR bond analysis216,217 of native and ensilicated TTCF. Peak values in
wavenumber were extracted from the FT-IR analysis and corresponded to their strength,
bond-type and vibrational mode.
3.5.4 FE-SEM of ensilicated material
Several batches of ensilicated TTCF were imaged using FE-SEM (figure 3-8). The
images display a fractal structure of sphere-like conglomerated silica particles (figure
3-9). The material itself seems to be very porous. Good consistency was observed
Figure 3-8: FE-SEM of ensilicated TTCF fragments. Images taken at (left) 200x and
(right) 900x magnification. Samples were coated with chromium before imaging.
between triplicate batches. The ellipsoidal shape of native TTCF (PDB: 1A8D164)
contributes to the final shape of the nano-particles formed. This is evidence that





Figure 3-9: FE-SEM triplicate run of ensilicated TTCF. (a-c-e) 15,000 x magnification,




















Figure 3-10: ImageJ analysis of ensilicated TTCF. Particles were sized using ImageJ
software for batches p1, p2 and p3. Data is visualised in frequency distribution over diameter
in nm.
ImageJ218 was used to measure particle sizes of ensilicated TTCF (figure 3-10).
Sizing reveals good consistency between replicate materials. However, there seem
to be a large spread within each sample distribution. This can be contributed to the
agglomerated state of the nanoparticles.
84
3.6 Summary
Ensilication is a previously developed method for the purpose of stabilising proteins
using silica203. It is based on sol-gel technology and yields a dry protein-loaded
powder, consisting of nanoparticles. TTCF, the vaccine protein model, was ensilic-
ated. Ensilication was found to have on average 64% efficiency. As large amounts
of protein were used for ensilication, this was considered to be an acceptable value.
Note, that there were some significant differences between ensilication efficiency
and total material yield. This is due to the material occasionally becoming (vitreous)
glassy rather than a powder. The impermeability of this glassy material prevents
quick release using the NaF buffer. Unfortunately, there is no clear evidence why
this occurs. An explanation for this could lie in the preparation of pre-hydrolysed
TEOS. The timing of both phases turning homogeneous varies on ambient condi-
tions and this could in effect lead to it to form larger dense silica particles in solution.
When the pre-hydrolysed TEOS is added to the protein for ensilication it results in
the filtrate progressing towards a glassy material once polymerised and dried. An-
other explanation is the presence of salt, which has not been sufficiently removed
after dialysis. It can also be affected by humidity and temperature when the filtrate
is dried.
A possible solution to this problem would be to use a climate chamber with optimised
settings for ensilication and drying to provide consistent conditions throughout the
ensilication process.
UV-vis and FT-IR analysis revealed the presence of protein within the material. UV-
vis showed the absorbance band between 250 - 300 nm with a peak at 280 indic-
ating presence of aromatic amino acids, such as tryptophan. The observed broad
absorption band is due to the presence of water (H2O). FT-IR analysis showed the
signal from ensilicated TTCF to be a combination of silica and protein specific bond
absorption. These optical methods confirmed successful ensilication of TTCF. The
measured protein concentration after release, using BCA, supported these findings.
FE-SEM imaging of the material displayed 200 - 400 nm solid silica nano-particles
which are in an agglomerated state. Compared to lysozyme203, these particles were
not perfectly spherical and indicated that ensilication does tailor fit proteins. Assess-
ment of protein stability after ensilication will be described in Chapter 5.
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Chapter 4
Small Angle X-Ray Scattering of
TTCF ensilication
4.1 Introduction
Scattering is deflection of electromagnetic radiation from an incident beam which is
focused onto a sample219. There are several types of scattering; elastic, inelastic
and quasi-elastic220,221. These define the interaction of a sample with electromag-
netic radiation. Changes in wavelength determine the category of scattering. This
chapter describes the utilisation of small angle x-ray scattering (SAXS)221–226 to elu-
cidate the ensilication mechanism. SAXS was carried out at Diamond Light Source,
Didcot (UK) and at the European Synchrotron Research Facility (ESRF) in Gren-
oble, France. Ensilication was monitored over time in situ, and with ex situ initiation,
at different ratios and pH. This was intended to observe any changes due to the
variations of key variables relating to the ensilication process227. Analysis led to a
proposed ensilication mechanism. The reason for using SAXS is due to the diffi-
culty in visualising ensilication via light scattering because of the inference caused
by silica228.
4.2 SAXS theory
X-ray radiation is part of the electromagnetic spectrum with a wavelength between
0.01 - 10 nm229. Synchrotron radiation facilities create x-rays via particle accel-
erators that increase the speed of electrons towards the speed of light contained
within a circular enclosure. Magnetic coils modulate the beam to create a sinusoidal
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wave with a specific amplitude and frequencymatching the desired wavelength. This
can be then selected and bent off the storage ring towards a beam-line. X-ray ra-
diation interacts with electrons in the atomic shell which start oscillating223. This
event causes elastic x-ray scattering at the site where an incident x-ray beam hits
the sample (figure 4-1). The angle of deflection can be limited at the detector to set
a range of sizes and is visualised for x-rays by Bragg’s Law230.
nλ  2d sin θ (4.1)
Where λ is the wavelength of x-rays (Å), d is the atomic spacing (Å) and θ is the
angle (°). Small angle x-ray scattering is able to detect 0.1 - 100 nm sized particles
at a typical angle of 2θ between 0.3 - 5°. In principle, the incident beam k0 is
scattered ks upon interaction with a sample. The elastic scattering220,221, no en-
ergy loss between incident and scattered photon, is then measured at the detector
q  ks − k0. As k0 = 2piλ and |k0| = |ks | the scattering is resolved by trigonomet-





Incident photon energy 
scattering angle
Figure 4-1: SAXS scattering basics. The incident beam of x-rays hits the target molecule.
Interaction with the sample causes electrons to oscillate. The oscillation is an energy (mo-
mentum) transfer with no loss, elastic scattering. Intensity can be measured over the wave
vector q which is expressed as = 4pi·sinθλ
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be adjusted into q2 
2pi






This does not record the amplitude, however does allow the measurement of scatter-
ing intensity. The collected 2D data is then, after instrumental correction, averaging
and background subtraction, plotted as 1-dimensional (1D) I(q) versus q. For a
dilute (mono)disperse system the intensity, ∆ I(q) is:
∆I(q)  N · I0 · ∆ρ2 · V2particle · P(q) · S(q) (4.3)
Here, intensity (I(q)) is the number of particles (N) multiplied by I0 which is the
scattered intensity of the incident beam. The contrast between particle and solvent
(∆ρ  ρparticle−ρsolvent) is accounted for as well as structure factor (S), typically S =
1, and volume (V1). The equation involves form factor (P) to indicate the geometrical
shape of said particle, e.g. sphere, ellipsoid or cubic etc. which contribute to the
overall scattering pattern in their own way226. More on the use of form factors and
fitting of experimental data described in the results section.
The 1D SAXS plot, I(q) versus q, displays three regions of interest (figure 4-2).
Low-q is the range at higher size and can indicate inter-particle effects and structure
factors. Intermediary zone can be fitted to elucidate the particle shape and size, form
factors. High-q region displays the interface between particles and solute. This is
high resolution and therefore contains great variation. Experimental data allows for
simple mathematical fitting that provide a start for data interpretation. The distance
distribution function p(r), Guinier, Porod and Kratky analysis allow estimations of the
particle dimension probability, radius of gyration (Rg), surface analysis and protein
folding assumptions222,224–226,231. The p(r) function224 calculates, in real-space, the
distance distribution between pairs of electrons in a macromolecule. This is visual-
ised with the probability on the y-axis and distance in Å on the x-axis. This method
is able to distinguish slight changes in protein conformation and also provides an Rg
value. The Guinier equation222 is fitted directly to the data in the form of:
I(q)  scale · exp[(−Q
2Rg2)
3 ] + background (4.4)
From this, the radius of gyration (Rg) provides average radii of a particle based on its
density and total size estimated from a particular axis, xyz. Porod analysis226,232

















Figure 4-2: SAXS 1D plot regions of interest. SAXS scattering of native TTCF above
shows regions where initial fitting can be performed. The apex of the exponential decay
allows for fitting of the Guinier function. The slope afterwards is indicative of a Porod slope.
High q region displays greater variability in the measured scattering. The decrease in scat-
tering at low q is due to the increase of scattering angle proportional to the scattered energy.
range from 0 to 4 where the highest number indicates that the surface is too dense
to be resolved in any basic geometrical structure. The Kratky plot,222 visualised by
I(q) ∗ q2 plotted against q, can suggest protein flexibility and derivative type shapes
such as globular or ellipsoidal. Overall, these initial assessments will guide towards
a representation of the actual process occurring and will allow fitting of mathematical
functions that other researchers have established for various types of reactions.
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4.3 SAXS method: Diamond Light Source
4.3.1 in situ TTCF ensilication
TTCF at 1 mg/ml in 50 mM Tris pH 7.0 buffer, 25 ml volume, was circulated using
a peristaltic pump at 2 ml/min through Teflon tubing with an internal diameter of 1.6
mm. The sample solution passed through a 1.5mm capillary flow cell in a loop before
addition of hydrolysed TEOS (figure 4-3). Both pump and injector were remotely















Figure 4-3: SAXS set-up at i22, Diamond. Continuous flow path of circulating protein in
buffer was set up. Using remotely controlled pump and injector, the speed of circulation was
set and the injection of hydrolysed silica was timed to additionally obtain pre-ensilication
scattering.
frequency was altered to 1 frame/sec for 5 seconds every 20 sec interval. Total time
of acquisition was 900 seconds. Pre-hydrolysed TEOS was added to the sample at
1:50 ratio after 3 seconds of measurement start. The incident X-ray energy was 12.4
keV. SAXS data were acquired using the Pilatus P3-2M detector at 2.2 m sample
distance. This resulted in a SAXS range of 0.008<q<0.75 Å-1. The experiment
was performed at room temperature. Native TTCF scattering was measured before
addition of hydrolysed TEOS. Empty capillary and buffer scattering were measured
and used for background correction.
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4.3.2 2D data processing
Measured 2D SAXS data was processed into 1D data using the Data Analysis Work-
beNch (DAWN) software.233 Figure 4-4 is an example of sample correction using
lysozyme. Lysozyme is a standard model protein used in many studies as a ref-
erence. The SAXS mask and detector calibration files, provided by the instrument
scientist, were loaded into a pipeline. Then the Poisson error was set and azimuthal
integration added. The pipeline was completed by adding division steps that divided
the data internally and with a scalar value (1.5) to compensate for the capillary width.














Figure 4-4: SAXS subtraction for lysozyme. Measured scattering was subtracted with
buffer and then empty capillary scattering. This removed the solvent and container effects.
cessed via:
sample  sample(+buffer +capillary) − bu f f er(-capillary) − capillar y (4.5)
Before the final step, all data was multiplied with a scalar (1e9) and was averaged
before output into a *.dat file. The processing yielded files containing a q-range of
0.008 - 0.75 Å-1.
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4.4 SAXS method: ESRF
4.4.1 ex situ TTCF ensilication
Pre-hydrolysed TEOS was prepared as previously described (section 3.2.2). This
was added to 10 ml of 1 mg/ml TTCF solution at 1:50 ratio at pH 7 in a glass beaker.
Using a sterile syringe, 1 ml of sample was taken and injected into a quartz capil-
lary (figure 4-5). SAXS measurements were performed on the Time-Resolved Ul-
tra Small-Angle Scattering beam-line ID02 at the ESRF, Grenoble, France234. The
incident X-ray energy was 12.46 keV and two sample-detector distances were em-
ployed at 1.5 and 10 m. SAXS data were acquired using the Rayonix MX-170HS
2θ
qX-ray






Figure 4-5: SAXS set-up at ID02, ESRF. Hydrolysed TEOS was added to TTCF in buffer
and this solution was then taken up using a syringe and subsequently injected into a quartz
capillary for SAXS measurement.
detector with exposure times between 0.01 and 0.03 sec. The measured 2D pat-
terns after normalization by incident flux, sample transmission, and the solid angle
were azimuthally averaged to obtain the 1D static scattering profiles as a function
of the magnitude of scattering vector, q. Where q is given by, q  4pi sin θλ , with λ
the incident X-ray wavelength (=0.0996 nm) and θ the scattering angle. This gave
two overlapping q-ranges of 0.0001<q<0.03 and 0.006<q<0.5 Å−1. The scatter-
ing background in each case was measured using buffer and the normalized back-
ground subtracted data is represented by I(q).
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4.4.2 TTCF ensilication ratios
Ensilication of TTCF at 1:50 ratio occurs rapidly in standard conditions, therefore ad-
ditional ratios of ensilication were measured to investigate any difference in particle
morphology and size. 1:20 and 1:100 silica to protein ratios were chosen to assess
as they will have significantly different amounts of silica present in the solution. The
procedure of measurement was equal to the 1:50 ratio, once the hydrolysed silica
was added to the TTCF solution, a sample was injected in the capillary and the
experiment initiated. Other implications could be the increased resolution of ensilic-
ation at 1:100 or the depletion of SiOH4 at 1:20 and the subsequent effects on the
ensilication process.
4.4.3 TTCF ensilication pH
Ensilication is heavily influenced by pH139. As with 1:50 ratio, the condensation and
polymerisation occurs rapidly at 1:100 ratio. pH 8 and 6, at this ratio, were chosen
to investigate whether these changes would influence ensilication speed, particle
morphology and size.
93
4.5 Results & Discussion
4.5.1 Initial data assessment
The morphology of native and released TTCF was obtained by using real-space
inversion P(r)224 function and Guinier222 approximation. The acquired SAXS signal
pattern between 0.006<q<0.51 Å-1 (ID02) and 0.008<q<0.35 Å-1 (i22) (figure 4-6, A)
where Rg is calculated via slope analysis at low q. The Rg (figure 4-6, D) obtained



























































Rg = 28.40 Å
Rg = 26.96 Å
Rg = 28.67 Å
Rg = 25.30 Å
A B
C D
Figure 4-6: SAXS TTCF data p(r), Kratky, Log view and Guinier plot. (a) Real-space
function displaying probability of radii (b) Kratky plot displaying intrinsic flexibility for TTCF
(c) Log view for SAXS data (d) Guinier analysis, slope fit and Rg values display similar sizes.
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SAXS MW analysis 1A8D Native Native Released
(ESRF) (Diamond) (ESRF)
Sequence weight (kDa): 52.22036 53.5455 53.5455 53.5455
Found molecular weight: (kDa) 45.594 48.598 41.918 39.014
Discrepancy (%): 14.53 10.18 27.74 37.25
Oligomeric state: monomer monomer monomer monomer
Table 4-1: Molecular weight analysis for TTCF scattering. Approximations using SAXS
reveals monomeric protein species of TTCF in solution.
for native TTCF (ID02) is 28.40 Å, (i22) 26.96 and released TTCF is 28.67 Å. The
observed sizes are in agreement with the homologous (96.7% sequence overlap)
published crystal structure of TTCF (PDB: 1A8D164,235,236) with an Rg of 25.30 Å.
This is obtained via simulated SAXS scattering of the crystal model and confirms the
P (r) function derived shape of an ellipsoidal particle (figure 4-6, A). Differences in
scattering intensity observed are either due to environmental differences (beamline
setup) or concentration variations. Observed r (Å-1) reveals consistency in particle
radius at 30 Å. However, at higher size there are interparticle effects or polydispersity
influences visible. It is also apparent that the protein does not present a Gaussian
distribution and the Kratky plot (figure 4-6, B) reveals intrinsic flexibility. The lower
signal for released protein in the Kratky plot is due to the reduced concentration after
release (figure 4-6, C). Additionally, the signal is affected by the presence of (soluble)
silica particulates in solution. However, our published study gives detailed analysis of
protein after release, described in the next Chapter227. Molecular weight analysis of
TTCF SAXS scattering237 revealedmonomeric states (table 4-1) and agreed with the
linearity of the Guinier approximation with the integration limit defined as: qm  8Rg .
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4.5.2 Native TTCF
Native TTCF at 1 mg/ml in Tris pH 7 buffer was measured at both (i22 & ID02) beam-
lines. Fitting was done using an ellipsoidal model226 with power law added (figure
4-7). Calculations were done using the sum of:
I(q)  scale · q−power + P(q , α)( scale
V
F2(q , α)) + background (4.6)
The ellipsoidal form factor includes the Fourier transform:
F(q , α)  3∆ρV(sin[qr(Rp , Re , α)] − cos[qr(Rp , Re , α)])[qr(Rp , Re , α)]3 (4.7)
where Rp: polar radius, Re : equatorial radius, ∆ρ: scattering length density (SLD)
difference between particle and solvent, α: axis angle, V : ellipsoid volume;
V  (4/3)piRpR2e (4.8)

















Figure 4-7: SAXS of native TTCF in 50 mM Tris pH 7.0 at Diamond and ESRF. Fitting






scattering length density (protein) 12.47 12.47
scattering length density (solvent) 9.44 9.44
radius (polar) Å 61.24 ± 0.11 57.68 ± 0.37
radius (equatorial) Å 21.54 ± 0.02 21.85 ± 0.06
Table 4-2: SAXS TTCF native fit parameters. Scale used as multiplication factor for fitting.
Background represents residual scattering near zero. SLD accounts for component scatter-
ing. Polar and equatorial radii provide structural information about the ellipsoidal particle.
The scattering length density (SLD) for TTCF was calculated using the molecular
density (1.37 g/ml) and its formula which provided an SLD of 12.4681 x 10−6 Å2.
The fit provides structural information about the length of the polar and equatorial
radii (table 4-2). Comparison of both reveal non significant differences between
native TTCF measured independently at both beamlines.
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4.5.3 TTCF ensilication 1:50
Ensilication of TTCF in situ was measured at Diamond. The pump flow system circu-
lated TTCF and, after 3 seconds, hydrolysed TEOS was added. Initial protein scat-
tering was measured after which the ensilication measurement was started. Frames
were taken each second up to 120 seconds. After which frames were taken every
15 seconds, 5 frames in 5 seconds up to a total time of 900 seconds. The subtrac-
ted SAXS scattering is displayed in figure 4-8. Observed is the jump in scattering at
high-q after silica has been injected into the loop. This increase in scattering con-
tinues with the protein apex shifting towards the lower q-range, suggesting particle
growth. At high q, silica particle scattering is increasing over time. The bump at
low-q disappears over time and reduces to a broad peak.
Ensilication of TTCF ex situ, where hydrolysed TEOS was added to a solution of
buffer TTCF before measurement, disabled observation of onset ensilication. How-
ever, it allowed monitoring of longer evolution (figure 4-9). Observed was the same
broad peak and silica scattering seen in the Diamond data. The signal evolved to a
smooth surface due to the extension of the high-q signal towards the low q region.


















Figure 4-8: SAXS 3D perspective in situ ensilication of TTCF. Continuous measurement
of the ensilication onset and up to 120 seconds after. Various transitions can be observed.
















Figure 4-9: 3D perspective in situ ensilication of TTCF (ID02). SAXS of TTCF ensilica-
tion with a longer duration of time. Fractal growth is indicated by the extension from high to
low q over time.
and mass fractal models for TTCF ensilication. The fractal model is of interest as it
describes the attachment of colloidal particles (silica species) to protein/ each other.
It provides a fractal dimension, D f , which is dependent on the ability of particles to
aggregate/ stick and is a function of the spatial dimension. This value is of import-
ance as it will suggest what type of reaction is occurring during ensilication238.
Fractals are defined as a geometric structure consisting of many individual units that
possess the same geometrical shape239. There are many examples of fractals found
in nature with trees being prominent.
4.5.3.1 Modelling of ensilication
Modelling of ensilication during onset and longer evolution involved the use of math-
ematical models that represented several structures present in the solution during
ensilication. The models have their own parameters and were combined to find an
agreeable complete fit of the SAXS scattering recorded. The models have been
designated model parameter keys, P, relating to SASview output tables A.2, A.3,
A.4 and A.5 described in the Appendix.
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Stage I
i22, in situ 0 - 60 seconds X-ray scattering measured in situ after addition of
silica, and up to 60 seconds, was fitted with several models combined into one.
Combination of these respective models, visualised below (figure 4-10) , indicated
a reasonable fit with a χ2 below 10. The power law model was intended to indicate
any large surfaces or instrumental scattering. The ellipsoidal model was used to
display the protein as a particle, where a fractal structure of the silica polymerising
and attaching to the protein is represented with a fractal model225.
(P1) power law + (P2) ellipsoid + (P3) mass fractal (stage I)

















Figure 4-10: Stage I fit model applied to scattering data. Individual fits highlight regions
of interest while the combined fit is used to follow transitions during the in situmeasurement.
I(q)  scale · q−power+P(q , α)  ( scaleV F2(q , α))+ scale · P(q)S(q)+background
where: P(q)  F(qR)2 and S(q)  (Γ(Dm−1)ζ(D−m1))[1+(qζ)2](Dm−1)/2 ·
(sin[(Dm−1) tan−1(qζ)])
q
with R: radius building block, Dm: fractal dimension, ζ(zeta): cut-off length. Where:
F(q , α)  3∆ρV(sin[qr(Rp , Re , α)] − cos[qr(Rp , Re , α)])[qr(Rp , Re , α)]3 (4.9)
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with Rp: polar radius, Re : equatorial radius, ∆ρ: scattering length density (SLD)
difference between particle and solvent, α: axis angle, V : ellipsoid volume;
V  (4/3)piRpR2e (4.10)
Stage II
i22, in situ 60 - 120 seconds After 60 seconds, during the ensilication, scattering
underwent a transition. This change required a new approach to fit these data (figure
4-11). The broad peakmodel was utilised because the data presented a broad peak.
The model represents scattering of various structures, in this case protein and silica,
at a specific size in the q range. It also included a Porod exponent, therefore making
the power law model redundant. The fractal portion of scattering remained.
(P1) broad peak + (P2) mass fractal (stage II)
















Figure 4-11: Stage II fit model applied to scattering data. Individual fits highlight regions
of interest while the combined fit is used to follow transitions during the in situmeasurement.
I(q)  Aqn + C1+(|q−q0 |ζ)m + scale · P2(q)S2(q) + background
Where: A: Porod law scale factor, n: the Porod exponent, C: Lorentzian scale factor,
m the exponent of q, ζ: the screening length.
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Stage III
ID02 in situ, ex situ initiation, 2 - 60 mins The scattering measured over longer
duration of time initially displayed the same scattering fitted with the broad peak and
mass fractal combined fit. After several minutes, this signal changed and a new
model was required to address this transition (figure 4-12). Observed was the broad
peak reduction and increase in mass fractal scattering. Therefore, the power law
model and mass fractal were combined which obtained a good fit.
(P1) broad peak + P2) mass fractal (stage II) (same as before)
(P1) power law + (P2) mass fractal (stage III)

















Figure 4-12: Stage III fit model applied to scattering data. Individual fits highlight regions
of interest while the combined fit is used to follow transitions during the in situmeasurement.
I(q)  scale · q−power + scale · P2(q)S2(q) + background
Note that each model and combined models in SASview have a scalar and back-
ground value. These are accounted for when fitting 1D SAXS data.
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4.5.3.2 Parameter output of SAXS fitting
Fitting of (1:50) ensilication scattering was done using three mathematical models
that indicated various stages during TTCF ensilication. The fittings were based on
biomolecular SAXS and silica scattering derived from sol-gel chemistry139. Com-
bined, they provided a good fit for this process. This is displayed below (figure 4-13)
where the three stages are clearly indicated. The red fit has been described earlier
for native TTCF (section 4.5.2). After silica is added to the buffer with protein, a clear
































Figure 4-13: Scaled TTCF in situ TTCF SAXS data. Sliced SAXS data for clarity with
fits based on three staged models to depict transitions occurring during ensilication. Red
displays the native fit for TTCF. Green (stage I) and blue (stage II).
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towards low-q and a broad peak appearing shortly after. This is also found in the
ESRF data (figure 4-14) and this suggests that the silica grows to a larger structure.
The parameters used in these fits were derived from native modelling and literature
values241. If there were multiple backgrounds within the formula, only one would be
set. This also applied to the scaling factor for each individual function because of the
shift in intensity and transitions occurring. Only the power law and ellipsoidal model
were allowed to have an implicit scale factor, where the fractal and overall scale

































Figure 4-14: Scaled TTCF in situ TTCF SAXS data. Sliced data for clarity with fits based
on three staged models to depict transitions occurring during ensilication. Red displays the
native fit for TTCF. Blue (stage II) and orange (stage II).
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algorithm to calculate variables that would be in align with real-world observations.
Limitations on sizes of radii and fractal particles were also based on this approach.
For more detail see the Appendix A.2. Outputs of all the fittings were gathered and
themost prominent parameters visualised (figure 4-15). Some interesting transitions
were taking place rapidly during the 1:50 ensilication. Important parameters in fitting
were the polar and equatorial radii, the cut-off length, fractal dimension and χ2 good-









































































Figure 4-15: Parameter output for SAXS fits. (top) Data for the flow in situ measurement.
Radial parameters show the growth of TTCF-silica nanoparticles. Cut-off length is the poly-
mer attaching to the protein. (bottom) Data for the longer evolution of ensilication. Important
parameters, D f , cut-off and radius (Å) show the growth of a larger fractal structure.
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ness of fit (gof). The first two parameters describe the protein particle sizes. Cut-off
length describes the static silica polymer accumulations and the fractal size. Fractal
dimension indicates the type of process taking place with gof being approximately 1.
The gof supports representation of the fitting to the actual process taking place. The
better the fit, the more likely the data visualises real events. From the visualisation
of parameter output it was apparent that the polar radius of the ellipsoidal protein
particle increases dramatically over a short period. The equatorial radius seemed
to increase as well but remained static after 30 seconds. The cut-off length which
rapidly increased in size, suggests the adhesion of silica polymer to the protein. The
radius of fractal particles remains static (figure 4-15, bottom) and is in line with the
fractal dimension (1.87) that indicates diffusion-limited (controlled) cluster aggrega-
tion (DLCA)139,238,242,243. The cut-off length is the minimum resolvable fractal size
measured using the fit model.
The DLCA process describes the aggregation of colloidal particles in solution243,
i.e. silica species large enough for electrostatic attachment to the protein. Once a
cluster is formed, growth occurs by other particles attaching to the external branches
of this entity. Diffusion is the rate-limiting step in this scenario and can be influenced
via temperature or viscosity. Agitation has an effect on the maximum size of large
fractal structures of protein and silica. The force created by the solute movement
will be greater once the fractal particles accumulate and invariably shear. With the
absence of agitation, sedimentation was observed.
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4.5.3.3 Convolution of SAXS ensilication data
There are visible differences in scattering between agitated and non-agitated
sample that suggest this reaction to be diffusion controlled (figure A-1, Appendix
A.6). Fitting revealed three stages during ensilication (figure 4-16):
Stage I: Formation and growth of low q particle radii initiated at the onset of
ensilication (figure 4-8, A, until 40 sec). Here, ensilication is observed via the
increase in ellipsoidal radii (polar, equatorial) over time, indicating silica forming
around the protein.
Stage II: Broad amorphous peak formation due to aggregation of silica.
Stage III: Fractal growth of silica particles associated with aggregation which relates
to increase in fractal dimension and cut-off length (figure 4-13, A). This is confirmed
by the mass fractal dimension (D f ) during the longer evolution (figure 4-14, B)
which provides an increase to D f = 1.87 and has been shown to be indicative of
fast silica growth and defines the mechanism of ensilication as a diffusion limited
cluster aggregation (DLCA) type process139,238,242,243.
Polymeric associates Poly-condensation Particles aggregate Non-porous and dry






Mass fractal growth Final material
Figure 4-16: Graphical representation of TTCF ensilication. Nucleation, induced via
electrostatics, initiates ensilication at positive external residues (lysine, arginine, blue)
present on the protein. Poly-condensation of SiOH4 results in silica coating of individual
proteins (stage I, green) which triggers aggregation (stage II, blue). Vacuum filtration of the
then turbid solution results in dried powder material containing protein loaded silica nano-


































time scale chi2 slope s Rg bkg
(min)  -  -  -  - (Å)  -
1 3.2 0.3 2.31 5.68e-39 1309 ± 35.36 0.005
2 22.9 0.3 2.35 2.12e-14 1386 ± 6.50 0.005
3 176.1 6.5 3.30 2.01e-13 1563 ± 1.63 0.005
4 471.9 13.2 3.76 5.84e-14 1717 ± 1.03 0.005
5 841.6 14.3 3.98 2.02e-27 1851 ± 0.85 0.005
30 2175.3 138.6 4.00 9.03e-15 2119 ± 0.68 0.005
Figure 4-17: ultra-SAXS supplementary data supporting the graphical representation.
Guinier-Porod slope and Rg analysis show the formation of large: nano-particles short after
initiation of ensilication process.
The findings are further supported by SAXS carried out a lower q-range (0.0008 to
0.05 Å-1) displaying large particle formation after silica addition (figure 4-17). Particle
sizes increasing to a stable range of 2000 - 2200 Å (200-220 nm) are observed.
These data suggest that once TTCF is coated with silica, it is prone to aggregate and
form a stable complex. FE-SEM imaging of the final dried material confirms these
sizes (figure 4-16). Overall, the SAXS data elucidated the ensilication mechanism by
providing evidence of a fast DLCA process where, once TTCF is coated, on average
2000 Å aggregates of protein-silica particles will form.
108
4.5.4 TTCF ensilication 1:20 and 1:100
SAXS experiments on different ratios of silica were intended to provide more evid-
ence on the influence of these conditions during ensilication. The expected obser-
vations were based on difference in rates of ensilication. From earlier experiments,
it was shown that more silica increased the polymerisation and therefore speeds up
ensilication. When there is less silica, it takes more times for the polymer fragments
to find each other and connect.
Looking at the time-resolved scattering data (figure 4-18), there is a smoother inter-
face to be seen in the higher silica ratio experiment. The opposite is the case when
using a significantly lower ratio of silica. There is a broad peak formation and some
increase in scattering at low q. However, the transitions were slow and there was
not much visually occurring. Buffer with added silica did turn turbid, however the
process was relatively slower than 1:50. After observing SAXS data of the 1:20 run,
the stage III (power law + mass fractal, figure 4-20, a) fit was applied to this higher
silica ratio. A similar trend comparable to the 1:50 data was observed. The fractal
dimension and cut-off length seem to behave similarly (figure 4-21). The sample-to-
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Figure 4-18: SAXS of TTCF ensilication experiment at 1:20 ratio. Observed is the
















Figure 4-19: SAXS of TTCF ensilication experiment at 1:100 ratio. Observed is the slow
transition with a fractal structure growing at high q and broad peak forming.
was not possible to capture any of the first two stages. The reaction here proceeded
directly to the final stage (III) once the measurement was started. For the 1:100
ratio, the opposite is the case (figure 4-19). Here, there is a slow transition (after 10
minutes) from the first stage of the ensilication process towards the second stage.
This is supported by the overall good fit (χ2) for the models at each stage (figure
4-20, B). The parameter output showed a similar trend to the 1:50 data in the first
two stages. The increase in polar and equatorial radii, the subsequent dip in these
radii and the following formation of an amorphous broad peak (Lorentz length, figure
4-22) are identical to the transitions occurring in the 1:50 ratio (figure 4-15). There
is a difference in fractal dimension. However, after experimenting with different val-
ues for the D f there was no significant change in any of the associated parameters.
Both fit models have good agreement on the radius of fractal building blocks at 10
Å. Overall, the SAXS experiments on adjusting the ratio of hydrolysed TEOS:protein
show an increase of the ensilication speed at higher amounts of silica added. When





















































Figure 4-20: SAXS scattering with model fits for 1:20 and 1:100 data. (a) stage III fit for
the fast ensilication at 1:20. (b) stage I and II fits for the slower progression of ensilication
at 1:100.








































Figure 4-21: Parameter output for SAXS fitting of 1:20. Stage III fit shows a similar trend
in output compared to 1:50 ensilication
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Figure 4-22: Parameter output for SAXS fitting of 1:100. Stage I & II fit shows a similar
trend in output compared to 1:50 ensilication. (top) Output radii of the fit models for polar,
equatorial, fractal building blocks and amorphous peak Lorentz length. (bottom left) cut-off
length and χ2 goodness-of-fit. (bottom right) Output fractal dimension and power (Porod)
slope.
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4.5.4.1 DLS of TTCF ensilication at 1:100
Ensilication was additionally monitored using DLS. The results show similarities with
the SAXS data, however there is increased variability. During the measurements,
it was apparent that the ensilication occurred too rapidly for the DLS ZetaSizer to
capture. Therefore, the reaction was initiated as it would be in normal conditions.
After initiation the volume was increased tenfold to allow for greater resolution dur-
ing measurements. The DLS output provided the mean intensity hydrodynamic dia-
meter (d.nm). The Z-average was not used for comparison as this would be the
average of all peaks and does not represent the data gathered. Experimental data
from the ultra-SAXS experiments was used to compare against the DLS data (fig-
ure 4-23). It was found that there was a high level of polydispersity which prevents
comparison to small range particles.

















Figure 4-23: SAXS and DLS at 1:100 ratio. Scattering data using similar techniques with
different wavelengths. DLS shows large aggregates forming. Particle sizes from SAXS were
calculated directly from applying the Guinier function and display consistent values.
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4.5.5 TTCF ensilication 1:100 ratio, pH 6 and 8
After establishing that varying ratios of silica influence the rate of ensilication, the
following was to performed to examine the effect of pH. As 1:100 ratio significantly
slowed the ensilication process, this was utilised to provide more resolution. This
decision was based on the fast transition occurring during the 1:50 in situ flow ex-
periment. From the time-resolved scattering, it is apparent that there are no obvious
transitions happening (figure 4-24) at pH 6. However, there are two scattering popu-
lations visible at pH 8. The visualised data (figure 4-24 and 4-25) showed scattering
for both data sets over time, 60 minutes pH 6 and 120 minutes at pH 8. For the
latter, there is an increase in signal present during the initial moments of this run
due to the introduction of silica to the system. These data were subsequently fit-
ted with the stage I model (figure 4-26). The sliced view of the fitted data showed
a transition during the first 10 minutes of ensilication after which the solution sta-
bilised. The signal showed no transition towards the stage II or III as observed in
















Figure 4-24: SAXS scattering of TTCF ensilication 1:100 at pH 6. 3D plot of intensity vs

















Q log10 (nm-1) Time (minutes)
500
0.5 0
Figure 4-25: SAXS scattering of TTCF ensilication 1:100 at pH 8. 3D plot of intensity vs
q over time. pH 8 scattering of TTCF ensilication does present a modest transition at early
stages. There seem to be two populations of scattering present.
bilised in solution after adding the hydrolysed TEOS. This stabilisation occurs after
10 minutes. The fit model provides several outputted parameters which can help
elucidate the effect of pH 8 on the ensilication of TTCF. The model distinguishes the
two populations where the low-mid q population is an ellipsoidal particle, represent-
ing the growing TTCF ensilicated particle, and the high-q population is the fractal
scattering caused by the polymeric silica particles. Parameters were calculated for
the ensilication of TTCF 1:100 at pH 8. The radii for the ellipsoidal particle, polar and
equatorial displayed an increase in size. Especially, the polar radius increased from
120 Å to 175 Å over time. The equatorial had a lower margin of growth, but was still
visible. The radius associated with the building blocks of the fractal structure dis-
played growth, however the growth was only minimal. These parameters suggest
that TTCF grows over its polar radius, similar to the 1:50 experiment. However, the
signal of the particle does not disappear in the scattering signal and points towards
the effect of pH. It was previously understood that once TTCF-silica particles reach
a particular size, aggregation is initiated (section 4.5.3.3). However, this was not
observed at pH 8. This absence of aggregation is also supported by the calculated
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cut-off length for the polymer-protein particle (figure 4-27). The scattering has large
fluctuations present during the initial stages but does settle over time with particles
having an approximate length of 200-300 Å. This trend is also visible in the fractal
dimension (D f ) as this parameter can identify the kind of polymerisation process
occurring. With a D f of 1.45 stabilising towards the end, this indicates a slow sol-gel
process. Note that this solution turned visibly turbid, therefore confirming ensilica-
tion was taking place. It also does present particles large enough to refract visible
light and make the solution cloudy, therefore there is some aggregation or gelation
taking place. This experiment displayed the stabilisation of TTCF-silica particles at
small sizes without the creation of large aggregates. The idea of individual stabilised
TTCF-silica particles with a lower amount of silica is not only beneficial to increase






























Figure 4-26: Stage I fitting of SAXS data for TTCF ensilication 1:100 ratio at pH 8. The
first 10 minutes display modest transitions in scattering. After this period the signal stabilised
as has a good fit with the fitting model. There are no transitions into stage II or III observed.
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Figure 4-27: Parameter output of stage I fitting for SAXS scattering of TTCF ensilic-
ation 1:100 at pH 8. The parameters for ellipsoidal radii and the fractal radius display an
increase in size. In particular, the polar radius displays the largest growth. Correlation length,
of polymer and protein, stabilises over time. The fractal dimension displays an initial rapid
increase and does also stabilise later on. The χ2, gof, displays a good agreement between
the experimental and fitted data.
the silica-protein ration can identify the minimum concentration necessary to ensilic-
ate all proteins in solution and optimise the time needed for this. Fluctuating the pH
does add a layer of additional control in a diffusion based system.
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4.6 Summary
Small angle x-ray scattering is a powerful tool to find a representative image of pro-
cesses occurring at nanometre scale226. The utilisation of high resolution beam-line
x-ray scattering allows for greater in-depth analysis. The elastic scattering analysed
in this setting was used to understand which events were occurring during ensilic-
ation223. Observation of scattering at various ratios and wave vectors provided un-
derstanding of the different phases of ensilication.
Initial assessment of protein scattering data provided the reference parameters. As
a protein is technically a polymer (polypeptide) it could cause confusion in under-
standing as the silica here acts as a polymer225. Therefore, TTCF was modelled
as an ellipsoid structure rather than a flexible object. Once TTCF was characterised
using the p(r), Guinier, Kratky and Porod analysis the subsequent aim was to under-
stand the transitions to the protein during ensilication. Based on previous evidence,
the hypothesis was to observe particle growth by addition of silica. The formed struc-
tures would aggregate which would cause the turbidity seen during ensilication.
The findings under standard protocol conditions displayed a three staged process
where, during stage I, small silica particulates adhere to the protein positive residues.
These particulates are not large enough to nucleate, however once clustered via
electrostatics nucleation is induced244. This then proceeds to the growth of the
TTCF-silica nano-particles. During this growth, a silica shell forms which is rep-
resented in the data as an amorphous broad peak (stage II). Once the polar and
equatorial radii reach a critical mass point, aggregation is induced. This was ob-
served during ultra-SAXS measurement which supports the statement. During the
final stage (stage III), the fractal scattering provided by the silica overtakes the in-
tensity in the measured q-range. This growth is characterised using the fractal di-
mension, D f , parameter and indicates fast silica growth with a value of -1.87139.
Earlier studies using SAXS on the condensation and polymerisation confirm this
finding240,241. The drying of the particles solidifies them between 200-400 nm.
The investigations on the influence of silica ratios supported the findings under
standard conditions (table 4-3). By changing the ratios of silica introduced to the
protein solution, it was possible to understand whether ensilication occurs or another
kind of reaction takes place. From the fitted data, it was evident that increasing or
decreasing the silica ratio would either push the reaction to stage III or slow it down
to visualise transitions between stage I and II. When adjusting the pH, it was found
that below pH 6.5 ensilication does not occur or is significantly reduced with the time
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ID02 i22 ID02 ID02
Ratio 1:20 1:50 1:50 1:100
pH 7 7 7 7 7 7 7 8
Stage III I II II III I II I
D f (arb.) 1.5 - 2.0 1.1 1.1 1.1 1.6 - 1.9 - - 1.0 - 1.5
Requat (Å) - 25 - 50 - - - 22 - 28 - 40 - 55
Rpolar (Å) - 50 - 165 -50 - - - 60 - 120 - 90 - 120 - 175
Cut-off (Å) 14- 69 10 - 600 165 - 20 12 20 - 80 > 1 > 1 50 - 300
χ2 (arb.) > 1 3.0 - 12 5.0 - 12 > 1 > 1 > 1 > 1 > 1
Lorentz (Å) - - 54 - 48 42 - 33 - - 40 - 30 -
R f rac (Å) 5.0 4.4 - 4.9 5.1 - 7.4 7.1 - 10 5.5 - 7.1 7.5 - 9.3 9.5 - 12 7.6 - 9.5
Table 4-3: SAXS ensilication parameter overview. Key parameters displayed are grouped
according to ratio, pH and stages. D f : fractal dimension; Requat ; equatorial radius; Rpolar :
polar radius; Cut-off: static protein and silica aggregates; Lorentz length: average particle
radius: R f rac : radius fractal particles: χ2: goodness-of-fit.
for nucleation being increased to a matter of days.
Another explanation could be the protonation of the protein, resulting in a change
of affinity between the silica and the protein. As the 1:50 ratio is already relatively
dilute, it is possible that some silica spheres can form over a longer course of time.
At pH 8, it seemed that the silica and protein particles reach an equilibrium early
on during stage I of the ensilication process. There is evidence of stable complexes
around 300 Å after 2 hours with no clear sign of increasing size. The data do present
an initial burst in growth, however this is followed with the parameters stabilising
quickly after. In summary, good evidence has been found to hypothesise a multi-
staged process during ensilication. To further improve the resolution, small angle
neutron scattering (SANS) might complement this study. SANS has the benefit of
contrast matching that would probe the silica protein formation even further.
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Chapter 5
TTCF protein stability after
ensilication
5.1 Introduction
Ensilication aims to stabilise vaccine proteins that are unsuitable for freeze-
drying227. These vaccines are therefore stored in liquid formulations which require
excipients to improve shelf-life79 and metal salts to enhance efficacy. These are the
modulators that affect vaccines detrimentally when exposed to fluctuating temperat-
ures.79 During such an event, proteins unfold, aggregate or precipitate. This results
in the loss of potency and does not infer protection against infectious disease. Up
to this point, the described results displayed successful ensilication of TTCF within
the silica and elucidated the mechanism of stabilisation via SAXS.
Here, the stability of TTCF before and after release was assessed. The material
was additionally stored for long term duration and tested at several time points. Ex-
periments in vivo allowed assessment of the immunogenicity retained after ensilica-
tion. Calorimetric and physical analysis during stress testing provided evidence as to
whether the material is thermally resilient. The combination of various protein ana-
lysis methods determined the feasibility of ensilication to thermally stabilise vaccine
proteins.
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5.2 Methods of protein stability
5.2.1 Initial release, thermal stability and long term storage
To test whether ensilication protects against heat, ensilicated powders (n=3) were
heated at 80 °C for 2 hours. TTCF is rapidly inactivated above 60 °C5, therefore
for TTCF a treatment temperature of 80 °C166 was employed. Triplicate ensilication
of TTCF was performed and released to be analysed using previously described
methods of SDS-PAGE, Circular Dichroism and ELISA (Chapter 2).
5.2.2 Western Blot
His-tag presence of purified and released TTCF was detected by Western Blot-
ting245. An SDS-PAGE was prepared with proteins separated based on molecular
weight. These were then transferred to a protein binding nitrocellulose membrane.
Filter pads and membrane were cut to size (8 x 6 cm) and soaked in transfer buffer
(1x Tris Buffered Saline). The SDS-PAGE gel was washed in transfer buffer and the
transfer set-up was stacked as follows; filter pad, membrane, gel, filter pad. This
sandwiched stack was then placed in a semi-dry blotting machine and a current
was run at 0.8 mA / cm2 for 1 hour 50 minutes to transfer the proteins from gel to
membrane. Protein transfer was verified using Poncheau S246 staining added to the
membrane for 1 min.
The stain was removed after confirming protein presence on the membrane. This
was done by several washes with ddH2O and TBS + Tween 20 (0.05 %) (T-BST).
The membrane was then incubated in 20 ml of TBST with 5 % casein (milk protein)
for 35 mins at room temperature. An antibody (anti-His IgG + HRP) with specificity
to histidine residues and a conjugated reporter enzyme were added to the solution
(at 1000x dilution) and incubated for 1 hour at room temperature. Several washes
in TBST and addition of luminol substrate mixture of reagent A+B initiated the sub-
strate conversion. Immediately after this, luminescent imaging was performed by an
imager equipped with the ClearLive program software.
5.2.3 in vivo animal titration study
Native TTCF at 1 mg/ml in 50mMTris-HCL pH 7.0 was used for an animal study, per-
formed at Newcastle University by Dr Yi Yang and Dr Kevin Marchbank. Five mice
(Charles River laboratories), 1 mice/group, were used in a 21 day’ immunisation pro-
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tocol. Groups were assigned based on native TTCF dosage as follows: 1/2.5/5 and
10 µg with a PBS only group as negative control. Following pre-immunisation bleed
(day 0), mice received an intra-peritoneal injection of the specified TTCF amounts.
Mice were bled weekly by tail venesection and a terminal bleed collected at day 21.
Serum was sent to the University of Bath and analysed using ELISA161.
5.2.4 in vivo animal study
Ensilicated TTCF was heated at 80 ◦C for 2 hours. After release from ensilication,
protein was dialysed in 50 mM Tris-HCL pH 7.0 using a 10k MWCO Slide-A-Lyzer™
dialysis cassette (ThermoFisher, UK), with Triton-X 100 lipopolysaccharide (LPS)
extraction before injection. Twenty BALB/C mice (Charles River lab.), 5 mice/group,
were used in a 48 day’ immunisation protocol performed at Newcastle University by
Dr Yi Yang and Dr Kevin Marchbank. Groups were assigned as follows:
• native TTCF (+ve control)
• heated TTCF (-ve control, denatured protein)
• ensilicated TTCF then released
• ensilicated TTCF + heated at 80◦C then released
Following pre-immunisation bleed (day 0), mice received an intra-peritoneal injection
5 µg per dose of treated TTCF. A PBS only group was also included as a further
negative control. Mice were bled weekly by tail venesection; a booster dose (5 µg
TTCF) was given at day 28 and a terminal bleed collected at day 42. Gathered serum
was sent to the University of Bath and analysed using ELISA.
5.2.4.1 ELISA analysis of serum samples
Purified recombinant TTCF was coated at 10 µg/ml, 100 µl/well onto high-binding
96-wells ELISA microtitre plates (Greiner, UK) in Na2CO3 buffer, pH 9.6 overnight
at 4◦C. Plates were washed three times with PBS and then blocked for 1 hour in
PBS-Tween 0.05% (PBS-T) containing 1%Casein (Sigma, UK). Plates were washed
3 x 150 µl/well with PBS-T. Anti-TTCF mouse monoclonal antibody (clone 10G5) at
a concentration of 1 µg/ml was added to act as a positive control and allow normal-
isation across ELISA plates. Fifty times pre-diluted samples (in PBS-T) and 10G5
were serially two-fold diluted before transfer to the ELISA plates and incubated for 1
hour. These were then washed again 3 times. Horse-radish peroxidase (HRP) con-
jugated goat-anti-mouse IgG (Sigma UK), at 1:10,000 dilution in PBS-T was then
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added for 1 hour incubation. Plates were washed 4x and freshly prepared tetra-
methyl-benzidine (TMB) substrate solution (0.1 M Sodium Acetate pH 6.0, 10 µg/ml
TMB, 0.015% H2O2) added, followed by 10% H2SO4 to stop the reaction. Absorb-
ances were read at 450 nm and corrected by subtraction of the reference read at
650 nm and normalised to the positive control (10G5 monoclonal antibody) absorp-
tion161. Statistical analysis was performed using SPSS v13 (IBM, USA), one-way
ANOVA with post-hoc Tukey HSD test.
5.2.5 Calorimetry of TTCF
Calorimetry is a physiochemical principle that can measure physical transition of
materials. It is commonly used to monitor protein unfolding (Tm) or for identifying
glass transition temperatures (Tg)247–250. This method is based on the change of
temperature in exothermic or endothermic reactions that materials undergo once
they are heated. Protein unfolding is an endothermic change, where conformational
changes lead to uptake of energy from its environment. To establish the thermal
resilience of ensilicated material, micro-calorimetry (a more sensitive form) was ap-
plied to identify the Tm of native TTCF. Following this, powder DSC was utilised to
screen ensilicated material for transitions that could indicate protein unfolding.
5.2.6 DSC
Weighed ensilicated TTCF powder (5.6 mg) was added to an aluminium calorimetry
pan. The apparatus (DSC Q20, TA instruments) was set to run a temperature range
from -10 to 100 °C for 3 cycles at 5 °C/min followed by a hold at each extremity
(figure 5-9) for 5 min. After cycles were completed, material was held at 100 °C for
5 hours to assess thermal resilience.
The Setaram µDSCwas used to measure native and released TTCFmelting temper-
atures. This machine is a heat-flux DSC. It indicates that the reference and sample
cells, nickel alloy, are contained within the same environment. Energy needed to
keep the reference cell at the same level as the sample cell is denoted as heat-
flow. This variable can have various units, however mW were used. The minimum
required sample concentration was 2 mg protein weight.
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5.2.7 TGA-DTA-MS
Thermogravimetric251 (TGA) differential thermal analysis (DTA) coupled with a mass
spectrometer229 (MS) was performed on lyophilised and ensilicated TTCF material.
It is a similar technique to DSC, with the temperature difference between the sample
and reference being measured instead of the heat flow. A Setsys Evolution 16/18
(Setaram) was used with alumina pans as sample holders; the reference pan was
left empty. The analysis of 0.95 ensilicated and 3.09 mg lyophilised TTCF was run
from 30 to 200 °C at 10 °C/min under argon flow at 20 ml/min. Alongside with the
DTA signal, the mass evolution of the sample was measured by thermogravimetry
(TGA) and evolved gases were detected using a mass spectrometer (MS) attached
to the instrument (Omnistar GSD 320, Pfeiffer Vacuum, equipped with a quadrupole
mass analyser and a SEM detector) through a stainless steel capillary. The MS was
set to record atomic mass units (amu) from 1-200 for duration of the run. Known de-
composition elements for proteins were investigated for (increasing) presence during
the analysis.
5.2.8 CD
Circular dichroism, used for determining the proportion of specific secondary struc-
tures,190–192,252 is also capable of studying protein unfolding. The CD spectrometer
can perform thermal ramps. Monitoring the ellipticity of a protein change over a lim-
ited range of temperatures can elucidate the thermal transition midpoint, Tm. Using
a modified Gibbs-Helmholtz equation, the absorbance data can be processed and
fitted with an equation which describes a two-state transition which is applicable for
the majority of protein253. Depending on which secondary structure is abundant,
the wavelength of analysis can be chosen. For most proteins this will be 222 nm.
For TTCF, absorbance at 200 nm represented the aborbances of major contributing
secondary structures present within this protein.
Native and released TTCF at a minimum of 50 µg/ml concentration was analysed.
The protein was dialysed beforehand into 10 mM Na2HPO4, NaH2PO4 buffer at pH
7.0 and CD was measured between 185 — 260 nm. The temperature ramp ini-
tially consisted from 20 to 70 ◦C at 5 ◦C intervals. Each measurement was set to
2 seconds per wavelength with a bandwidth of 2 nm. The second ramp was set
from 50 — 70 ◦C at 1 ◦C interval. Both ramps were incremental at 1 ◦C/min. Ac-
quired data was converted to delta epsilon and fitted using the custom equation in
the MatLab™software package. The data was processed using:
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Parameters
h=-20000 ; starting enthalpy in cal/mol = -6.0643
tm=60 ; starting TM (observed) in deg. C.
u=-10; delta epsilon of 100% folded helical protein
l=-1; delta epsilon of unfolded protein
Variables
v=col(1) ; temperature in deg. C
w=col(2) ; delta epsilon
Equations
m=tm+273.15; convert Centigrade to Kelvin
t=v+273.15; convert Centigrade to Kelvin
k=exp((h/(1.987*t))*((t/m)-1)); calculate folding constant at any given temperature
y=k/(1+k); calculate fraction folded at any given temperature
f=((u-l)*y)+ l ; calculate ellipticity at any given temperature
fit f to w; fit the calculated ellipticity to the observed ellipticity
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5.3 Results & Discussion
5.3.1 Initial release
TTCF was ensilicated, released and analysed using SDS-PAGE, Western Blot, CD
and ELISA. Native TTCF was used as a control. Various samples during ensilica-
tion were taken and visualised on a gel. There is protein present in the flow through
which has not been incorporated as shown on the SDS-PAGE and WB images (fig-
ure 5-1) where a bright band is visible in the respective lane. Subsequent washes do
native native
kDa TTCF TTCF














Figure 5-1: Initial SDS andWB of TTCF ensilication. (top) SDS-PAGE of native, released
and washing steps after ensilication. Amount (w/v) was normalised before loading on the
gel. Visualisation achieved using Coomassie stain. (bottom) Western blot of the same gel
using an anti-histidine antibody. Bands visualised by measured chemiluminescence.
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present a slight band in the first wash on theWB. This displays the sensitivity of using
an antibody detection method compared to the same gel stained using Coomassie.
Newly purified TTCF was added to verify consistency between batches (outermost































Figure 5-2: Initial assessment of released TTCF from silica using CD (top) and ELISA
(bottom). CD spectra obtained between 320 - 185 nm for native and released TTCF. Data
were converted from millidegrees to ∆ε and normalised according to concentration. ELISA
absorbance was obtained from detection of bound native and released TTCF using 10G5
and secondary antibody conjugated with HRP. Substrate conversion was read at 450 nm
and subsequently plotted as antibody concentration over absorbance.
lanes). The anti-histidine IgG antibody with HRP enzyme conjugate allowed as-
sessment of any N-terminal shearing of the protein during ensilication. There was
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no evidence found for this. The apparent bands at 44 and 52 kDa represents TTCF
with bound and free sulfhydryl groups. Following the analysis using SDS-PAGE and
WB, released TTCF was dialysed overnight into 10 mM sodium phosphate buffer
(pH 7 adjusted with HCl) to remove any interference from the silica present in the
release buffer during CD. The spectra from 320 to 195 nm showed a similar pattern
between released and native TTCF (figure 5-2). This is promising as CD provides
structural information about the state of secondary structures present in the protein.
Differences in delta epsilons values between native and released were due to back-
ground subtraction differences. This technicality does not change the outcome of
this result. CD is sensitive to changes in secondary structures. Alterations in these
would shift the peak position left or right-hand, as this was not observed it confirms
the retention of native structure.
Finally, native TTCF and released were coated onto a high-binding microtitre plate
to assess antigenic (functional) conformation. The monoclonal antibody detected
no differences between native and released protein. Therefore, it was safe to say
that it was possible to stabilise TTCF within the silica and retrieve its native state
afterwards, in ambient conditions.
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5.3.2 Thermal stability
To asses the thermal stability of TTCF, three batches of purified TTCF protein were
ensilicated. From each batch, 5 mg was heated at 80 ◦C for 2 hours with native TTCF
in solution as a negative control. Heated and untreated material were released sub-
sequently and analysed using SDS-PAGE in triplicate (figure 5-3). The native and
untreated released protein did not show an increase in shear, which would result
in additional bands. Heat treated released acted accordingly with these results. In
contrast, the heated unprotected protein seemed to have completely sheared due to
the heating of protein which is visualised as a smear on the gel.
To verify the secondary structure integrity, released samples from one batch were
dialysed into 10 mM phosphate buffer. The circular dichroism of these samples was
measured from 260— 185 nm, far UV. The machine output in millidegrees was con-
verted to delta epsilon which allowed normalisation of concentration variances. Res-
ults displayed an overall similar pattern (figure 5-4). The heat treated and untreated
released material possessed very similar patterns compared to native absorbance
Figure 5-3: SDS-PAGE of native TTCF, untreated released, heat-treated released and
heat-treated native227. Samples were normalised and 5 µg of protein was loaded in each
respective lane. Heat-treated samples were exposed to 80 ◦C for 2 hours before analysis.
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Figure 5-4: CD spectra of TTCF thermal stability. CD spectra between 260 - 185 nm of
native, released and heat treated (native & released) TTCF samples were obtained. Sample
data were converted from millidegrees to ∆ε and normalised according to concentration.
Deconvolution of each spectra was subsequently performed using DichroWeb.
suggesting no loss of or very small loss secondary structure. There is a difference
observed in the released material where there is increased chirality between 205
and 222nm. This could likely be due to background subtraction errors.
Unprotected native which was heated did not show chirality as its absorbance of
both rotational polarised lights was effectively zero. This meant the protein had
completely unfolded and lost its tertiary and secondary structure. The CD spec-
tra of these samples were deconvoluted using the CDSSTR (reference set 6) al-
gorithm254–256 to define the individual contributions of major secondary structures
(table 5-1). It was found that the overall contributions of α-helices, β-sheets and
random coils did not significantly differ between native, released and heat treated
Sample Helix1 Helix2 Strand1 Strand2 Turns Unordered Total Resi
native -0.01 0.03 0.22 0.12 0.2 0.43 0.99 0.044
released -0.01 0.03 0.24 0.13 0.2 0.39 0.98 0.043
heated rel -0.01 0.03 0.22 0.12 0.19 0.42 0.97 0.047
Table 5-1: Deconvolution of secondary structures TTCF circular dichroism. Individual
contributions to the overall CD spectrum. Observed is the similarity of distribution across all
samples excluding heated native. Helix 1: α-helix, regular; Helix 2: α-helix, distorted; Sheet
1: β-sheet, regular; Sheet 2: β-sheet, distorted; Turns: β-turns; Unordered: random coils.
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Figure 5-5: TTCF antibody binding capacity before and after ensilication227. ELISA
assay was performed on native TTCF (blue), native TTCF heated for 2 h at 80 ◦C (purple),
TTCF released from ensilication (orange) and ensilicated TTCF heated for 2 h at 80 ◦C
and released (yellow). Data are visualised as antibody concentration over absorbance with
standard error of the mean (SEM), n = 3.
released. The normalized root-mean-square deviation257 (NRMSD) shows that the
fitting across the samples is equal, therefore allowing good confidence in the as-
sumption that the TTCF protein in various stages has retained its secondary struc-
tural integrity. ELISA was then performed after confirming the retention of primary
and secondary structure of TTCF heat treated material. The protein was bound to a
microtitre plate and detected using a monoclonal antibody, 10G5, specific to TTCF.
The result from this analysis displayed the preservation of antigenic epitopes present
on the protein (figure 5-5). An antigen requires structural integrity and specific con-
formation to be bound by an antibody, therefore it was safe to say that the protected
material, either heat treated and untreated retained its native conformation. This
was observed from the non-significant absorbance difference between the native
and ensilicated groups calculated using the non-parametric Kruskal-Wallis test. Un-
protected heated material had lost all of its antigenicity as it lacked the ability to be
bound by the monoclonal antibody.
TTCF was also lyophilised to provide a comparison between lyophilisation and en-
silication. Freeze-drying is a widely used method to stabilise proteins. Both en-
silicated and lyophilised material were exposed to the same conditions described
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ensilicated (reconstituted, heated, released)
lyophilised (reconstituted)
lyophilised (reconstituted, heated)
Figure 5-6: ELISA on lyophilised TTCF227. (top) Lyophilised and ensilicated material were
heated, then reconstituted and released respectively. Bound TTCFwas detected using 10G5
antibody and secondary antibody against IgG conjugated with HRP. Data were plotted an-
tibody concentration over measured absorbance at 450 nm. (bottom) Same experiment as
above, however buffer was added to lyophilised and ensilicated material before heating. En-
silicated material was released thereafter. TTCF was then bound onto the microtitre plate
for detection.
earlier. The reconstituted and heated materials were analysed using ELISA to as-
sess whether the antigenic properties were retained in comparison to freeze-drying.
The results (figure 5-6) display binding capacity of native versus both methods.
There is no difference between the three samples, with the native heated serving
as a negative control. Note that these materials were exposed in dry state. The
same figure (figure 5-6, bottom) indicates that hydration before heating completely
removes any binding capacity of both methods. This suggests that both materials
would be susceptible to increased humidity and temperature combined. The overall
result indicates ensilication to be as protective as freeze-drying.
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5.3.3 in vivo
Confirming the retention of TTCF at all relevant protein levels, the logical way for-
ward was to verify its functionality in vivo. Before the in vivo study on TTCF was
performed, optimal dosage needed was to be determined. Five mice were injected
with increasing dosage of native TTCF. Their serum was collected every 7 days up
to 21 in total. The serum was analysed using ELISA (see Appendix A.7 for plate re-
sponses). The results were convoluted and visualised. Data presented (figure 5-7)
clearly show an optimal immune response at 5 µg/dose. The 10 µg/dose displays
a lower overall response which is an indication of immunological threshold where-
after an antigen starts to be tolerated by the immune system. Therefore, 5 µg/dose
was chosen as the effective concentration in the following in vivo study. This prelim-
inary data increased the confidence that released TTCF would induce an immune
response based on biochemical data.
Ensilicated TTCF, made for this study, was tested directly after release with no dia-
lysis to exclude that this was a critical step during release. Dialysis is normally per-
formed overnight at 4◦C in a large volume of target buffer. This helps to refold pro-
teins that are slightly unfolded. The ELISA analysis found good binding capacity of
various released samples compared to native TTCF. These were analysed using the
mouse serum obtained from the titration study. This implicates some binding due to
linear epitopes which do not require the protein to possess a specific conformation.
However, the signal from these samples were in decent alignment with native TTCF.
It may be that dialysis partially refolds the protein after incubation as the released




























Figure 5-7: Serum ELISA TTCF titration. Serum IgG responses to various doses of native
TTCF injected in mice. Overview of combined results where absorbance data is normalised
to 10G5 standard.
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samples were diluted in high pH sodium bicarbonate buffer before overnight binding
on the microtitre plate (figure A-3, Appendix A.8).
The protective capacity of ensilication on TTCF was then confirmed in vivo. This ex-
periment included 4 groups of mice consisting of 5 mice per group. Each group was
assigned as described in methods section 5.2.4. Observed was an early stage im-
mune response in the mice injected with native TTCF and this immune response was
matched when the mice were injected with TTCF which had been stored as ensilic-
ated powder and released prior to immunisation (figure 5-8).The results confirmed
the protective capacity of ensilication to maintain normal protein/epitope conforma-
tion at ambient temperature, as well as when the ensilicated material was heated at
80 °C for 2 hours (responses per day, see Appendix A.9). The ensilicated material




























Figure 5-8: Serum IgG responses from mice immunised with TTCF after ensilication.
Normalised absorbance values against monoclonal 10G5 (RU: relative units) with secondary
anti-IgG antibody for detection of class-switched antibodies. Sample groups consisted of 5
mice which were immunised with 5 µg of TTCF at the start of experiment and boosted at 28
days (arrow). Data are expressed as mean +/- SD (n=5). Statistical analysis was performed
applying one-way ANOVA with post-hoc Tukey HSD test. Comparison vs native TCCF (ns
= non-significant) or vs native TTCF heated to 80 °C to denature and inactivate ((∗ p < 0.05,
∗∗0.01 and ∗∗∗ 0.001,)
used during this study was stored in powdered form for 1 month at room temperature
and then transported using commercially available means without any specialised
equipment. The ensilicated TTCF was protected from elevated temperature denat-
uration, as demonstrated by the lack of specific immune response when unprotected
and heat-denatured TTCF was injected into mice. After 28 days, the booster shot
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was given which is reflected by the immune response. Statistics revealed no signific-
ant differences between the responding groups and a significant difference between
the groups and denatured protein.
5.3.4 Calorimetry
DSC was employed to probe the thermal resilience of ensilicated TTCF (figure 5-9).
The run, which included several ramps between -10 to 100◦C showed no endo-
thermic transitions that could indicate protein unfolding. The first cycle displayed a
large downwards slope which could be associated with bound H2O being liberated
from this material. This slope does not present itself in subsequent cycles. After 5
repeats, the hold at 100◦C does not indicate any noticeable changes in this material.


















Figure 5-9: DSC calorimetry experiment of ensilicated TTCF. Three cycles of -10 to 100
◦C with a hold of 100◦C for three hours does not present a sharp endothermic peak.
The DSC experiment was repeated for 1 cycle from 20 to 200◦C using a TG-DTA-
MS (figure 5-10). TGA signal reported a weight loss of 11% for ensilicated and 3%
for lyophilised TTCF. This loss of mass for ensilicated TTCF material is in line with
previous data reported on ensilicated lysozyme where it was found to lose 10% of
mass during the TGA203,227. Mass spectrometer signal reported the loss of weight
associated with water loss at atomic mass unit (amu) of 18. Interestingly, the unpro-
tected TTCF showed an endothermic transition at 150 ◦C. This is not observed in the
protected TTCF and displays the protective capacity of ensilication. Temperatures
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Figure 5-10: TGA-DTA-MS of ensilicated TTCF. (top) Ensilicated TTCF displays a weight
reduction of 10 % during heating. The DTA shows an endothermic transition associated with
liberation of water supported by the MS peak. (bottom) Unprotected TTCF shows a small
weight loss with associated water signal increasing. At 149 ◦C there is a sharp endothermic
peak present, indicating a transition taking place.
136
above 50◦C are highly unlikely to occur during vaccine transportation. However, this
data is reassuring of ensilication stabilising capacity.
Circular dichroism was employed to assess protein unfolding under thermal stress.
TTCF native, released and heat treated were measured between 260 - 185 nm from
50 to 70 ◦C. An initial global run was performed from 5 to 85 ◦C to probe the nature
of TTCF unfolding. The CD data were converted into delta epsilon (thermal ramp
data, see Appendix A.10). This value at 200 nm for all measurements was plot-
ted versus temperature and fitted using the Gibbs-Helmholtz equation (figure 5-11).
Good fits were observed for each data set. There were some differences in the un-
folding pattern between the native and ensilicated samples. However, an additional
repeat displayed this to be a concentration dependent occurrence as this unfolding
pattern was similar to released and heat-treated released measured at identical pro-
tein concentration.




















Figure 5-11: TTCFGibbs-Helmholtz fitted CD data. Delta epsilon valuesmeasured at 200
nm were plotted versus temperature. The Gibbs-Helmholtz fit was applied to this data with
set starting points. Good fits were obtained and calculated parameters were deconvoluted
further to obtain calorimetric identifiers of protein stability. Native, release and heat-treated
TTCF were run at 1 ◦C increment between 50 - 70 ◦C. Native TTCF global was run at 5 ◦C
increment between 5 - 90 ◦C
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Figure 5-12: TTCF fitted CD data van’T Hoff plots and first derivatives. (top and bottom
left) Data fitted with linear regression to the global and limited range runs. (top and bottom
right) First derivatives of fitted CD spectra. Peaks correlate with thermal unfolding of TTCF.
Processed calculated data were visualised in van ’T Hoff plots and first derivatives
of unfolding (figure 5-12). The fitting showed that all varieties of TTCF were struc-
turally unaffected with no significant differences in thermal transition midpoints ob-
served between native (global) 61.41 ◦C, native (local) 59.16◦C, released 60.84◦C
and heat-treated released 59.01◦C.
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5.3.5 Long term storage
Ensilicated TTCF was released and analysed after 2 weeks, 1 month, 3 months, 1
year and 2 years of storage at room temperature (20 - 22 ◦C) to assess long term
storage. The material was released using the standard protocol and analysed using
the experiments described for all three protein levels. The initial triple batch (R1-3)
used for the thermal stability experiment was used until the third month of storage.
Limited amounts of material were available for testing, therefore additional batches
were made for storage at longer durations.
The SDS-PAGE and ELISA analysis for the first three months showed the material
retaining its primary and tertiary structural integrity (figure 5-13). The CD data ac-
quired for these samples showed increased background errors due to technicalities.
Therefore, these data could not provide any reliable information about the second-
ary structures (Appendix A.11). However, since analysis of tertiary structure showed
good antibody binding this was not of concern.
The 1 and 2 year samples were difficult to release using NaF buffer. This material
displayed signs of vitrification and meant the filtrate had changed from a powder-like
state towards a glassy dense state. The reason for this has not yet been identified.
To resolve this, 0.1 M of NaOH was used to dissolve the glass like material. Once
this was dissolved, solution pH was quickly adjusted using HCl to neutralise any free
hydroxyl radicals. Analysis of the material did confirm incorporation of TTCF.
SDS-PAGE analysis of vitrified samples stored over long term showed presence
of TTCF polypeptide molecular weight (figure 5-14). This confirms the retention of
TTCF at primary level.
The ELISA analysis of these samples was done with use of mouse serum obtained
from the in vivo experiment (figure 5-15). Resultant response in absorbance is a
convolution of linear and conformational epitopes present. It is promising to have
found protein after release from ensilicated material which does not dissolve when
using NaF buffer. Ensilicated lysozyme was used as a release buffer control. This
material did dissolve in the standard protocol buffer.
Overall, TTCF can be stored using ensilication up to two years. However, vitrification
renders thematerial unusable for release in standard conditions. NaOH is a powerful
denaturant and would not be a suitable replacement for NaF. Therefore, more control


























































Figure 5-13: SDS-PAGE and ELISA of released TTCF after storage up to 3 months
at room temperature. (left) SDS-PAGE analysis of TTCF polypeptide weight after release
from storage. R1-3 represent triplicate ensilicated batches and N1-3 are the native purified
TTCF solutions used for ensilication. D = denatured TTCF, native TTCF heated at 80 ◦C for
2 h. (right) ELISA analysis for N1-3 and R-3. TTCF was bound and detected using 10G5
with secondary anti-IgG conjugated with HRP. Data were plotted as antibody concentration
over averaged absorbance at 450 nm. Error bars display SEM (n=3).
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Figure 5-14: SDS-PAGE of released TTCF after storage up to 2 years. A gradient gel
(4 - 20 %) was used to run native TTCF and released TTCF from ensilicated material that
was stored at room temperature for 1 week, 3 months, 1 year and 2 years. The latter two
samples were released using 0.1 M NaOH for 1 hour rotating at room temperature with pH
to 7 afterwards.




















Figure 5-15: ELISA of released TTCF after storage up to 2 years. Ensilicated TTCF was
released using NaOH and pH to 7. Protein was bound and detected using serum from the
in vivoexperiment. Secondary antibody was targeted at IgG response. Data were plotted as
log2-dilution over absorbance. Serial dilution started at 50x.
141
5.4 Summary
After establishing that TTCF could be successfully ensilicated, it was necessary to
determine whether the protein could be released from the silica shell and retain its
structural integrity. Initial release experiments were performed to analyse the three
levels of TTCF protein structure after dissolving the silica shell. Primary structure
was investigated by SDS-PAGEwhich showed retention of the polypeptide length (52
kDa). Western blot confirmed that there was no shearing indicating that the protein’s
primary structure was unaffected by release. Secondary structure was examined by
CD which displayed similar structural patterns between native and released. More
importantly, the analysis of tertiary structure by ELISA showed identical responses
from native and released TTCF. This confirmed retention of the 10G5 recognised
conformational epitope161. Since all structural levels appeared to have been main-
tained, the study was progressed towards the examination of the thermal resilience
of ensilicated TTCF.
Ensilicated material was heated together with native TTCF and examined with the
methodologies described above to assess the protective capacity of ensilication.
The data showed no difference between native, released and heat-treated released
material while heated non-ensilicated TTCF had lost its structure at all levels. De-
convolution of the CD pattern confirmed retention of secondary structures with the
overall contributions of -helices, -sheets and random coils not significantly differing
between native, released and heat treated released. The binding capacity meas-
ured in the ELISA displayed no significant difference again with the aforementioned
groups.
The immunogenic capability of the released and heat treated material was analysed
in an in vivo experiment. The initial titration experiment suggested 5 µg of TTCF
would produce an optimal dose response. Serum analysis showed no significant
differences in response between native, released and heat treated releasedmaterial.
This supported the evidence from the thermal stability experiment and showed that
ensilication is a viable method for vaccine stabilisation.
The biophysical properties of ensilicated, native and released TTCF were probed us-
ing calorimetry. The aim of this was to identify whether the energetic value required
for denaturation was affected by ensilication. Ensilicated material was subjected to
repetitive thermal ramps using a DSC apparatus. A broad endothermic peak was
observed which was associated with water coming off the material. This was du-
plicated in an experiment using TGA-DTA-MS. The sample mass loss showed cor-
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relation with the mass spectrometer peak for water. Lyophilised TTCF showed an
endothermic peak in the DTA which was not observed in ensilicated material. This
demonstrated the protective capacity of ensilication.
Calorimetric analysis of native and released protein was done using CD. Fitting of CD
spectra at specific wavelengths with samples heated over time showed a two state
transition between folded and unfolded state. Comparison of the fitted parameters
showed no difference in thermal transition temperatures and therefore indicated that
TTCF was not physically affected by ensilication and release.
The long term storage study showed retention of TTCF for up to two years. Producing
a large batch to be examined throughout the two year study was a challenge as
the production of large amounts of recombinant antigen (>1 gram) was expensive
and time consuming. Therefore, the study had to be done in using three separate
batches of ensilicated TTCF. This exposed a major challenge in protein ensilication
as the method does not always provide powder-like material. Instead, the dried
sample may vitrify into a dense glassy state. There are several possible parameters
that may cause this: TEOS starting material, humidity, temperature, presence of
salt ions, duration of ensilication or buffer preparations. Investigation into these was
beyond the scope of this study, however it needs to be addressed for future studies.
In all, ensilication protects and stabilises TTCF over time and against thermal stress






The ensilication methodology was initially developed with use of hen egg-white lyso-
zyme203. This ubiquitous 14 kDa protein plays a significant role in protection against
bacterial pathogens. It is able to break down the cell-walls of Gram− bacteria. This
protein has been well studied and characterised on many occasions. Other proteins
such as insulin and horse haemoglobin were also evaluated in the ensilication pro-
ject. In this Chapter, an account is made of the additional studies that supplemented
the lysozyme project. The aim was to complement the findings of TTCF ensilication
and show the versatility of protein ensilication.
6.2 Methods
6.2.1 Released lysozyme crystal structure
The crystal structure of released lysozyme was examined and compared to the nat-
ive hen egg-white lysozyme to confirm structural retention on a fundamental level.
Ensilicated lysozyme was released and crystallised. This crystal was then analysed
using x-ray diffraction (XRD) and a 3D-model refined.
6.2.1.1 Lysozyme crystallography
Crystallisation of lysozyme released from silica was achieved with use of the
‘hanging drop’ vapour diffusion technique. Pure lysozyme has been crystallised on
many occasions before and the conditions mentioned here have been adapted from
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literature for use within this procedure. Released lysozyme was dialysed in 0.1 M so-
dium acetate pH 4.6 and concentrated to 25 mg/ml. In a 24-well crystallisation plate,
700 µl of 1.5 M NaCl in 0.1 M sodium acetate pH 4.6 was added to each reservoir.
The lysozyme solution was mixed 1:1 on a siliconised coverslip with reservoir solu-
tion creating a 2 µl droplet. Diffusion within the covered well provided changes in
the precipitant causing the reservoir solution to retain more water, thus resulting in
the formation of crystals within the droplet as the protein concentration increased,
until equilibrium was obtained. Crystals were formed after approximately 5 days
incubation at 18°C.
6.2.1.2 Lysozyme X-ray diffraction
Crystals were flash frozen in a loop (reservoir solution + 25% glycerol) under a con-
tinuous nitrogen cryo stream (Oxford Cryosystems Cobra) and full data set was col-
lected on an in-house rotating anode X-ray source (Rigaku MicroMax-007HF) with a
Saturn 944 + CCD detector. The structure of released lysozyme was resolved using
molecular replacement (using Balbes) and refined (using Phenix) with model build-
ing in COOT. This work was performed by a collaborator (see Acknowledgements).
6.2.2 Lysozyme in vivo
To conduct the lysozyme in vivo experiment, several samples were prepared and
analysed before continuing with the animal study.
6.2.2.1 Material preparation and analysis
Lyophilised lysozyme (native control) was dissolved, 27 mg, in 10 ml of 50 mM Tris-
HCl pH 7 buffer. Two millilitres were heat-treated separately. Previously made en-
silicated lysozyme, under standard protocol conditions (section 3.2), was split in two
with half being heat-treated prior to release. Heat-treatment was performed for 5
hours at 95◦C in a thermal heating block. Samples were contained in 1.5 ml eppen-
dorfs. Enzyme kinetic analysis (EnzCheck™ lysozyme assay kit, ThermoFisher,
UK), normalised using protein concentration determined by BCA assay, validated
the samples for use in the animal study. The analysis was performed according to
manufacturers instruction.
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6.2.2.2 Sample preparation before intra-peritoneal injection
Ensilicated samples were released in 1:1 ratio of 190 mM NaF pH 2.65 and Tris-HCl
pH 7 buffer. Ensilicated lysozyme (7.5 mg), ensilicated heated treated lysozyme
(7.8 mg) and ensilicated lysozyme (5.8 mg, Master sample for comparison) were
dissolved in 10 ml of release buffer. After 1 hour incubation on a roller bank, 3 ml
of each sample was added to a Slide-A-Lyzer™10k MWCO dialysis cassette to be
buffer-exchange into Tris-HCl overnight at 4◦C. The following day, samples were
extracted from their cassettes. Quick UV-absorbance analysis using a NanoDrop™
One Microvolume UV-Vis Spectrophotometer (Thermo Scientific) analyser verified
protein presence. Samples were filtered using a 0.22 µm spin column. Samples
were sterile filtered for 1 min at 16,000 x g. Final concentrations were checked
using the NanoDrop system. 50 µg of lysozyme was used per dosage with 10 µg of
LPS added for each mouse to boost the immune response.
6.2.2.3 Animal mouse study
The lysozyme in vivo study include 25 mice with 5 mice designated per group under
the following conditions:
• Native lysozyme (+ve)
• Native heat-treated, denatured (-ve)
• Ensilicated, released
• Ensilicated, heat-treated, released
• Ensilicated master sample (long term storage > 3 years, provided by Dr Y-C.
Chen), released
Each mouse received an intra peritoneal injection. Blood was collected by tail vene-
section on days 0, 7, 14, 21, 28, 35 with a final bleed on day 42. At day 28, mice
were given a booster dose of stored sample of the same condition.
6.2.2.4 ELISA serum analysis
Native lysozyme was coated on a 96-well microtitre plate (10 µg / ml, 100 µl / well) at
4°C overnight in PBS pH 7.4. Plates washed 3x with PBS and blocked with 1% Ca-
sein in PBS-T (0.05%) for 2 hours. After four washes serum was added. This was
diluted in a two-fold titration starting at 50 times dilution and corrected for serum
volume before being transferred to the ELISA plate. Monoclonal, Hyhel-10258, anti-
body was added to two wells in each plate and diluted accordingly with the samples.
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This was used to normalise the plates. After 1-hour incubation, goat-anti-mouse
IgG + HRP was added in 1:5000 dilution to PBS-T (0.05%) and added to each plate
for another 1-hour incubation at room temperature. Finally, after extensive wash-
ing, TMB substrate was added and the reaction ended after addition of 10% H2SO4.
Absorbances were read at 450 nm with a reference at 650 nm and subtracted sub-
sequently.
6.2.2.5 ELISA data processing
Serum absorbances collected for all conditions were normalised using the HyHel-
10 monoclonal antibody responses. These values were output in relative units (RU)
and allowed comparison between all ELISA plates. Samples were plotted in RU
responses at 200x dilution over the experiment duration. An overview of all re-
sponses per day is visualised in the Appendix A.13. Samples that showed devi-
ating responses with a blood sample volume below 10 µl were masked. Minimum
replicates were n=3 up to n=5.
6.2.3 Calorimetric analysis of lysozyme using CD
Ensilicated lysozyme was released, in triplicate, and dialysed according as previ-
ously described (section 5.2.8). The measurement settings were identical to the
TTCF experiments. Triplicate batches of native lysozyme, reconstituted in sodium
phosphate buffer, were analysed using the thermal CD ramp253. Data recorded data
in millidegrees was normalised to delta epsilon. Spectral data at 222 nm was fitted
using the same equation as for TTCF. Thermal transition temperatures and van ’T
Hoff plots were visualised using MatLab™.
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6.3 Results & Discussion
6.3.1 Lysozyme crystal structure
Lysozyme crystals were formed after several days of incubation at ambient temper-
ature. One of these crystals was placed into the sample holder for the XRD (see
Figure 6-1: Released lysozyme crystal and refined 3D structure. (left) released lyso-
zyme crystal grown after 5 days incubation. (right) refined 3D structure of released lysozyme
overlayed with the hen-egg white lysozyme PDB 2w1x259 structure used for molecular re-
placement.
collection and refinement details, Appendix A.12). After alignment and additional
checks, the diffraction patterns were collected and the model was refined using the
PDB 2w1x259 protein sequence for molecular replacement (figure 6-1). The com-
piled protein structure from released lysozyme was overlayed with 2w1x. The res-
ults found a 100% match between both crystal structures. This confirmed complete
structural retention of hen egg-white lysozyme after ensilication.
6.3.2 Lysozyme in vivo
Protein concentrations of prepared material were quantified using BCA (table 6-1).
Based on these values, the enzyme kinetics were assessed using the Enzcheck™
analysis. Results showed good consistency between native and ensilicated treated
material. Following dialysis and sterile filtration, LPS was added and this solution




native 2.70 85719 31747
released 0.48 16576 34533
released (heated) 0.53 6110 11528
denatured 1.11 73 66
Table 6-1: Lysozyme, ensilicated sample preparation for in vivo study. Proteins con-
centrations for each sample was quantified using BCA and subsequently checked for en-
zyme activity in IU/ml.
completion of the experiment and analysed using ELISA (overview per day, Ap-
pendix A.13). The responses were compared to internal HyHEL-10 standard and
visualised (figure 6-2). Master sample represented ensilicated lysozyme produced
(and released here for in vivo) during the proof-of-concept study for this protein227,
which had been stored for over 3 years. Other samples were made 1 month before
the in vivo study.






























Figure 6-2: Lysozyme in vivo serum responses measured by ELISA. 5 mice per group
were injected, intra-peritioneally, with native, released (including master sample), heat
treated released and heated native lysozyme. Serum was collected each week and ana-
lysed using ELISA. Master sample stored > 3 years at room temperature was used for long
term stability assessment. Average responses, normalised using HyHel-10 monocolonal, at
200x dilution are visualised. Statistical analysis was carried out using a one-way ANOVA
with post-hoc Tukey HSD where *P <0.05, ns = non-significant.
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Lysozyme is an antigen to mice and the in vivo experiment showed an increased
response for released and heated treated released material compared to others.
The latter presented the highest responses with great variation in each time point.
A possible explanation for the could be the increased adhesion of LPS to a partially
unfolded protein that exposed its hydrophobic region. Adhesion of LPS to lysozyme
has been utilised before260. In this study, the binding of lysozyme to LPS prevented
a normal immune response to LPS which includes septic shock. The suggestion
of a partially unfolded protein can be deduced from the enzymatic activity of this
sample which was a third compared to released. This could have then enhanced the
immunological response to the lysozyme which was seen in the serum responses.
It is apparent that there was no initial response in all groups after injection. This
could be because of tolerance. When a foreign protein is introduced in the body,
there is a threshold presence after which the immune system will tolerate such an
entity261. It is unclear why native lysozyme with added LPS did not respond and
therefore this experiment should be repeated.
6.3.3 Calorimetric analysis of lysozyme using CD
Spectrophotometric measurements of lysozyme while heating allowed assessment
of protein thermal stability using circular dichroism (Appendix A.14). Thermody-
namic analysis of lysozyme unfolding showed no significant difference in thermal
transition temperatures between native and released lysozyme (figure 6-3). These
were 73.47 ◦C ± 0.12 ◦C for native and agreed with literature values262–264. Re-
leased lysozyme showed a Tm of 72.10 ◦C ± 0.99 ◦C. Statistics using t-test cal-
culated P > 0.05 therefore retaining the null hypothesis. This aligned with findings,
which were seen in the TTCF experiments and confirms the thermal resilience of
ensilicated protein.
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Figure 6-3: Lysozyme fitted CD data van’T Hoff plots and first derivatives. (left) Non-
linear least squares regression fits to native and released lysozyme. (top right) First derivat-
ives of fitted CD spectra. Peaks correlate with thermal unfolding of lysozyme. (bottom right)
van ’t Hoff plot of lysozyme unfolding. Statistical analysis performed using Student’s t test.
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6.4 Summary
The capability of ensilication to retain native structure was examined using XRD.
The crystallisation of released lysozyme and subsequent analysis by XRD showed
an exact match with PDB 2w1x crystal model of native hen egg-white lysozyme259.
This showed that protein folding was unaffected by ensilication and release.
The in vivo lysozyme experiment showed no significant differences observed
between the released, native and denatured lysozyme. This may be due to the high
variability seen within each group. The released heated sample induced the overall
highest immune response and can be related to a partially unfolded protein. This
was deduced from the enzymatic analysis. Additionally, there were no immediate
responses after immunisation suggesting a possible dosage threshold. These ob-
servations are in contrast with the TTCF experiment and suggest further optimisation
required in the experimental design.
Calorimetric analysis of native and released lysozyme showed no significant differ-
ence in thermal midpoint transitions. Using circular dichroism and application of the
thermodynamic fit, the data (n=3) strongly suggest no apparent influence of silica
on the reconstituted protein conformation. This is in alignment with the biochemical
and enzymatic data gathered in previous studies203.
The evidence presented here shows that ensilication retains the protein structure of
lysozyme after release. The calorimetric results confirm this finding and strengthen




7.1 Aims of the project
Ensilication is a stabilising method for proteins that renders them immobilised within
a silica matrix203,227. This physically prevents protein unfolding following exposure
to thermal fluctuations, an event that is frequently seen during the shipment of vac-
cines19,29–31,33,265,266. The cold-chain logistics network, specifically built for this
purpose, ensures refrigeration temperatures through distribution15. However, tech-
nical and handling errors plague this system15,32,34,35. Over half the vaccines are
exposed to freezing and or heating11. As these valuable biological mixtures con-
tain proteins, the exposure renders them ineffective resulting in a large proportion
of people not vaccinated. Ensilication has been proven effective using a proxy pro-
tein, lysozyme203,227. Here, the native structure and functionality was retained even
after stress testing the material. Ensilication is a sol-gel based process using TEOS
as a precursor metal alkoxide. The hydrolysation yields polymeric species that en-
capsulates the protein within a silica shell139. Ensilicated protein is then converted
in to a dried powder to be stored and used when required. This study intended to
build on this previous success and expand it towards its ultimate use: developing
thermostable vaccines.
7.2 Properties of TTCF
Several methodologies were utilised to understand and assess the native state of
TTCF and its biochemical parameters before progressing towards ensilication.
SDS-PAGE showed a band at 52 kDa which was the reported molecular weight
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of this protein181. TTCF occasionally showed an additional band at 44 kDa and
this was likely due to the presence of bound cysteine residues which were not fully
reduced178. The addition of DTT should have prevented this but could be improved
with increased duration of the sample incubation.
Far-UV CD data showed the presence α-helices with equal proportions of β-sheets
and random coils in line with an earlier study on TTCF180. Near-UV data were not
measured as the tertiary structure was assessed using another sensitive methodo-
logy.
ELISA, using a monoclonal antibody raised against TTCF, showed a sigmoidal dose
response as expected161. A histidine antibody was utilised as a capture antibody
but presented cross binding with the detection antibody (10G5). This situation was
resolved by coating the protein directly onto the microtitre plate well surface. How-
ever, this resulted in the protein being partially disguised from the detection antibody.
In future studies, this method could be improved with the utilisation of a capture an-
tibody without cross-binding.
DLS, after several attempts, provided the hydrodynamic diameter of 7.345 ± 2 d.nm
and zeta-potential, +3.54mV, in Tris buffer. The former was in line with sizes reported
in the crystal structure164. The latter indicated an unstable solution of TTCF at pH 7
in Tris buffer with, more importantly, an overall positive charge. This was assumed
from the results with lysozyme227.
Bioinformatics using the PDB:1A8D TTCF structure proved useful in mapping posit-
ive and negatively charged regions which confirmed the suitability of this protein for
ensilication227.
7.3 Ensilication of TTCF
TTCF was successfully ensilicated with an average incorporation of 64%. We be-
lieved this was an acceptable level of incorporation as at least half of the protein
used for ensilication is stabilised. However, recombinant proteins are an expens-
ive source material and therefore improving the ensilication efficiency is imperative.
One way of doing so could be the introduction of electrostatic effectors or balancing
the ionic strength. Achieving this would shift the overall outer charge of the protein
exposed to the aqueous environment and make it more favourable for silica species,
undergoing condensation and polymerisation, to improve attachment. Lysozyme is
a positively charged protein with a pI > 11 and has 95% ensilication efficiency227,
which makes a good argument for altering the surface charges as the zeta-potential
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for TTCF was identified to be in the unstable region. DLS could measure the stabil-
ising charge effects of added solutes, which would have to be compatible with the
ensilication process.
The material was analysed using FE-SEM and showed angled ellipsoidal particles
with sizes ranging from 200 - 400 nm. This was due to the apparent aggregation and
agglomeration that occurs during ensilication and drying of the material. At present,
this is not an issue as we are setting a precedent for vaccine thermostabilisation
via ensilication. For future uses it is necessary to optimise and control particle size
of protein-silica conglomerates and implement uniformity to create a consistent ma-
terial. Another study done within our group found a possible way267. The study
focused on the ensilication of lysozyme using flow-chemistry and showed control
over particle size by using either glycine or lysine instead of tris in combination with
the removal of chloride ions267. This was a promising find and needs further explor-
ation.
It would also help to add an easier way of extracting small amounts of filtrate. This,
however, renders a new possible issue that might come to pass if this method is
taken to larger quantities: scalability.
FT-IR and UV-vis confirmed the incorporation of protein within silica. The absorb-
ances of amide peaks and convolution of both SiO2 and protein were evident. Com-
parison between triplicate batches revealed no differences in morphology. This,
however, does not indicate whether the material can be released, to check if it has
been vitrified. Using release buffer and testing the material for release with use of
ensilicated reference material as a control is, at time of writing, the only option. In-
vestigation into the parameters that affect vitrification would reduce time and efforts
spent on preparation of recombinant proteins and the subsequent waste of these.
Additionally, the addition of BCA reagent to ensilicated powder resulted in a dark
purple colour developing. This indicated that there are peptide bonds available for
the reduction of copper. This suggests exposure of protein partially incorporated
within the material or that the material possesses enough porosity for the buffer to
penetrate through the material. The latter would explain why it releases quickly.
The assessment of porosity for the aggregated conglomerates would be an inter-
esting addition. The Brunauer–Emmett–Teller (BET) method is able to measure the
surface area of a solid material268. However, if the pores are present they might be
packed with protein and provide no additional information on the distribution of silica,
whether this is vitrified or not. Initial experiments would elucidate if this occurs.
Due to the interference of silica in many methodologies, the conformation of protein
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within the ensilicated matrix has not been addressed. An approach to this could be
UV resonance Raman spectroscopy (UVRR). Based on the difference in relaxation
energies of vibrational molecules it is sensitive to conformational changes of protein
structures and other small molecules including polymers269. This was seen in a
study where the conformation of sol-gel entrapped ligand-bound haemoglobin was
studied269,270. Researchers were able to understand the conformational changes
this protein underwent when incorporated within the silica matrix270,271. It would be
an appropriate strategy to pursue and complete the analysis of ensilicated material.
7.4 Mechanism of TTCF ensilication
To probe the stabilisation mechanism of ensilication, SAXS was employed. This
methodology provides an averaged representable image of processes occurring at
nanometre scale221–226. TTCF was ensilicated while being monitored in situ and
for a longer duration at two independent beamlines234. Data gathered from these
experiments provided comparable images. It was found that TTCF has an ellipsoidal
shape using the distance distribution function and fitting using an ellipsoidal model
with a goodness of fit (χ2) close to 1. Other types of analysis such as the Kratky plot
confirmed this observation.
The shape and morphology of TTCF were calculated based on one concentration.
To strengthen our observations, additional concentrations should have been em-
ployed as these can influence protein morphology or aggregation272. Unfortunately,
there were limited amounts of material available. For future experiments, it would
be advised to include 0.5 mg/ml up to 5 mg/ml protein concentrations.
Ensilication under standard conditions proceeded rapidly within the first twominutes.
Analysis of the data gathered in this window showed a three staged transition. First,
ångström sized silica particulates attached to the protein therefore increasing its
scattering intensity. Second, the apex of the ellipsoidal particle shifted towards the
low-q region of the SAXS plot which indicated particle growth. Finally, it was appar-
ent a fractal-like object was forming.
Additionally, TTCF was ensilicated at different ratios and pH. The analysed data dis-
played the effect of these parameters on the ensilication process. Changing the
ratios increased or decreased the speed of the ensilication process with 1:20 pro-
gressing faster towards a fractal stage and 1:100 slowing down to provide increased
resolution between stage I and II. Adjusting both parameters led to a interesting ef-
fect seen in the pH 8 and 1:100 ratio. The particles formed seem to stabilise early
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on without aggregation occurring. This process did not progress towards the latter
stage which might be indicative of a limiting factor such as the depletion of silicate
polymeric species139.
The initial observations, on the onset of ensilication, were made based on data from
the in situ experiment (i22) which were gathered from one session. The experiments
where ensilication was initiated ex situ (ID02) had multiple repeats on several para-
meters and displayed a consistent image. Therefore, an argument could be made
for repeating the initial experiment to show reproducibility. Another argument could
be made for repeating the ex situ experiments with agitation. This would confirm the
DLCA process as agitation improves particle collision in solution, thereby affecting
diffusion.
Fitting of the SAXS data was initially focussed on the basis of a core-shell ellips-
oid241. This model was assumed on the hypothesis that TTCF was the central core
and silica would form an even shell around, using TTCF protein as a template. This
would lead to a monodisperse solution of TTCF-silica nanoparticles that would sedi-
ment and stick together. The reality did not differ much from this assumption. Fitting
elucidated a DLCA type process where TTCF acted as a nucleation centre. This was
deduced based on the slope of the SAXS plots which provided a fractal dimension,
D f . Our hypothesis assumed a perfect uniform particle, which would have a slope
D f > 3 indicating a surface fractal. The findings led to a D f between 1.5 - 2 over
several experiments which provided the understanding of the ensilication process.
It would be interesting to run these SAXS experiments by adding other moieties to
influence the fractal dimension.
7.5 Protein stability of TTCF and Lysozyme
Verifying protein stability of TTCF before and after release was carried out using the
same methods for analysing primary, secondary and tertiary protein levels of native
TTCF. Additional methods such as calorimetry aided in providing biophysical data.
Initial release of ensilicated TTCF showed retention of structure and antibody binding
capacity of the protein. This set the basis for proceeding towards the thermal stability
experiment. Heated ensilicated material withstood 2 hours of extreme temperatures
showing ensilication to possess an exceptional level of thermal resilience. There
were slight differences in CD spectra, representing secondary structures, however
these were found not to be significant as confirmed using ELISA which indicated no
difference in tertiary structure.
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In a study where tetanus toxoid (TT), i.e. the full inactivated protein, was encapsu-
lated in PGLA micro-spheres, researchers found similar observations using CD and
ELISA119. Additionally, they performed a long term thermal stability experiment at
elevated temperature, 37◦C, for >6 - 30 days and determined the functional level of
the protein. It was shown that the addition of amino acid excipients improved the
stability of PGLA encapsulated TT119.
The final test of protein stability was to conduct an in vivo study. This would help
to show immunogenic retention of heat treated and released TTCF ensilicated ma-
terial. The study showed no significant difference between the native,released and
heat treated released material. There was a significant difference between these
groups and the denatured native antibody responses which supported the findings.
The secondary immunisation showed an increase in the measure serum immune re-
sponse, however we expected a higher increase as seen in in vivo data for tetanus
toxoid273. This could have been due to the lack of alum adjuvant which is commonly
utilised.
Future projects will have to investigate the incorporation of adjuvants within the silica
matrix. The current understanding is that metal ions (specifically aiming at alum) will
influence the sol-gel process, therefore there might be some difficulty with alum139.
The worst case scenario is where aluminosilicates are formed, zeolites. Possible
solution to this problem would be to ship ensilicated vaccines with vials of adjuvants
which can be kept at room temperature due to the absence of protein. After reconsti-
tution and release of ensilicated material, this could be mixed with the adjuvant. Syr-
inge filter injection needles could then prevent any undissolved silica from passing
into the patient. Protein based adjuvants would not pose a problem as these could
be incorporated together with the antigenic protein.
The preparation of samples during the in vivo experiment involved release and dia-
lysis. Therefore, further studies will be required to investigate the toxicology of TTCF-
silica nanoparticles (in buffer) if injected directly. Moreover, there has been a study
that uses protein-silica nanoparticles coated in combination with polyethyleneimine
(PEI) which successfully demonstrated this as a viable injectable vaccine delivery
carrier for the Japanese encaphelitis virus (JEV)274.
Calorimetric experiments were carried out to understand the biophysics of protein
folding. Powder DSC and TGA-DTA-MS showed no endothermic transitions in en-
silicated material that could indicate protein unfolding. Calorimetric analysis of a CD
temperature ramp elucidated the equilibrium constant and Tm value (60◦C) at which
the TTCF protein unfolded. There were no significant differences found between the
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Tm of native, released and heat treated released TTCF. This confirmed that silica
did not structurally affect the TTCF protein. Native and released lysozyme were also
assessed using the method above and showed no difference in Tm values. This was
confirmed in another study where lysozyme was ensilicated at various ratios, 1:20,
1:50 and 1:100275. The calorimetric analysis using µDSC of native and released
lysozyme were in alignment with the findings here.
Ensilicated, released lysozyme was crystallised and analysed using x-ray diffraction
and showed full retention of native structure. The refined model matched the crystal
model of native lysozyme259 and confirmed that ensilication works with other pro-
teins. Crystallisation of released TTCF was attempted, however no crystals formed
during this project.
The in vivo experiment of lysozyme showed immune responses to released, heat
treated but not native lysozyme. The results from this experiment indicated experi-
mental optimisation to be required.
Long term storage of ensilicated TTCF is possible. The analysis of released TTCF
uncovered the main problem with the ensilication methodology. Vitrification of en-
silicated material resulted in a situation where the protein could not be released by
the standard NaF buffer. The reason why the ensilicated material vitrified is thought
to be due to environmental conditions when ensilication occurs. Temperature, hu-
midity and drying speed can affect the end material. The only way to establish that
TTCF was present in the ensilicated material was to dissolve the silica with NaOH.
This is a highly denaturing condition, however allowed the measurement of poly-
peptide length and serum polyclonal antibody binding. These showed retention of
the material up to two years at ambient temperatures. This sets a precedent for sus-
tainability of ensilicated vaccine storage compared to conventional around the clock
refrigeration.
7.6 Other work
Enzymatic digestion, using trypsin, of ensilicated TTCF was performed to under-
stand which parts of TTCFwere ensilicated and exposed. The attempts in visualising
this were not successful, however are still of interest. The reason could be because
of steric hindrance, where the enzyme catalytic site is sterically hindered from cata-
lysing exposed amino acid residues. If a solution could be found, these short poly-
peptides could then be visualised using Western Blot for specificity or SDS-PAGE
for molecular weight. Additionally, mass-spectrometry could be utilised to support
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the findings.
Manduca Sexta caterpillars were also used to test the release of ensilicated proteins.
These insects do no possesses a mammalian immune system and were used to
verify whether ensilicated material could be ingested, digested andmeasured in their
blood. The ELISAs performed on the collected blood did not show a measurable
signal compared to control. Oral delivery is still of interest and could be explored and
optimised in the future. A preliminary study done in our group showed the release
of lysozyme when passed through an artificial digestive system203.
Another project within our group involved the use of a monoclonal antibody against
breast cancer, Rituximab™. Here, we ensilicated the antibody and verified its mo-
lecular integrity using a method designed in the Pudney group at the University of
Bath276. It was based on the fluorescence spectroscopy of tryptophan residues. By
measuring the area under the curve and integrated this with a mathematical model
which would calculate its central spectral mass (CSM)277. The model provided addi-
tional parameters that could elucidate whether the protein was unfolded, aggregated
(the main problem with antibodies which reduces their functionality) or was moving
towards either direction. We found released Rituximab™ to have a similar CSM to
that of native, thereby confirming it could be successfully stabilised using ensilica-
tion278.
7.7 Future perspectives
Ensilication has been shown to perform excellently for stabilising TTCF and does not
affect the structural integrity of the protein after release. The successful response
in vivo shows the feasibility of ensilication to thermally stabilise vaccines. As TTCF
is part of the DTP vaccine, a logic path forward is to work towards a thermostable
DTP vaccine. Each of the additional bacterial antigens could be ensilicated. The
approach towards assessment of these would be in line with the approach for TTCF.
The main parameter that would need extensive investigation is the use of metal
salts for boosting the immune response and ensuring longevity of protection79. Metal
salts, however, influence the ensilication procedure139. Positively charged ions could
have an impact on the soluble silica species, which are negatively charged, pre-
venting them from adhering to and polymerising around the protein of interest. An
argument could be made for adding metal salts after release, which could simplify
storage and avoid drastic changes to the ensilication process.
There is an argument for the addition of rotary evaporation during the preparation of
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hydrolysed TEOS as it would eliminate ethanol which is protein denaturing.
Buffer optimisation is another field in which ensilication could benefit. Short exper-
iments showed glycine to be an effective replacement for tris buffer. This has a
lower pKa which could improve electrostatic control and preferential hydration84. A
study where additives were used to stabilise adenovirus vectors showed an improve-
ment in thermal stability from hours to months279. The researchers employed simple
chemical moieties such as poly-ethylene-glycol and sucrose to enhance the stability
of these viruses and showed the importance of simple rational design.
The release method involves the formation of hydrofluoric acid (HF– ), which is able
to chelate proteins, for the dissolution of silica. This acid affects protein tertiary
structure and would be unsuitable for ultimate use. Therefore, alternatives will need
to be investigated.
Finally, the process will have to be made scalable. Vaccine manufacturers produce
antigens in batches that will create tens of thousands of doses. The ability to stabilise
this high amount of purified protein is essential for ensilication and requires more
investigation.
7.8 Conclusion
This project utilised biochemical and physical methodologies to understand and as-
sess the native state of TTCF. TTCF was successfully ensilicated with the analysis
showing incorporation of protein within the silica shell. The retention of TTCF protein
structure before and after ensilication was verified and showed no significant differ-
ences. SAXS experiments at two different locations provided an aligned view on
the stabilisation mechanism of ensilication. This was classed as a staged diffusion
limited cluster aggregation type reaction. Protein immobilisation in silica was shown
to have no influence on TTCF and lysozyme protein state after release measured
by calorimetry. Immunogenicity of released and heat treated TTCF was maintained
and shown in the in vivo study. Ensilicated material showed retention of TTCF after
long term storage, up to two years. These observations confirm that ensilication can
be utilised for the development of thermostable vaccines which could lead to the end




A.1 ExPasy ProtParam analysis
FASTA sequence of recombinant TTCF:
10 20 30 40 50
MGHHHHHHHH HHSSGHIEGR HMLDNEEDID VILKKSTILN LDINNDIISD
60 70 80 90 100
ISGFNSSVIT YPDAQLVPGI NGKAIHLVNN ESSEVIVHKA MDIEYNDMFN
110 120 130 140 150
NFTVSFWLRV PKVSASHLEQ YGTNEYSIIS SMKKHSLSIG SGWSVSLKGN
160 170 180 190 200
NLIWTLKDSA GEVRQITFRD LPDKFNAYLA NKWVFITITN DRLSSANLYI
210 220 230 240 250
NGVLMGSAEI TGLGAIREDN NITLKLDRCN NNNQYVSIDK FRIFCKALNP
260 270 280 290 300
KEIEKLYTSY LSITFLRDFW GNPLRYDTEY YLIPVASSSK DVQLKNITDY
310 320 330 340 350
MYLTNAPSYT NGKLNIYYRR LYNGLKFIIK RYTPNNEIDS FVKSGDFIKL
360 370 380 390 400
YVSYNNNEHI VGYPKDGNAF NNLDRILRVG YNAPGIPLYK KMEAVKLRDL
410 420 430 440 450




Ala (A) 18 3.90% Lys (K) 32 6.90%
Arg (R) 17 3.60% Met (M) 8 1.70%
Asn (N) 48 10.30% Phe (F) 17 3.60%
Asp (D) 33 7.10% Pro (P) 14 3.00%
Cys (C) 3 0.60% Ser (S) 37 7.90%
Gln (Q) 7 1.50% Thr (T) 21 4.50%
Glu (E) 18 3.90% Trp (W) 8 1.70%
Gly (G) 29 6.20% Tyr (Y) 28 6.00%
His (H) 19 4.10% Val (V) 24 5.10%
Ile (I) 42 9.00% Pyl (O) 0 0.00%
Leu (L) 44 9.40% Sec (U) 0 0.00%
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A.1.1 TTCF descriptors
Number of amino acids: 467
Molecular weight: 53545.50
Theoretical pI: 6.83
Total number of negatively charged residues (Asp + Glu): 51








Total number of atoms: 7484
Extinction coefficients:
Extinction coefficients are in units of M-1 cm-1 at 280 nm measured in water.
Ext. coefficient 85845
Abs 0.1% (=1 g/l) 1.603, assuming all pairs of Cys residues form cystines
Ext. coefficient 85720
Abs 0.1% (=1 g/l) 1.601, assuming all Cys residues are reduced
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 = fixed values Limits 45 200 Å
15 150 Å



























unit (seconds) (mm-1)  -  - (mm-1) Å Å  -
  
*106/Å2   *106/Å2 (mm-1) Å  - Å  -  -
5 0.0006 3.1 6.35E-08 0 24.23 52.61 4.78E-05 17.5 9.44 0 8.14 1.1 4.24 0.001 1 2.72
6 0.0006 3.1 7.17E-08 0 24.72 52.34 4.56E-05 17.5 9.44 0 8.92 1.1 4.36 0.001 1 3.17
7 0.0006 3.1 5.82E-08 0 24.73 53.94 4.47E-05 17.5 9.44 0 9.58 1.1 4.41 0.001 1 3.28
8 0.0006 3.1 6.12E-08 0 25.13 54.56 4.28E-05 17.5 9.44 0 10.32 1.1 4.39 0.001 1 2.73
9 0.0006 3.1 7.14E-08 0 25.34 55.34 4.17E-05 17.5 9.44 0 11.05 1.1 4.44 0.001 1 2.97
10 0.0006 3.1 6.61E-08 0 25.21 57.25 4.14E-05 17.5 9.44 0 11.54 1.1 4.44 0.001 1 3.01
11 0.0006 3.1 7.41E-08 0 26.54 57.92 3.78E-05 17.5 9.44 0 12.71 1.1 4.38 0.001 1 3.06
12 0.0006 3.1 7.34E-08 0 26.29 59.32 3.74E-05 17.5 9.44 0 13.33 1.1 4.42 0.001 1 2.49
13 0.0006 3.1 8.09E-08 0 25.94 63.40 3.81E-05 17.5 9.44 0 13.82 1.1 4.34 0.001 1 2.46
14 0.0006 3.1 7.65E-08 0 26.51 65.38 3.58E-05 17.5 9.44 0 15.05 1.1 4.40 0.001 1 3.03
15 0.0006 3.1 7.99E-08 0 26.75 72.14 3.50E-05 17.5 9.44 0 15.91 1.1 4.33 0.001 1 2.92
16 0.0006 3.1 7.98E-08 0 27.68 73.78 3.25E-05 17.5 9.44 0 17.43 1.1 4.54 0.001 1 3.16
17 0.0006 3.1 7.93E-08 0 27.64 80.14 3.27E-05 17.5 9.44 0 17.92 1.1 4.56 0.001 1 2.93
18 0.0006 3.1 8.43E-08 0 28.89 82.84 3.04E-05 17.5 9.44 0 19.35 1.1 4.55 0.001 1 2.66
19 0.0006 3.1 7.53E-08 0 29.37 92.14 2.94E-05 17.5 9.44 0 20.61 1.1 4.67 0.001 1 2.91
20 0.0006 3.1 8.25E-08 0 30.23 94.13 2.86E-05 17.5 9.44 0 21.70 1.1 4.65 0.001 1 2.47
21 0.0006 3.1 8.15E-08 0 31.68 106.40 2.64E-05 17.5 9.44 0 24.03 1.1 4.61 0.001 1 2.83
22 0.0006 3.1 7.92E-08 0 33.18 112.18 2.53E-05 17.5 9.44 0 25.61 1.1 4.74 0.001 1 3.13
23 0.0006 3.1 8.10E-08 0 34.75 117.92 2.40E-05 17.5 9.44 0 27.75 1.1 4.72 0.001 1 3.24
24 0.0006 3.1 7.42E-08 0 36.79 125.13 2.27E-05 17.5 9.44 0 30.74 1.1 4.83 0.001 1 4.15
25 0.0006 3.1 8.16E-08 0 38.67 126.78 2.15E-05 17.5 9.44 0 33.32 1.1 4.95 0.001 1 4.40
26 0.0006 3.1 7.40E-08 0 40.79 129.80 2.05E-05 17.5 9.44 0 36.82 1.1 4.88 0.001 1 3.47
27 0.0006 3.1 7.94E-08 0 42.78 139.26 1.97E-05 17.5 9.44 0 40.82 1.1 4.80 0.001 1 4.25
28 0.0006 3.1 7.77E-08 0 44.41 137.23 1.94E-05 17.5 9.44 0 43.77 1.1 4.78 0.001 1 4.01
29 0.0006 3.1 7.36E-08 0 46.33 137.26 1.95E-05 17.5 9.44 0 45.99 1.1 4.83 0.001 1 3.46
30 0.0006 3.1 7.11E-08 0 46.89 145.21 2.02E-05 17.5 9.44 0 48.03 1.1 4.83 0.001 1 4.28
31 0.0006 3.1 7.22E-08 0 48.87 150.95 1.94E-05 17.5 9.44 0 55.05 1.1 4.89 0.001 1 3.33
32 0.0006 3.1 8.58E-08 0 49.96 151.17 1.97E-05 17.5 9.44 0 56.85 1.1 4.90 0.001 1 3.88
33 0.0006 3.1 9.06E-08 0 50.38 155.97 2.01E-05 17.5 9.44 0 61.49 1.1 4.87 0.001 1 3.40
34 0.0006 3.1 8.87E-08 0 50.30 160.57 2.11E-05 17.5 9.44 0 58.77 1.1 4.91 0.001 1 3.56
35 0.0006 3.1 9.30E-08 0 51.00 161.80 2.12E-05 17.5 9.44 0 63.27 1.1 4.89 0.001 1 3.04
36 0.0006 3.1 9.30E-08 0 51.00 161.80 2.12E-05 17.5 9.44 0 63.28 1.1 4.89 0.001 1 3.04
37 0.0006 3.1 1.10E-07 0 51.41 159.72 2.12E-05 17.5 9.44 0 67.14 1.1 4.87 0.001 1 3.63
38 0.0006 3.1 1.17E-07 0 51.29 159.91 2.12E-05 17.5 9.44 0 68.02 1.1 4.90 0.001 1 2.95
39 0.0006 3.1 1.33E-07 0 51.40 146.45 2.08E-05 17.5 9.44 0 70.68 1.1 5.03 0.001 1 3.30
40 0.0006 3.1 1.40E-07 0 51.38 139.79 2.03E-05 17.5 9.44 0 75.34 1.1 4.91 0.001 1 3.10
41 0.0006 3.1 1.46E-07 0 50.84 138.78 2.04E-05 17.5 9.44 0 76.98 1.1 4.93 0.001 1 3.50
42 0.0006 3.1 1.57E-07 0 49.80 137.01 2.06E-05 17.5 9.44 0 77.05 1.1 4.94 0.001 1 3.63
43 0.0006 3.1 1.59E-07 0 49.63 131.53 2.00E-05 17.5 9.44 0 80.38 1.1 4.90 0.001 1 3.51
44 0.0006 3.1 1.64E-07 0 48.95 133.12 1.99E-05 17.5 9.44 0 84.48 1.1 4.83 0.001 1 3.84
45 0.0006 3.1 1.65E-07 0 49.52 121.27 1.90E-05 17.5 9.44 0 89.18 1.1 5.06 0.001 1 4.66
46 0.0006 3.1 1.67E-07 0 48.59 116.87 1.87E-05 17.5 9.44 0 94.07 1.1 4.91 0.001 1 5.06
47 0.0006 3.1 1.74E-07 0 48.61 109.20 1.80E-05 17.5 9.44 0 108.49 1.1 4.95 0.001 1 5.49
48 0.0006 3.1 1.76E-07 0 48.63 102.22 1.75E-05 17.5 9.44 0 115.89 1.1 5.03 0.001 1 5.48
49 0.0006 3.1 1.81E-07 0 49.88 90.25 1.64E-05 17.5 9.44 0 140.21 1.1 4.95 0.001 1 6.55
50 0.0006 3.1 1.71E-07 0 50.27 83.66 1.58E-05 17.5 9.44 0 152.86 1.1 5.14 0.001 1 6.32
51 0.0006 3.1 1.75E-07 0 51.90 74.35 1.50E-05 17.5 9.44 0 196.13 1.1 5.04 0.001 1 5.98
52 0.0006 3.1 1.67E-07 0 50.52 75.96 1.50E-05 17.5 9.44 0 216.70 1.1 4.89 0.001 1 6.99
53 0.0006 3.1 1.65E-07 0 52.66 66.65 1.46E-05 17.5 9.44 0 246.66 1.1 4.93 0.001 1 6.14
54 0.0006 3.1 1.63E-07 0 56.03 55.96 1.45E-05 17.5 9.44 0 282.53 1.1 4.96 0.001 1 7.06
55 0.0006 3.1 1.59E-07 0 55.14 56.10 1.41E-05 17.5 9.44 0 392.48 1.1 4.96 0.001 1 7.60
56 0.0006 3.1 1.59E-07 0 54.43 54.41 1.43E-05 17.5 9.44 0 383.83 1.1 4.91 0.001 1 8.07
57 0.0006 3.1 1.59E-07 0 53.93 53.84 1.44E-05 17.5 9.44 0 389.66 1.1 4.97 0.001 1 8.94
58 0.0006 3.1 1.61E-07 0 53.12 53.18 1.46E-05 17.5 9.44 0 472.24 1.1 4.81 0.001 1 9.18
59 0.0006 3.1 1.62E-07 0 52.56 52.52 1.48E-05 17.5 9.44 0 428.91 1.1 4.90 0.001 1 11.09
60 0.0006 3.1 1.49E-07 0 52.21 52.20 1.44E-05 17.5 9.44 0 665.88 1.1 4.90 0.001 1 11.20
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_dim_mass p2_radius p2_scale scale_factor χ2
unit seconds mm-1  - Å  - q  -  -  - mm-1 Å  - Å  -
60 0.0006 4.49 54.88 80 0.030 2.65 0.006 2.9E-04 0 164.71 1.1 5.05 1.0E-03 1 11.8
61 0.0006 4.29 53.74 80 0.029 2.65 0.006 3.1E-04 0 138.07 1.1 5.05 1.1E-03 1 11.9
62 0.0006 4.57 53.88 80 0.030 2.65 0.006 3.0E-04 0 143.40 1.1 5.16 1.1E-03 1 12.0
63 0.0006 4.26 52.82 80 0.030 2.65 0.006 3.1E-04 0 112.76 1.1 5.13 1.1E-03 1 11.8
64 0.0006 4.31 49.30 80 0.028 2.65 0.006 3.3E-04 0 92.94 1.1 5.13 1.1E-03 1 10.6
65 0.0006 4.14 51.66 80 0.029 2.65 0.006 3.3E-04 0 87.81 1.1 5.26 1.1E-03 1 11.0
66 0.0006 4.44 47.56 80 0.028 2.65 0.006 3.3E-04 0 87.52 1.1 5.19 1.1E-03 1 10.2
67 0.0006 4.23 49.86 80 0.029 2.65 0.006 3.4E-04 0 78.49 1.1 5.31 1.1E-03 1 10.1
68 0.0006 4.13 48.45 80 0.029 2.65 0.006 3.4E-04 0 72.45 1.1 5.41 1.1E-03 1 8.5
69 0.0006 4.19 50.03 80 0.029 2.65 0.006 3.4E-04 0 69.92 1.1 5.47 1.1E-03 1 9.3
70 0.0006 4.28 49.44 80 0.029 2.65 0.006 3.4E-04 0 66.50 1.1 5.46 1.2E-03 1 10.1
71 0.0006 4.41 47.03 80 0.028 2.65 0.006 3.4E-04 0 64.56 1.1 5.50 1.2E-03 1 8.4
72 0.0006 4.18 48.48 80 0.029 2.65 0.006 3.5E-04 0 56.40 1.1 5.57 1.2E-03 1 8.5
73 0.0006 4.29 48.29 80 0.029 2.65 0.006 3.5E-04 0 53.94 1.1 5.68 1.2E-03 1 7.7
74 0.0006 4.21 47.60 80 0.029 2.65 0.006 3.5E-04 0 52.67 1.1 5.69 1.2E-03 1 8.2
75 0.0006 4.01 48.16 80 0.029 2.65 0.006 3.6E-04 0 48.29 1.1 5.74 1.2E-03 1 7.8
76 0.0006 4.14 49.29 80 0.030 2.65 0.006 3.5E-04 0 51.58 1.1 5.84 1.2E-03 1 7.6
77 0.0006 4.15 48.68 80 0.030 2.65 0.006 3.4E-04 0 52.61 1.1 5.72 1.2E-03 1 7.1
78 0.0006 4.06 48.59 80 0.030 2.65 0.006 3.7E-04 0 43.72 1.1 5.90 1.3E-03 1 7.2
79 0.0006 4.26 47.93 80 0.030 2.65 0.006 3.6E-04 0 44.78 1.1 5.95 1.3E-03 1 7.7
80 0.0006 4.11 48.22 80 0.030 2.65 0.006 3.6E-04 0 43.95 1.1 5.95 1.3E-03 1 6.2
81 0.0006 3.99 48.63 80 0.030 2.65 0.006 3.6E-04 0 41.67 1.1 6.05 1.3E-03 1 6.7
82 0.0006 3.93 48.68 80 0.030 2.65 0.006 3.7E-04 0 40.36 1.1 6.10 1.3E-03 1 7.3
83 0.0006 3.95 47.00 80 0.030 2.65 0.006 3.8E-04 0 36.25 1.1 6.18 1.4E-03 1 6.3
84 0.0006 4.06 47.00 80 0.030 2.65 0.006 3.7E-04 0 37.00 1.1 6.17 1.4E-03 1 6.3
85 0.0006 4.02 47.35 80 0.030 2.65 0.006 3.7E-04 0 37.76 1.1 6.16 1.4E-03 1 5.5
86 0.0006 3.92 49.66 80 0.031 2.65 0.006 3.7E-04 0 37.14 1.1 6.20 1.4E-03 1 5.6
87 0.0006 3.78 48.59 80 0.031 2.65 0.006 3.9E-04 0 33.18 1.1 6.30 1.4E-03 1 6.1
88 0.0006 4.04 47.57 80 0.031 2.65 0.006 3.7E-04 0 35.07 1.1 6.47 1.4E-03 1 5.7
89 0.0006 3.77 47.49 80 0.031 2.65 0.006 3.8E-04 0 33.76 1.1 6.36 1.4E-03 1 4.9
90 0.0006 3.83 47.00 80 0.031 2.65 0.006 3.8E-04 0 32.53 1.1 6.43 1.5E-03 1 6.2
91 0.0006 3.78 47.81 80 0.031 2.65 0.006 3.9E-04 0 31.51 1.1 6.46 1.5E-03 1 5.2
92 0.0006 3.68 48.61 80 0.032 2.65 0.006 3.9E-04 0 30.73 1.1 6.52 1.5E-03 1 5.8
93 0.0006 3.74 47.68 80 0.031 2.65 0.006 3.9E-04 0 30.08 1.1 6.62 1.5E-03 1 5.2
94 0.0006 3.73 47.97 80 0.031 2.65 0.006 3.9E-04 0 30.17 1.1 6.71 1.5E-03 1 4.9
95 0.0006 3.68 48.39 80 0.032 2.65 0.006 3.9E-04 0 28.85 1.1 6.61 1.5E-03 1 4.7
96 0.0006 3.68 49.26 80 0.032 2.65 0.006 3.8E-04 0 29.86 1.1 6.61 1.5E-03 1 5.4
97 0.0006 3.65 47.25 80 0.032 2.65 0.006 3.8E-04 0 29.96 1.1 6.62 1.5E-03 1 5.0
98 0.0006 3.59 48.67 80 0.032 2.65 0.006 4.0E-04 0 27.86 1.1 6.70 1.6E-03 1 5.6
99 0.0006 3.64 47.96 80 0.032 2.65 0.006 4.0E-04 0 27.25 1.1 6.77 1.6E-03 1 5.5
100 0.0006 3.59 48.32 80 0.032 2.65 0.006 3.9E-04 0 28.43 1.1 6.79 1.6E-03 1 4.8
101 0.0006 3.59 47.92 80 0.032 2.65 0.006 3.9E-04 0 27.69 1.1 6.86 1.6E-03 1 5.6
102 0.0006 3.55 48.29 80 0.032 2.65 0.006 3.9E-04 0 27.21 1.1 6.98 1.6E-03 1 5.6
103 0.0006 3.43 48.23 80 0.033 2.65 0.006 4.0E-04 0 26.93 1.1 6.91 1.6E-03 1 5.0
104 0.0006 3.40 48.28 80 0.033 2.65 0.006 4.1E-04 0 25.05 1.1 6.90 1.7E-03 1 5.8
105 0.0006 3.45 48.37 80 0.033 2.65 0.006 4.0E-04 0 26.01 1.1 7.00 1.6E-03 1 5.1
106 0.0006 3.34 48.49 80 0.033 2.65 0.006 4.0E-04 0 24.87 1.1 7.00 1.7E-03 1 5.9
107 0.0006 3.33 48.53 80 0.033 2.65 0.006 4.0E-04 0 25.69 1.1 6.97 1.7E-03 1 5.0
108 0.0006 3.28 48.61 80 0.033 2.65 0.006 4.0E-04 0 25.05 1.1 7.00 1.7E-03 1 5.4
109 0.0006 3.23 48.99 80 0.033 2.65 0.006 4.1E-04 0 23.87 1.1 7.07 1.7E-03 1 6.0
110 0.0006 3.30 48.40 80 0.033 2.65 0.006 4.0E-04 0 24.47 1.1 7.14 1.7E-03 1 6.1
111 0.0006 3.24 48.89 80 0.033 2.65 0.006 4.1E-04 0 24.15 1.1 7.12 1.7E-03 1 5.7
112 0.0006 3.40 48.79 80 0.033 2.65 0.006 4.0E-04 0 24.55 1.1 7.13 1.7E-03 1 5.7
113 0.0006 3.16 48.96 80 0.034 2.65 0.006 4.1E-04 0 23.93 1.1 7.18 1.7E-03 1 6.2
114 0.0006 3.17 49.19 80 0.034 2.65 0.006 4.1E-04 0 23.32 1.1 7.24 1.8E-03 1 5.1
115 0.0006 3.13 48.73 80 0.034 2.65 0.006 4.1E-04 0 22.96 1.1 7.23 1.8E-03 1 4.9
116 0.0006 3.18 48.97 80 0.034 2.65 0.006 4.1E-04 0 22.90 1.1 7.28 1.8E-03 1 6.3
117 0.0006 3.09 48.07 80 0.034 2.65 0.006 4.2E-04 0 22.31 1.1 7.33 1.8E-03 1 5.6
118 0.0006 3.08 48.21 80 0.034 2.65 0.006 4.1E-04 0 22.98 1.1 7.20 1.8E-03 1 7.4
119 0.0006 3.06 48.41 80 0.034 2.65 0.006 4.2E-04 0 22.28 1.1 7.38 1.8E-03 1 5.8
120 0.0006 3.00 48.61 80 0.033836 2.65 0.006 4.2E-04 0 21.44 1.1 7.41 0.001843 1 6.4
p2_radius






 = fixed values Limits 0 5  -
10 100 Å















dim_mass p2_radius p2_scale scale_factor χ2
unit seconds mm
-1
 - Å  - q  -  -  - mm
-1
Å  - Å  -
1 0.0001 2.97 42.74 80 0.025 2.65 2.62E-03 9.8E-05 0 11.37 1.1 7.13 3.3E-04 1 0.6
2 0.0001 2.85 57.47 80 0.035 2.65 5.65E-03 5.7E-05 0 19.23 1.1 6.56 3.4E-04 1 0.7
3 0.0001 1.95 38.99 80 0.034 2.65 3.95E-03 8.9E-05 0 10.96 1.1 8.06 4.1E-04 1 0.6
4 0.0001 1.54 35.93 80 0.037 2.65 3.99E-03 1.0E-04 0 10.82 1.1 9.21 4.0E-04 1 0.7
5 0.0001 1.57 30.97 80 0.035 2.65 3.46E-03 1.3E-04 0 11.26 1.1 9.19 3.7E-04 1 0.7
6 0.0001 1.63 33.92 80 0.038 2.65 4.02E-03 1.2E-04 0 11.64 1.1 10.00 4.5E-04 1 0.8










 = fixed values Limits 0 4  -
0 inf Å
 = key variables 1 6 Å
0 15 Å
Time p1_background p1_power p1_scale p2_background p2_cutoff_length
p2_fractal
dim_mass p2_radius p2_scale scale_factor χ2
unit min (mm-1)  -  - (mm-1) Å Å Å  -  -  -
6 0 3.79 1.15E-05 0.0001 21.94 1.64 6.29 1 1.77E-04 0.67
7 0 3.74 2.04E-05 0.0001 19.84 1.80 4.82 1 1.38E-04 0.73
8 0 3.71 2.28E-05 0.0001 21.54 1.76 5.32 1 1.51E-04 0.56
9 0 3.69 2.48E-05 0.0001 21.82 1.77 5.62 1 1.55E-04 0.59
10 0 3.70 2.58E-05 0.0001 22.01 1.81 6.21 1 1.43E-04 0.53
11 0 3.70 2.97E-05 0.0001 21.47 1.87 5.39 1 1.30E-04 0.53
12 0 3.72 3.07E-05 0.0001 21.16 1.93 5.10 1 1.20E-04 0.50
13 0 4.00 5.98E-06 0.0001 25.55 1.79 6.70 1 1.51E-04 0.64
14 0 3.73 2.49E-05 0.0001 24.38 1.86 6.06 1 1.36E-04 0.55
15 0 3.69 3.45E-05 0.0001 24.30 1.90 5.41 1 1.26E-04 0.59
16 0 3.71 2.72E-05 0.0001 26.63 1.83 6.81 1 1.42E-04 0.61
17 0 3.66 4.47E-05 0.0001 24.26 1.95 5.37 1 1.16E-04 0.60
18 0 3.72 2.98E-05 0.0001 26.69 1.88 6.50 1 1.29E-04 0.54
19 0 3.59 5.90E-05 0.0001 26.68 1.92 5.64 1 1.22E-04 0.58
20 0 3.62 4.72E-05 0.0001 28.17 1.88 6.62 1 1.31E-04 0.48
21 0 3.60 5.69E-05 0.0001 28.80 1.91 5.79 1 1.24E-04 0.51
22 0 3.49 9.77E-05 0.0001 28.52 1.93 5.57 1 1.20E-04 0.52
23 0 3.58 5.95E-05 0.0001 30.40 1.90 6.55 1 1.24E-04 0.57
24 0 3.51 7.90E-05 0.0001 31.44 1.90 6.59 1 1.24E-04 0.62
25 0 3.51 8.57E-05 0.0001 30.95 1.93 5.65 1 1.18E-04 0.60
26 0 3.49 9.17E-05 0.0001 31.86 1.93 5.57 1 1.16E-04 0.57
27 0 3.59 5.04E-05 0.0001 35.07 1.88 6.17 1 1.29E-04 0.57
28 0 3.51 7.25E-05 0.0001 35.40 1.90 5.82 1 1.21E-04 0.60
29 0 3.61 4.41E-05 0.0001 36.84 1.89 6.06 1 1.25E-04 0.56
30 0 3.52 6.80E-05 0.0001 37.61 1.89 5.96 1 1.22E-04 0.61
31 0 3.54 5.94E-05 0.0001 38.25 1.91 5.90 1 1.19E-04 0.62
32 0 3.53 6.06E-05 0.0001 39.72 1.89 6.13 1 1.24E-04 0.54
33 0 3.44 9.41E-05 0.0001 40.50 1.88 6.23 1 1.24E-04 0.54
34 0 3.46 7.53E-05 0.0001 43.60 1.86 6.26 1 1.27E-04 0.55
35 0 3.58 4.52E-05 0.0001 43.83 1.89 6.01 1 1.19E-04 0.63
36 0 3.54 4.53E-05 0.0001 46.91 1.86 6.43 1 1.28E-04 0.56
37 0 3.52 5.45E-05 0.0001 44.96 1.90 6.00 1 1.17E-04 0.59
38 0 3.81 1.11E-05 0.0001 50.80 1.85 6.47 1 1.30E-04 0.61
39 0 3.44 6.99E-05 0.0001 48.76 1.88 6.26 1 1.22E-04 0.58
40 0 3.82 9.50E-06 0.0001 53.29 1.86 6.47 1 1.25E-04 0.53
41 0 4.00 3.77E-06 0.0001 55.04 1.86 5.77 1 1.26E-04 0.62
42 0 3.48 5.18E-05 0.0001 50.99 1.90 6.27 1 1.15E-04 0.55
43 0 3.36 7.58E-05 0.0001 56.32 1.85 6.72 1 1.27E-04 0.51
44 0 3.46 4.65E-05 0.0001 54.75 1.88 6.30 1 1.17E-04 0.56
45 0 3.51 3.76E-05 0.0001 56.72 1.88 5.56 1 1.17E-04 0.56
46 0 3.80 6.98E-06 0.0001 60.17 1.87 6.46 1 1.18E-04 0.51
47 0 3.63 1.72E-05 0.0001 60.43 1.88 6.52 1 1.17E-04 0.54
48 0 4.00 2.42E-06 0.0001 63.46 1.88 5.62 1 1.17E-04 0.53
49 0 4.00 4.40E-08 0.0001 65.31 1.82 7.01 1 1.31E-04 0.53
50 0 3.86 4.44E-06 0.0001 64.90 1.88 6.42 1 1.15E-04 0.54
51 0 3.57 1.63E-05 0.0001 65.97 1.88 5.75 1 1.16E-04 0.59
52 0 3.74 7.34E-06 0.0001 68.32 1.87 6.64 1 1.17E-04 0.59
53 0 3.48 2.51E-05 0.0001 68.41 1.88 6.54 1 1.15E-04 0.63
54 0 3.48 1.96E-05 0.0001 74.17 1.86 6.83 1 1.19E-04 0.58
55 0 3.22 7.92E-05 0.0001 69.97 1.89 5.63 1 1.12E-04 0.62
56 0 4.00 1.60E-06 0.0001 73.47 1.88 5.96 1 1.15E-04 0.62
57 0 3.62 8.26E-06 0.0001 76.50 1.88 6.67 1 1.13E-04 0.53
58 0 3.90 1.44E-06 0.0001 78.61 1.89 5.67 1 1.12E-04 0.60
59 0 3.66 5.15E-06 0.0001 76.80 1.90 5.64 1 1.10E-04 0.55
60 0 4.00 5.03E-07 0.0001 81.46 1.88 6.81 1 1.13E-04 0.65






A.3 1:20 SAXS data table
min max unit
 = fixed values Limits p1_power 0 4  -
p2_cutoff_length 10 150 Å
 = key variables p2_radius 0 20 Å
p2_fractal_dim_mass 1 6 Å
q = 0.08<q <0.51 Å-1






 -  - mm
-1
 - Å Å  - -  -
1 0.0001 8.97E-09 3.62 0 5.31E-04 14.82 5.16 1.50 1.05 1
2 0.0001 2.19E-09 3.95 0 5.29E-04 15.05 5.41 1.55 0.72 1
3 0.0001 7.41E-09 3.71 0 3.91E-04 12.33 5.00 1.81 0.90 1
4 0.0001 3.87E-09 3.85 0 3.93E-04 13.43 5.15 1.81 0.54 1
5 0.0001 2.06E-09 3.99 0 3.90E-04 14.57 5.15 1.81 0.49 1
6 0.0001 2.08E-09 4.00 0 3.71E-04 14.89 5.18 1.85 0.53 1
7 0.0001 2.12E-09 4.00 0 3.59E-04 15.44 5.21 1.87 0.52 1
8 0.0001 2.17E-09 4.00 0 3.38E-04 15.83 5.24 1.90 0.64 1
9 0.0001 2.29E-09 3.99 0 3.45E-04 16.81 5.23 1.90 0.48 1
10 0.0001 2.22E-09 4.00 0 3.30E-04 17.25 5.17 1.92 0.56 1
11 0.0001 2.24E-09 4.00 0 3.22E-04 17.86 5.19 1.94 0.51 1
12 0.0001 4.16E-09 3.87 0 3.38E-04 18.97 5.19 1.92 0.76 1
13 0.0001 2.90E-09 3.95 0 3.10E-04 19.05 5.17 1.96 0.45 1
14 0.0001 3.74E-09 3.90 0 3.03E-04 19.76 5.13 1.97 0.44 1
15 0.0001 5.83E-09 3.81 0 2.88E-04 19.85 4.80 2.00 0.58 1
16 0.0001 2.36E-09 4.00 0 3.02E-04 21.65 5.16 1.97 0.52 1
17 0.0001 2.40E-09 4.00 0 3.00E-04 22.38 5.17 1.97 0.50 1
18 0.0001 2.88E-09 3.96 0 2.94E-04 23.06 5.14 1.98 0.54 1
19 0.0001 4.14E-09 3.89 0 2.90E-04 23.64 4.93 1.99 0.52 1
20 0.0001 4.50E-09 3.87 0 2.93E-04 24.59 5.19 1.98 0.45 1
21 0.0001 3.44E-09 3.92 0 2.90E-04 25.50 5.18 1.98 0.51 1
22 0.0001 2.40E-09 4.00 0 2.94E-04 26.94 5.20 1.97 0.51 1
23 0.0001 3.34E-09 3.93 0 2.91E-04 27.43 5.25 1.97 0.60 1
24 0.0001 4.32E-09 3.88 0 2.92E-04 28.19 5.28 1.97 0.59 1
25 0.0001 4.20E-09 3.88 0 2.85E-04 28.99 5.18 1.98 0.54 1
26 0.0001 2.86E-09 3.96 0 2.93E-04 30.70 5.31 1.96 0.47 1
27 0.0001 2.47E-09 4.00 0 2.89E-04 31.45 5.25 1.97 0.50 1
28 0.0001 2.66E-09 3.97 0 2.95E-04 32.95 5.33 1.96 0.44 1
29 0.0001 2.47E-09 3.99 0 2.95E-04 33.95 5.38 1.96 0.46 1
30 0.0001 2.44E-09 4.00 0 2.88E-04 34.21 5.29 1.97 0.53 1
31 0.0001 2.39E-09 4.00 0 2.91E-04 35.69 5.33 1.96 0.54 1
32 0.0001 3.19E-09 3.94 0 2.87E-04 36.37 5.29 1.97 0.47 1
33 0.0001 2.39E-09 4.00 0 2.85E-04 37.46 5.24 1.97 0.62 1
34 0.0001 2.42E-09 4.00 0 2.87E-04 38.63 5.27 1.97 0.53 1
35 0.0001 2.38E-09 4.00 0 2.87E-04 39.71 5.32 1.97 0.52 1
36 0.0001 2.40E-09 4.00 0 2.91E-04 41.12 5.19 1.96 0.52 1
37 0.0001 2.55E-09 3.99 0 2.84E-04 41.53 5.29 1.97 0.53 1
38 0.0001 2.70E-09 3.97 0 2.84E-04 42.53 5.32 1.97 0.46 1
39 0.0001 2.35E-09 4.00 0 2.82E-04 43.73 5.27 1.97 0.55 1
40 0.0001 6.48E-09 3.79 0 2.81E-04 44.16 5.25 1.97 0.61 1
41 0.0001 2.33E-09 4.00 0 2.80E-04 45.89 5.28 1.97 0.53 1
42 0.0001 2.36E-09 4.00 0 2.82E-04 46.94 5.31 1.97 0.52 1
43 0.0001 2.32E-09 4.00 0 2.83E-04 48.54 5.19 1.97 0.57 1
44 0.0001 2.32E-09 4.00 0 2.81E-04 49.33 5.15 1.97 0.51 1
45 0.0001 2.30E-09 4.00 0 2.80E-04 50.95 5.33 1.97 0.52 1
46 0.0001 4.21E-09 3.87 0 2.79E-04 51.06 5.29 1.97 0.59 1
47 0.0001 2.29E-09 4.00 0 2.81E-04 53.08 5.15 1.97 0.54 1
48 0.0001 2.29E-09 4.00 0 2.82E-04 54.19 5.13 1.97 0.59 1
49 0.0001 5.05E-09 3.83 0 2.79E-04 54.63 5.32 1.97 0.62 1
50 0.0001 2.18E-09 4.00 0 2.81E-04 57.29 5.32 1.97 0.52 1
51 0.0001 2.83E-09 3.95 0 2.78E-04 57.53 5.30 1.97 0.58 1
52 0.0001 2.19E-09 4.00 0 2.85E-04 60.37 5.40 1.96 0.77 1
53 0.0001 2.21E-09 4.00 0 2.76E-04 60.09 5.14 1.98 0.63 1
54 0.0001 5.23E-09 3.82 0 2.76E-04 60.75 5.30 1.97 0.66 1
55 0.0001 2.87E-09 3.94 0 2.76E-04 62.42 5.11 1.98 0.58 1
56 0.0001 2.91E-09 3.94 0 2.76E-04 63.57 5.13 1.98 0.67 1
57 0.0001 2.20E-09 4.00 0 2.74E-04 65.06 5.13 1.98 0.58 1
58 0.0001 2.16E-09 4.00 0 2.76E-04 66.69 5.15 1.97 0.65 1
59 0.0001 2.09E-09 4.00 0 2.76E-04 68.24 5.35 1.97 0.70 1
60 0.0001 2.09E-09 4.00 0 2.74E-04 69.27 5.29 1.97 0.71 1
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A.4 1:100 pH 7 SAXS data table
min max unit
 = fixed values Limits 20 75 Å
40 200 Å



















unit (minutes) (mm-1)  -  - (mm-1) Å Å  -   *106/Å2   *106/Å2 (mm-1) Å  - Å  -  -
1 0.0001 2.83 5.72E-09 0 22.56 60.51 1.06E-05 17.5 9.44 0 0.47 5.17 7.55 0.001 1 0.54
2 0.0001 3.15 1.51E-09 0 22.49 77.05 1.05E-05 17.5 9.44 0 0.55 4.39 8.87 0.001 1 0.52
3 0.0001 3.49 1.08E-09 0 21.23 103.52 1.20E-05 17.5 9.44 0 0.68 3.33 7.89 0.001 1 0.55
4 0.0001 3.46 1.88E-09 0 22.97 97.96 1.08E-05 17.5 9.44 0 0.63 3.95 8.11 0.001 1 0.56
5 0.0001 3.25 6.45E-09 0 22.93 106.23 1.10E-05 17.5 9.44 0 0.59 4.36 8.13 0.001 1 0.62
6 0.0001 3.81 4.93E-10 0 25.10 119.18 1.01E-05 17.5 9.44 0 1.20 1.50 8.84 0.001 1 0.66
7 0.0001 3.26 8.09E-09 0 27.18 99.88 8.88E-06 17.5 9.44 0 0.69 3.98 9.09 0.001 1 0.72
8 0.0001 3.42 4.11E-09 0 27.14 96.83 9.30E-06 17.5 9.44 0 0.66 4.17 8.86 0.001 1 0.78
9 0.0001 3.68 1.31E-09 0 28.69 90.49 8.89E-06 17.5 9.44 0 1.29 1.79 9.25 0.001 1 0.80
min max unit
 = fixed values Limits 0 5  -
30 100 Å


















p2_radius p2_scale scale_factor χ2
unit (minutes) mm-1  - Å  - q  -  -  - mm-1 Å  - Å  -
10 0.0001 2.17 40.10 2.44E+04 0.028 3.1 7.12E-02 4.0E-07 0 0.11 5.92 9.77 5.9E+00 1 0.9
11 0.0001 2.31 39.67 2.78E+04 0.028 3.1 7.19E-02 3.4E-07 0 0.09 6.00 10.10 1.6E+01 1 0.8
12 0.0001 2.19 39.14 3.92E+04 0.028 3.0 1.57E-01 2.5E-07 0 0.08 6.00 9.15 4.6E+01 1 0.7
13 0.0001 2.45 36.62 3.50E+04 0.028 3.2 6.98E-02 2.8E-07 0 0.10 5.99 9.37 9.4E+00 1 0.7
14 0.0001 2.45 36.48 3.89E+04 0.028 3.2 6.05E-02 2.6E-07 0 0.10 5.99 9.44 1.1E+01 1 0.7
15 0.0001 2.62 35.85 4.23E+04 0.028 3.2 7.37E-02 2.2E-07 0 0.09 6.00 9.77 1.9E+01 1 0.6
16 0.0001 2.69 35.34 4.23E+04 0.028 3.1 1.28E-01 2.2E-07 0 0.06 4.35 9.65 4.9E+01 1 0.6
17 0.0001 2.25 42.18 2.13E+04 0.035 2.7 5.87E-01 3.9E-07 0 0.04 3.08 9.75 1.3E+01 1 0.6
18 0.0001 2.10 45.19 1.20E+04 0.038 2.4 1.15E+00 6.3E-07 0 0.04 2.57 9.88 5.1E+00 1 0.9
19 0.0001 2.39 37.96 2.41E+04 0.032 3.2 6.23E-02 3.7E-07 0 0.10 6.00 10.62 1.8E+01 1 0.6
20 0.0001 2.61 36.12 3.69E+04 0.031 3.3 6.20E-02 2.5E-07 0 0.10 6.00 9.99 1.9E+01 1 0.6
21 0.0001 2.40 36.69 4.14E+04 0.032 3.2 8.98E-02 2.2E-07 0 0.08 6.00 10.03 6.7E+01 1 0.6
22 0.0001 2.60 34.79 4.30E+04 0.029 3.4 4.22E-02 2.2E-07 0 0.09 6.00 10.25 2.3E+01 1 0.6
23 0.0001 2.45 34.85 4.58E+04 0.031 3.4 5.13E-02 2.0E-07 0 0.11 5.99 10.26 9.2E+00 1 0.7
24 0.0001 2.24 44.91 1.59E+04 0.038 2.7 6.44E-01 4.8E-07 0 0.01 2.03 11.05 1.3E+01 1 0.8
25 0.0001 2.14 37.76 3.92E+04 0.034 3.2 1.14E-01 2.4E-07 0 0.05 4.13 10.25 4.0E+01 1 0.7
26 0.0001 2.12 38.73 2.78E+04 0.035 3.2 7.25E-02 3.4E-07 0 0.12 5.87 10.54 5.4E+00 1 0.6
27 0.0001 2.40 34.22 4.91E+04 0.032 3.3 7.90E-02 1.9E-07 0 0.08 6.00 10.29 6.3E+01 1 0.6
28 0.0001 2.23 35.45 4.74E+04 0.033 3.4 4.37E-02 2.0E-07 0 0.11 6.00 10.55 7.9E+00 1 0.6
29 0.0001 2.26 35.52 3.66E+04 0.033 3.4 4.43E-02 2.6E-07 0 0.12 6.00 10.68 6.3E+00 1 0.7
30 0.0001 2.26 34.65 3.74E+04 0.032 3.4 4.04E-02 2.7E-07 0 0.10 6.00 10.56 2.0E+01 1 0.7
31 0.0001 2.28 34.66 3.76E+04 0.032 3.4 3.47E-02 2.6E-07 0 0.12 6.00 10.86 5.4E+00 1 0.7
32 0.0001 1.73 41.31 2.42E+04 0.038 2.9 3.13E-01 4.0E-07 0 0.07 4.54 10.78 2.2E+01 1 0.7
33 0.0001 2.28 36.04 3.83E+04 0.033 3.4 4.22E-02 2.5E-07 0 0.10 5.98 10.89 1.4E+01 1 0.6
34 0.0001 2.21 34.33 4.16E+04 0.033 3.4 5.15E-02 2.3E-07 0 0.10 6.00 10.86 1.4E+01 1 0.6
35 0.0001 2.31 33.03 4.73E+04 0.032 3.4 4.21E-02 2.1E-07 0 0.11 6.00 10.99 8.3E+00 1 0.6
36 0.0001 2.38 32.06 4.20E+04 0.031 3.4 4.65E-02 2.3E-07 0 0.10 5.99 10.93 1.6E+01 1 0.7
37 0.0001 2.11 35.60 4.07E+04 0.034 3.4 5.45E-02 2.5E-07 0 0.10 6.00 11.09 1.8E+01 1 0.7
38 0.0001 1.92 35.09 4.03E+04 0.035 3.2 1.05E-01 2.6E-07 0 0.05 3.95 10.84 4.1E+01 1 0.7
39 0.0001 1.87 36.39 5.32E+04 0.036 3.2 1.50E-01 2.0E-07 0 0.05 4.02 10.86 4.4E+01 1 0.7
40 0.0001 1.99 33.76 4.24E+04 0.034 3.3 6.27E-02 2.5E-07 0 0.10 6.00 11.01 2.1E+01 1 0.6
41 0.0001 2.25 32.09 3.46E+04 0.032 3.4 4.46E-02 2.9E-07 0 0.10 5.99 11.31 1.8E+01 1 0.8
42 0.0001 2.25 31.57 4.27E+04 0.031 3.5 3.26E-02 2.4E-07 0 0.10 5.99 11.27 1.8E+01 1 0.7
43 0.0001 2.31 31.43 4.68E+04 0.031 3.5 3.70E-02 2.2E-07 0 0.09 6.00 11.30 2.5E+01 1 0.6
44 0.0001 2.05 31.91 3.86E+04 0.032 3.4 4.76E-02 2.8E-07 0 0.12 6.00 11.04 6.8E+00 1 0.6
45 0.0001 2.26 31.09 3.78E+04 0.031 3.4 4.33E-02 2.7E-07 0 0.12 5.99 11.46 6.0E+00 1 0.7
46 0.0001 2.11 30.08 4.26E+04 0.032 3.4 4.71E-02 2.5E-07 0 0.10 5.99 11.05 1.5E+01 1 0.7
47 0.0001 2.22 30.52 4.28E+04 0.031 3.5 3.17E-02 2.5E-07 0 0.10 6.00 11.50 2.2E+01 1 0.6
48 0.0001 2.25 30.88 4.02E+04 0.032 3.3 5.94E-02 2.6E-07 0 0.08 6.00 11.45 5.1E+01 1 0.7
49 0.0001 2.27 30.01 3.60E+04 0.031 3.4 4.32E-02 2.8E-07 0 0.10 6.00 11.57 1.9E+01 1 0.6
50 0.0001 2.21 31.59 4.16E+04 0.032 3.4 5.13E-02 2.5E-07 0 0.10 6.00 11.66 2.3E+01 1 0.7
51 0.0001 2.23 30.53 4.16E+04 0.031 3.4 5.37E-02 2.5E-07 0 0.12 5.99 11.72 6.4E+00 1 0.6
52 0.0001 2.16 31.03 2.68E+04 0.033 3.3 4.37E-02 3.8E-07 0 0.10 6.00 11.94 2.2E+01 1 0.7
53 0.0001 2.23 30.01 5.46E+04 0.031 3.5 3.98E-02 2.0E-07 0 0.09 6.00 11.72 3.3E+01 1 0.7
54 0.0001 1.99 31.12 4.50E+04 0.034 3.3 9.39E-02 2.4E-07 0 0.08 6.00 11.71 5.8E+01 1 0.7
55 0.0001 2.03 30.82 3.99E+04 0.033 3.3 6.43E-02 2.7E-07 0 0.10 6.00 11.63 1.8E+01 1 0.7
56 0.0001 2.32 30.00 4.74E+04 0.031 3.4 4.11E-02 2.2E-07 0 0.12 6.00 11.83 8.2E+00 1 0.8
57 0.0001 2.29 30.36 4.44E+04 0.032 3.2 1.02E-01 2.2E-07 0 0.08 6.00 11.97 7.3E+01 1 0.8
58 0.0001 2.14 30.01 4.48E+04 0.032 3.4 5.42E-02 2.4E-07 0 0.10 6.00 11.42 1.5E+01 1 0.6
59 0.0001 2.31 30.00 3.80E+04 0.030 3.4 4.42E-02 2.7E-07 0 0.10 5.99 12.10 2.1E+01 1 0.8
60 0.0001 2.29 30.37 3.47E+04 0.032 3.3 6.01E-02 2.9E-07 0 0.10 5.99 12.09 1.9E+01 1 0.9
p2_radius













A.5 1:100 pH 8 SAXS data table
min max unit
 = fixed values Limits 1 75 Å
75 200 Å














(fractal) p3_scale scale_factor χ2
unit (minutes) (mm-1)  -  - (mm-1) Å Å  - *106/Å2   *106/Å2 (mm-1) Å  - Å  -  -
1 0.0001 2.97 1.40E-08 0 41.01 148.30 6.84E-06 17.5 9.44 0 47.75 1.00 7.67 0.0002 1 0.63
2 0.0001 3.05 1.26E-08 0 44.85 120.52 6.73E-06 17.5 9.44 0 108.07 1.00 7.88 0.0002 1 0.66
3 0.0001 2.94 1.41E-08 0 46.31 118.26 7.20E-06 17.5 9.44 0 308.77 1.00 8.44 0.0002 1 0.60
4 0.0001 2.92 1.41E-08 0 47.32 123.27 7.81E-06 17.5 9.44 0 290.95 1.03 7.93 0.0002 1 0.60
5 0.0001 2.92 1.41E-08 0 47.82 121.23 8.32E-06 17.5 9.44 0 299.31 1.06 8.09 0.0002 1 0.64
6 0.0001 3.03 1.41E-08 0 48.17 135.18 9.34E-06 17.5 9.44 0 78.72 1.09 8.59 0.0002 1 0.62
7 0.0001 2.95 1.41E-08 0 48.62 122.66 9.28E-06 17.5 9.44 0 297.69 1.09 8.12 0.0002 1 0.67
8 0.0001 2.96 1.41E-08 0 48.43 122.86 9.73E-06 17.5 9.44 0 353.62 1.10 8.03 0.0002 1 0.65
9 0.0001 2.86 1.41E-08 0 49.86 127.60 9.61E-06 17.5 9.44 0 375.98 1.12 8.20 0.0002 1 0.75
10 0.0001 2.89 1.41E-08 0 49.33 126.34 1.01E-05 17.5 9.44 0 279.02 1.13 8.21 0.0002 1 0.69
11 0.0001 2.84 1.41E-08 0 50.09 125.45 1.02E-05 17.5 9.44 0 390.38 1.14 8.30 0.0002 1 0.65
12 0.0001 2.91 1.41E-08 0 50.67 125.26 1.04E-05 17.5 9.44 0 311.92 1.16 8.19 0.0002 1 0.67
13 0.0001 2.85 1.41E-08 0 50.74 131.27 1.05E-05 17.5 9.44 0 254.06 1.17 8.78 0.0002 1 0.72
14 0.0001 2.74 1.41E-08 0 50.39 130.31 1.07E-05 17.5 9.44 0 489.07 1.16 8.88 0.0002 1 0.87
15 0.0001 2.73 1.41E-08 0 51.13 129.35 1.07E-05 17.5 9.44 0 458.13 1.18 8.42 0.0002 1 0.83
16 0.0001 2.76 1.41E-08 0 51.56 128.09 1.08E-05 17.5 9.44 0 375.25 1.19 8.45 0.0002 1 0.76
17 0.0001 2.71 1.41E-08 0 50.98 132.46 1.12E-05 17.5 9.44 0 334.31 1.20 8.44 0.0002 1 0.83
18 0.0001 2.05 1.41E-08 0 51.38 131.69 1.12E-05 17.5 9.44 0 493.18 1.20 8.60 0.0002 1 0.72
19 0.0001 2.52 1.41E-08 0 51.13 134.89 1.15E-05 17.5 9.44 0 333.26 1.21 8.47 0.0002 1 0.74
20 0.0001 2.73 1.41E-08 0 51.62 133.58 1.16E-05 17.5 9.44 0 349.07 1.22 8.52 0.0002 1 0.77
21 0.0001 2.90 1.41E-08 0 51.57 138.47 1.18E-05 17.5 9.44 0 182.67 1.23 8.48 0.0002 1 0.81
22 0.0001 2.74 1.41E-08 0 51.57 135.89 1.19E-05 17.5 9.44 0 311.52 1.23 8.60 0.0002 1 0.85
23 0.0001 0.27 1.41E-08 0 51.69 136.76 1.20E-05 17.5 9.44 0 426.97 1.23 8.53 0.0002 1 0.82
24 0.0001 1.81 1.41E-08 0 52.03 137.46 1.19E-05 17.5 9.44 0 381.50 1.24 8.59 0.0002 1 0.72
25 0.0001 2.42 1.41E-08 0 51.82 141.77 1.19E-05 17.5 9.44 0 320.22 1.25 8.76 0.0002 1 0.67
26 0.0001 2.54 1.41E-08 0 52.28 138.11 1.21E-05 17.5 9.44 0 279.10 1.25 8.71 0.0002 1 0.82
27 0.0001 2.69 1.41E-08 0 51.74 142.92 1.24E-05 17.5 9.44 0 266.41 1.25 8.66 0.0002 1 0.81
28 0.0001 2.70 1.41E-08 0 52.96 139.69 1.21E-05 17.5 9.44 0 223.41 1.27 8.81 0.0002 1 0.75
29 0.0001 2.66 1.41E-08 0 52.38 142.56 1.23E-05 17.5 9.44 0 290.71 1.27 8.70 0.0002 1 0.72
30 0.0001 1.47 1.41E-08 0 52.17 140.65 1.24E-05 17.5 9.44 0 388.87 1.26 8.83 0.0002 1 0.78
31 0.0001 3.04 1.41E-08 0 52.79 145.28 1.28E-05 17.5 9.44 0 114.11 1.29 8.88 0.0002 1 0.89
32 0.0001 2.61 1.41E-08 0 52.69 138.70 1.24E-05 17.5 9.44 0 316.88 1.28 8.87 0.0002 1 0.84
33 0.0001 2.14 1.41E-08 0 52.78 144.07 1.26E-05 17.5 9.44 0 276.56 1.28 8.77 0.0002 1 0.69
34 0.0001 2.56 1.41E-08 0 52.65 143.01 1.28E-05 17.5 9.44 0 309.34 1.28 8.90 0.0002 1 0.82
35 0.0001 2.66 1.41E-08 0 52.84 139.52 1.27E-05 17.5 9.44 0 278.78 1.29 8.89 0.0002 1 0.80
36 0.0001 2.77 1.41E-08 0 53.05 141.88 1.27E-05 17.5 9.44 0 237.51 1.29 8.90 0.0002 1 0.79
37 0.0001 2.17 1.41E-08 0 53.00 143.38 1.28E-05 17.5 9.44 0 351.96 1.29 8.88 0.0002 1 0.76
38 0.0001 2.67 1.41E-08 0 52.26 147.78 1.32E-05 17.5 9.44 0 291.35 1.29 8.90 0.0002 1 0.79
39 0.0001 2.28 1.41E-08 0 53.33 141.72 1.28E-05 17.5 9.44 0 306.20 1.30 8.99 0.0002 1 0.78
40 0.0001 2.73 1.41E-08 0 53.48 146.89 1.28E-05 17.5 9.44 0 241.95 1.31 9.03 0.0002 1 0.82
41 0.0001 1.96 1.41E-08 0 53.90 142.03 1.27E-05 17.5 9.44 0 281.75 1.31 9.11 0.0002 1 0.83
42 0.0001 2.49 1.41E-08 0 52.94 148.70 1.31E-05 17.5 9.44 0 281.45 1.31 9.10 0.0002 1 0.86
43 0.0001 2.35 1.41E-08 0 53.00 148.04 1.33E-05 17.5 9.44 0 276.48 1.31 9.03 0.0002 1 0.74
44 0.0001 2.43 1.41E-08 0 53.42 147.70 1.31E-05 17.5 9.44 0 294.07 1.31 9.08 0.0002 1 0.92
45 0.0001 2.27 1.41E-08 0 52.90 149.60 1.34E-05 17.5 9.44 0 307.44 1.31 9.05 0.0002 1 0.91
46 0.0001 2.37 1.41E-08 0 53.81 151.44 1.33E-05 17.5 9.44 0 242.27 1.32 9.13 0.0002 1 0.85
47 0.0001 2.25 1.41E-08 0 53.69 146.72 1.31E-05 17.5 9.44 0 307.44 1.32 9.17 0.0002 1 0.81
48 0.0001 2.50 1.41E-08 0 53.30 147.42 1.34E-05 17.5 9.44 0 312.17 1.31 9.13 0.0002 1 0.94
49 0.0001 2.24 1.41E-08 0 53.73 152.40 1.33E-05 17.5 9.44 0 249.63 1.32 9.06 0.0002 1 0.92
50 0.0001 2.52 1.41E-08 0 53.01 153.86 1.38E-05 17.5 9.44 0 253.10 1.32 9.14 0.0002 1 0.88
51 0.0001 2.28 1.41E-08 0 53.49 151.49 1.37E-05 17.5 9.44 0 290.53 1.32 9.12 0.0002 1 0.91
52 0.0001 2.17 8.27E-09 0 53.54 154.57 1.37E-05 17.5 9.44 0 248.48 1.33 9.28 0.0002 1 0.92
53 0.0001 2.62 1.41E-08 0 53.67 150.79 1.37E-05 17.5 9.44 0 247.26 1.33 9.12 0.0002 1 0.94
54 0.0001 2.48 1.41E-08 0 53.96 150.19 1.36E-05 17.5 9.44 0 241.72 1.33 9.27 0.0002 1 0.88
55 0.0001 2.55 1.41E-08 0 54.17 151.51 1.37E-05 17.5 9.44 0 227.73 1.34 9.18 0.0002 1 0.85
56 0.0001 3.32 3.93E-09 0 54.73 168.70 1.48E-05 17.5 9.44 0 72.79 1.37 9.24 0.0002 1 0.99
57 0.0001 1.48 1.41E-08 0 53.69 159.51 1.40E-05 17.5 9.44 0 226.52 1.34 9.24 0.0002 1 0.91
58 0.0001 2.18 1.41E-08 0 53.92 153.75 1.39E-05 17.5 9.44 0 251.65 1.34 9.23 0.0002 1 0.91
59 0.0001 1.89 1.41E-08 0 53.84 154.62 1.38E-05 17.5 9.44 0 263.75 1.34 9.27 0.0002 1 0.86
60 0.0001 2.67 1.41E-08 0 54.27 155.01 1.39E-05 17.5 9.44 0 213.11 1.35 9.34 0.0002 1 1.00
61 0.0001 1.30 1.41E-08 0 54.68 155.68 1.35E-05 17.5 9.44 0 229.88 1.35 9.69 0.0002 1 1.14
62 0.0001 2.12 1.41E-08 0 54.60 149.87 1.38E-05 17.5 9.44 0 260.51 1.35 9.33 0.0002 1 0.93
63 0.0001 2.19 1.41E-08 0 54.51 154.09 1.39E-05 17.5 9.44 0 257.77 1.35 9.27 0.0002 1 0.84
64 0.0001 1.81 1.41E-08 0 54.12 154.53 1.44E-05 17.5 9.44 0 256.32 1.35 8.80 0.0002 1 0.80
65 0.0001 1.53 1.41E-08 0 54.21 152.19 1.40E-05 17.5 9.44 0 335.75 1.35 9.28 0.0002 1 0.84
p1_power
p3_fractal dim mass






66 0.0001 2.14 1.41E-08 0 53.95 154.61 1.44E-05 17.5 9.44 0 296.79 1.35 9.27 0.0002 1 0.98
67 0.0001 2.13 3.07E-09 0 54.58 156.73 1.42E-05 17.5 9.44 0 222.83 1.35 9.27 0.0002 1 0.84
68 0.0001 2.21 1.41E-08 0 54.51 154.68 1.40E-05 17.5 9.44 0 275.55 1.36 9.43 0.0002 1 0.97
69 0.0001 1.70 1.41E-08 0 54.39 157.34 1.42E-05 17.5 9.44 0 261.54 1.36 9.43 0.0002 1 0.91
70 0.0001 3.08 2.25E-09 0 54.87 167.49 1.42E-05 17.5 9.44 0 173.70 1.37 9.46 0.0002 1 0.96
71 0.0001 2.26 1.41E-08 0 54.64 157.67 1.43E-05 17.5 9.44 0 231.21 1.36 9.42 0.0002 1 0.92
72 0.0001 1.57 1.41E-08 0 54.25 161.75 1.46E-05 17.5 9.44 0 258.77 1.36 8.96 0.0002 1 0.90
73 0.0001 2.17 1.41E-08 0 54.24 159.97 1.45E-05 17.5 9.44 0 249.66 1.36 9.43 0.0002 1 0.85
74 0.0001 2.40 1.41E-08 0 55.06 156.96 1.43E-05 17.5 9.44 0 238.49 1.36 9.42 0.0002 1 0.88
75 0.0001 2.79 1.36E-08 0 54.69 161.77 1.47E-05 17.5 9.44 0 175.29 1.37 9.49 0.0002 1 1.01
76 0.0001 2.27 1.41E-08 0 54.67 161.11 1.46E-05 17.5 9.44 0 254.37 1.36 9.38 0.0002 1 0.88
77 0.0001 2.05 1.41E-08 0 54.77 161.99 1.46E-05 17.5 9.44 0 266.78 1.36 9.39 0.0002 1 1.01
78 0.0001 2.09 1.41E-08 0 54.53 167.13 1.44E-05 17.5 9.44 0 247.78 1.37 9.44 0.0002 1 1.03
79 0.0001 2.64 1.41E-08 0 54.96 160.60 1.44E-05 17.5 9.44 0 250.02 1.37 9.38 0.0002 1 0.95
80 0.0001 2.10 1.41E-08 0 54.63 161.20 1.44E-05 17.5 9.44 0 267.38 1.37 9.51 0.0002 1 0.94
81 0.0001 2.41 1.41E-08 0 54.54 160.19 1.46E-05 17.5 9.44 0 272.46 1.37 9.46 0.0002 1 1.00
82 0.0001 1.27 1.41E-08 0 54.44 168.80 1.52E-05 17.5 9.44 0 242.90 1.37 9.08 0.0002 1 0.78
83 0.0001 2.04 1.41E-08 0 54.61 162.71 1.48E-05 17.5 9.44 0 254.88 1.37 9.14 0.0002 1 0.88
84 0.0001 2.04 1.41E-08 0 54.69 160.20 1.47E-05 17.5 9.44 0 283.45 1.38 9.21 0.0002 1 0.94
85 0.0001 2.52 1.41E-08 0 54.72 159.78 1.50E-05 17.5 9.44 0 290.22 1.37 9.02 0.0002 1 0.90
86 0.0001 2.22 1.41E-08 0 54.78 167.29 1.50E-05 17.5 9.44 0 252.73 1.37 9.15 0.0002 1 0.83
87 0.0001 2.43 1.41E-08 0 55.17 164.78 1.49E-05 17.5 9.44 0 239.37 1.38 9.24 0.0002 1 0.93
88 0.0001 2.13 1.41E-08 0 54.81 163.29 1.49E-05 17.5 9.44 0 280.34 1.37 9.55 0.0002 1 1.01
89 0.0001 1.97 1.41E-08 0 55.12 166.82 1.49E-05 17.5 9.44 0 244.60 1.38 9.21 0.0002 1 0.83
90 0.0001 1.99 1.41E-08 0 55.29 163.44 1.49E-05 17.5 9.44 0 222.55 1.38 9.71 0.0002 1 1.17
91 0.0001 2.28 1.41E-08 0 55.45 159.35 1.50E-05 17.5 9.44 0 267.44 1.38 9.20 0.0002 1 0.95
92 0.0001 2.06 1.41E-08 0 55.45 166.52 1.48E-05 17.5 9.44 0 256.74 1.38 9.36 0.0002 1 1.09
93 0.0001 1.88 1.41E-08 0 55.83 168.36 1.47E-05 17.5 9.44 0 217.11 1.38 9.74 0.0002 1 1.07
94 0.0001 1.93 1.41E-08 0 55.15 161.14 1.50E-05 17.5 9.44 0 296.60 1.38 9.35 0.0002 1 0.96
95 0.0001 2.04 1.41E-08 0 55.46 164.36 1.49E-05 17.5 9.44 0 264.72 1.38 9.26 0.0002 1 0.98
96 0.0001 2.20 1.41E-08 0 54.87 166.35 1.52E-05 17.5 9.44 0 270.51 1.38 9.22 0.0002 1 0.89
97 0.0001 2.11 1.41E-08 0 55.93 166.14 1.49E-05 17.5 9.44 0 253.67 1.39 9.39 0.0002 1 0.97
98 0.0001 2.12 1.41E-08 0 55.34 167.59 1.51E-05 17.5 9.44 0 228.23 1.38 9.77 0.0002 1 1.20
99 0.0001 2.58 1.41E-08 0 55.49 163.03 1.51E-05 17.5 9.44 0 272.79 1.39 9.38 0.0002 1 0.96
100 0.0001 2.38 1.41E-08 0 55.32 168.22 1.51E-05 17.5 9.44 0 258.81 1.39 9.39 0.0002 1 0.89
101 0.0001 2.08 1.41E-08 0 55.52 171.22 1.51E-05 17.5 9.44 0 226.85 1.39 9.84 0.0002 1 1.17
102 0.0001 2.29 1.37E-08 0 55.57 170.17 1.51E-05 17.5 9.44 0 229.48 1.39 9.85 0.0002 1 0.97
103 0.0001 1.87 1.41E-08 0 55.94 166.95 1.48E-05 17.5 9.44 0 269.11 1.39 9.84 0.0002 1 1.17
104 0.0001 2.08 1.41E-08 0 55.41 165.28 1.52E-05 17.5 9.44 0 273.56 1.39 9.80 0.0002 1 1.15
105 0.0001 1.92 1.41E-08 0 55.51 167.93 1.52E-05 17.5 9.44 0 248.19 1.39 9.76 0.0002 1 1.17
106 0.0001 2.68 1.41E-08 0 55.61 176.06 1.56E-05 17.5 9.44 0 193.79 1.39 9.41 0.0002 1 1.01
107 0.0001 1.91 1.41E-08 0 55.90 172.33 1.53E-05 17.5 9.44 0 251.34 1.39 9.35 0.0002 1 0.97
108 0.0001 2.19 1.41E-08 0 55.54 166.53 1.52E-05 17.5 9.44 0 261.01 1.39 9.88 0.0002 1 1.00
109 0.0001 2.03 1.41E-08 0 56.03 166.15 1.53E-05 17.5 9.44 0 236.99 1.40 9.41 0.0002 1 1.12
110 0.0001 1.20 1.41E-08 0 56.15 168.39 1.51E-05 17.5 9.44 0 234.22 1.40 10.03 0.0002 1 1.22
111 0.0001 2.11 1.41E-08 0 55.64 172.14 1.53E-05 17.5 9.44 0 241.37 1.40 9.77 0.0002 1 1.13
112 0.0001 2.12 1.41E-08 0 55.69 168.84 1.55E-05 17.5 9.44 0 268.68 1.39 9.37 0.0002 1 1.05
113 0.0001 0.39 1.41E-08 0 56.46 169.06 1.51E-05 17.5 9.44 0 243.17 1.40 9.92 0.0002 1 1.18
114 0.0001 0.97 1.41E-08 0 56.12 171.50 1.54E-05 17.5 9.44 0 239.29 1.40 9.45 0.0002 1 1.03
115 0.0001 1.97 1.41E-08 0 56.21 169.08 1.54E-05 17.5 9.44 0 236.79 1.40 9.55 0.0002 1 1.20
116 0.0001 2.06 1.41E-08 0 56.03 176.69 1.52E-05 17.5 9.44 0 240.74 1.40 9.87 0.0002 1 1.13
117 0.0001 2.09 1.41E-08 0 56.01 171.29 1.55E-05 17.5 9.44 0 262.80 1.40 9.43 0.0002 1 1.03
118 0.0001 2.42 1.41E-08 0 55.67 174.95 1.55E-05 17.5 9.44 0 237.88 1.40 9.93 0.0002 1 1.10
119 0.0001 2.09 5.06E-09 0 55.87 172.60 1.56E-05 17.5 9.44 0 271.08 1.40 9.48 0.0002 1 1.04
120 0.0001 2.31 1.41E-08 0 55.55 172.90 1.60E-05 17.5 9.44 0 255.54 1.40 9.38 0.0002 1 0.91
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A.6 Kratky plots of TTCF ensilication

































































Figure A-1: Kratky plots of TTCF ensilication. (top) The agitated sample setup measure-
ment at Diamond (Bottom) The static sample measurement at ESRF (bottom)
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A.7 ELISA titration





















































































































































Figure A-2: ELISA serum TTCF titration overview. Serum responses of mice injected
with various doses of TTCF over a 6 week time period. 10G5 used as inter plate control for
normalisation.
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A.8 ELISA release without dialysis





























Figure A-3: ELISA binding assay of native and released ensilicated material without
dialysis. Non-dialysed released TTCF was diluted in bicarbonate buffer and bound onto an
ELISA plate. Mouse polyclonal serumwas used tomeasure released TTCF binding capacity.
R = released, RH = heat treated released, old = 1 month, new = 1 week after ensilication.
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A.9 ELISA TTCF in vivo










































































native denatured released heat treated released
Figure A-4: ELISA serum TTCF in vivo overview Serum responses of 5 mice/group in-
jected with various samples of TTCF over a 6 week time period. 10G5 used as inter plate
control for normalisation.
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native denatured released heat treated released
Figure A-5: ELISA serum TTCF in vivo overview Serum responses of 5 mice/group in-
jected with various samples of TTCF over a 6 week time period. 10G5 used as inter plate
control for normalisation.
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A.10 CD thermal ramp TTCF


























































Figure A-6: CD thermal ramp native TTCF within a limited range. CD spectra between
260—185 nm were acquired for each temperature interval starting at 50◦C up to 70◦C with
1◦C increments. Range was based on the global run to provide accurate unfolding temper-
atures, Tm.
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Figure A-7: CD thermal ramp heat treated released TTCF within a limited range. CD
spectra between 260—185 nm were acquired for each temperature interval starting at 50◦C
up to 70◦C with 1◦C increments. Range was based on the native TTCF global run to provide
accurate unfolding temperatures, Tm.
178
A.11 CD long-term







































Figure A-8: CD long term, 2weeks - 3months. Spectra obtained from analysis of released
TTCF at 2 weeks, 1 month and 3months. Low resolution of the data is due to technical errors
during sample preparation and instrument optimisation.
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A.12 Lysozyme XRD parameters
X-ray data collection statistics
Spacegroup P4322
Unit cell dimensions (Å) 78.60 78.60 37.04
90.00 90.00 90.00
Mosaicity 0.72
Resolution range (last shell) 55.58 - 1.75 (1.82 - 1.75)
Total number of reflections 101347
Number of unique reflections 11498
Average redundancy (last shell) 8.81 (5.96)
Rmerge (last shell) 0.039 (0.128)
Rmeas (last shell) 0.041 (0.140)
RmeasA (I+, I- reflns kept apart) (last shell) 0.04 (0.144)
Reduced ChiSquared (last shell) 0.95 (0.69)
Output <I/sigI> (last shell) 37.6 (9.1)
Model refinement statistics
Resolution range (Å) 30.822 - 1.754
Number of protein atoms 1054












A.13 ELISA lysozyme in vivo




















































































Figure A-9: ELISA serum lysozyme in vivo overview Serum responses of 5 mice/group
injected with various types of lysozyme over a 6 week time period. HyHel-10 monoclonal
antibody used as inter plate control for normalisation.
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Figure A-10: ELISA serum lysozyme in vivo overview Serum responses of 5 mice/group
injected with various types of lysozyme over a 6 week time period. HyHel-10 monoclonal
antibody used as inter plate control for normalisation.
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A.14 CD thermal ramp lysozyme







































































Figure A-11: CD thermal ramp native and released lysozyme in a limited range. CD
spectra between 260—185 nm were acquired for each temperature interval starting at 60◦C
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